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Abstract 
 
The nuclear receptor family represents a large class of transcription factors that 
regulate metabolism, differentiation and development. Most of the nuclear receptor 
family members are orphan receptors, so called because no ligands were known when 
they were identified. Although for some receptors ligands have been identified by 
now, many receptors, such as the estrogen related receptor α (ERRα), still remain 
orphan. The activity of all nuclear receptors requires the recruitment of coregulators, 
which are able to enhance or repress their activity. Our work has focused on PGC-1α, 
which responds to physiological signals, such as cold, fasting and exercise, and was 
characterized as an important factor in the regulation of energy homeostasis and 
metabolic pathways. In my thesis work, we demonstrate that PGC-1α regulates the 
expression and activity of the orphan nuclear receptor ERRα. Our findings suggest 
that PGC-1α may act as a protein ligand, substituting for the lack of small lipohilic 
ligands for this receptor. The expression of PGC-1α and ERRα is parallel in tissues 
with high energy demand, and induced in vivo when animals are exposed to cold. 
Furthermore, our studies demonstrate that ERRα is important for PGC-1α signaling, 
since diminished ERRα levels significantly reduce the induction of mitochondrial 
biogenesis by PGC-1α. Binding sites for ERRα are observed in many genes encoding 
for mitochondrial proteins, and in vitro studies suggest that ERRα activates the 
transcription of at least a subset of the genes by binding to their promoters. 
Furthermore, ERRα fused to the potent VP16 activation domain is sufficient to induce 
mitochondrial biogenesis. We suggest that PGC-1α and ERRα regulate the 
transcription of genes encoding mitochondrial proteins in response to metabolic 
requirements. 
 
Previous studies from our lab identified PGC-1α as a potent regulator of 
glucocorticoid receptor (GR) function in vitro. In support of our studies, other groups 
have shown that PGC-1α coactivates GR on the PEPCK promoter, the key enzyme of 
gluconeogenesis. Further data has shown that glucocorticoids and glucagon regulate 
the expression of PGC-1α. This led us to investigate the role of PGC-1α in GR 
signalling in SAOS2 cells. Our preliminary data suggest that glucocorticoids strongly 
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influence PGC-1α signaling, enhancing some PGC-1α pathways and suppressing 
others. Finally, our data provide support to the hypothesis that PGC-1α is not a 
general enhancer of glucocorticoid responses, but rather provides specificity to GR 
signalling. PGC-1α expression leads to the activation of a distinct set of genes by GR. 
Future studies should provide more insight into this relationship. 
 
 vii 
Chapter I: Introduction 
 
Chapter I: Introduction 
 
 
Overview of transcriptional regulation by nuclear receptors 
 
All cellular processes involved in development, differentiation, cell growth and 
metabolism are constantly regulated by the transcriptional activation or repression of 
many different genes. The misregulation of even a single component often leads to 
disease, such as obesity, diabetes or cancer (Rosmond, 2002; Smith and Kantoff, 
2002; Spiegelman and Flier, 2001; Tenbaum and Baniahmad, 1997). Therefore, the 
control of gene expression and the mechanisms of achieving specificity in 
transcriptional pathways have attracted increasing amount of attention in the last two 
decades (reviewed in Orphanides and Reinberg, 2002). The transcription of genes is 
regulated in a highly organized fashion to ensure protein expression in a spatially and 
temporally defined manner. Mechanisms must exist that allow cells to integrate 
intracellular and extracellular signals to their differentiation state, cell cycle stage or 
metabolic state, and ensure appropriate transcriptional responses. 
 
One class of extracellular signals are steroid hormones. These are small lipophilic 
molecules that are produced by endocrine glands and transported through the blood, 
and that can diffuse through the plasma membrane to the cell interior. They exert their 
transcriptional effects by binding and activating nuclear receptors, which are among 
the most intensively studied and probably best-understood transcription factors to date 
(reviewed in Aranda and Pascual, 2001; Mangelsdorf et al., 1995). Several facts have 
established nuclear receptors as valuable tools for studying the mechanisms that 
provide specificity in transcriptional regulation. First, nuclear receptors are important 
modulators of all aspects of physiology. Second, the expression of many nuclear 
receptors, for example the glucocorticoid receptor (GR), is ubiquitous (Jenkins et al., 
2001), yet the responses they elicit are cell type- or physiological state-dependent. 
Third, nuclear receptors are regulated through small lipophilic ligands, which are 
good experimental tools for turning on and of the activity of the receptors, as well as 
have therapeutic applications. 
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For several years, the regulation of transcription by nuclear receptors was imagined in 
a simple way. Hormones ‘slip’ into the cells and ‘waken’ up the inactive receptor, 
which then binds to DNA and activates transcription. However, things are not as 
simple as they seem. First, nuclear receptors activate or repress transcription mostly, 
but not always, in a ligand-dependent manner. The identification of the first steroid-
related receptors, the estrogen related receptors (ERRs), for which no ligand was 
known, founded the subgroup of orphan nuclear receptors (Giguere et al., 1988). 
Today, many dietary lipids and endogenous metabolites have been identified as 
ligands for some of the orphan nuclear receptors. These receptors are thought of as 
important metabolic sensors and targets for drug development (reviewed in Blumberg 
and Evans, 1998; Giguere, 1999; Moller, 2001). Second, increasing evidence suggests 
that nuclear receptors are not sufficient by themselves to interact with RNA 
polymerase II and activate or repress transcription. In fact, the transcriptional activity 
of nuclear receptors is modulated through several different classes of coregulators. In 
the last few years, biochemical and yeast two hybrid approaches have identified many 
nuclear receptor interacting proteins that act as coregulators, leading either to the 
activation (coactivators) or repression (corepressors) of transcription (reviewed in 
Glass and Rosenfeld, 2000; McKenna et al., 1999; Naar et al., 2001). 
 
By definition, coactivators or corepressors do not interact directly with DNA, but are 
recruited to regulatory regions of target genes via protein-protein interactions with 
DNA binding transcription factors. Once recruited, they exert several different 
activities that may modify chromatin, the basal transcription machinery factors and/or 
RNA polymerase II (reviewed in Collingwood et al., 1999; Glass and Rosenfeld, 
2000; McKenna et al., 1999). The first nuclear receptor coactivators proposed in the 
1980s were the binding proteins of the basic transcription factor TFIID, namely the 
TATA-binding protein (TBP) (Hahn et al., 1989; Horikoshi et al., 1989; Kao et al., 
1990) and the TBP-associated factors (TAFs) that built a bridge between DNA-
specific transcription factors and the basal transcriptional machinery (Dynlacht et al., 
1991; Pugh and Tjian, 1990). A few years later, a new class of coregulators was 
defined with the identification of a 160-kDa estrogen receptor (ER)-associated protein 
(ERAP-160; (Halachmi et al., 1994)), which later on turned out to be a splicing 
variant of the steroid receptor coactivator-1 ((SRC-1); Kamei et al., 1996; Onate et al., 
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1995). The group of M.G. Parker, at the same time, identified the coregulators RIP80, 
RIP140 and RIP160 (Cavailles et al., 1994), which interact with ER in the presence of 
an agonist ligand. Shortly after, the characterization of GRIP-170, a 170 kDa GR-
interacting protein (Eggert et al., 1995), demonstrated that this class of cofactors is 
essential for the transcriptional activity of the nuclear receptors, and suggested that it 
may be a functionally limiting component. To date, more than 50 coactivators and 
several corepressors of nuclear receptors have been identified (reviewed Collingwood 
et al., 1999; Glass and Rosenfeld, 2000; McKenna et al., 1999). The different 
coregulators have been proposed to regulate transcription either alone, sequentially, 
combinatorially or as big multiprotein complexes. 
 
Increasing efforts in the last few years aim in unraveling the mechanisms of 
transcriptional regulation through coregulators, and elucidating their biological roles 
(reviewed in Glass and Rosenfeld, 2000; McKenna et al., 1999; Naar et al., 2001). 
While a few coregulators are expressed in a tissue-specific manner, most are 
expressed ubiquitously, similar to what has been observed for several nuclear 
receptors. Therefore, the presence of many different coactivators, corepressors and 
nuclear receptors in the same tissue and at the same time seems to be a common 
theme. Given that each coregulator can interact with multiple nuclear receptors and 
vice versa, understanding the mechanisms that lead to specific transcription factor – 
coregulator complexes, and the biological roles of these specific partnerships is 
fundamental. 
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Nuclear receptors 
 
 
Nuclear receptor structure 
 
The classical structural features of this family of transcription factors are, first, the 
two well conserved zinc finger domains that bind to DNA (DBD), and second, a C-
terminal domain that binds ligand (ligand binding domain, LBD) and carries a 
transcriptional activation function (reviewed in Aranda and Pascual, 2001). In 
addition, all nuclear receptors harbor nuclear localization signal (NLS). Nuclear 
receptors also have a variable N-terminal domain, which in some cases carries a 
second transcriptional activation function. Accordingly, nuclear receptors can be 
divided into five regions based on structural and functional similarities (see figure 1): 
the variable N-terminal region (A/B) that may contain a transcriptional activation 
function (AF-1); the conserved DBD, which also includes a dimerization domain (C); 
variable hinge region (D); a conserved LBD with a second dimerization domain and 
the conserved transcriptional activation function AF-2 (E); and a variable C-terminal 
region (F). Whereas the AF-1 activity can function independently of ligand binding, 
the AF-2 activity is strictly ligand-dependent. (reviewed in Warnmark et al., 2003). 
The AF-2 domain is essential to determine the binding of the appropriate coactivator 
or corepressor molecule to the receptor.  
Nuclear receptors are all thought to be evolutionarily related and have possibly 
derived from a common ancestral gene via gene duplication and/or exon shuffling 
(Laudet, 1997; Sluder et al., 1999). The regions C (DBD) and E (LBD) represent the 
most conserved elements (Evans, 1988; Green and Chambon, 1988). 
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igure 1. Nuclear receptor domains 
Structure of a classical nuclear receptor. Typical domains and functions are indicated. AF 
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known. Although structurally related, they carry very different functions in the 
regulation of homeostasis, metabolism, cell cycle and development, and bind 
structurally diverse ligands. Moreover, for several of the orphan receptors no 
physiological ligand has been identified up to now (Blumberg and Evans, 1998; 
Giguere, 1999). Although the majority of nuclear receptors consist of the classical 
features described in the previous section, some members contain only a subset of 
them. For example, SHP (small heteromeric partner) and DAX-1, two closely related 
members, are atypical receptors that have a LBD but lack a DBD. They seem to 
heterodimerize with other nuclear receptors, via the LBD, and serve as repressors 
(Howell et al., 1998; Seol et al., 1996; Wan et al., 2000). In addition to the 
classification on the basis of sequence similarity, nuclear receptors have been 
classified into three groups, based on the nature of their ligands (see figure 2; 
reviewed in (Chawla et al., 2001). 
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igure 2. Nuclear receptors can be classified in three groups according to their ligands. 
(Adapted from Chawla et al., 2001). 
) Classical endocine receptors with high affinity hormonal ligands 
rticoid (GR), 
F
 
 
1
They include the steroid hormone receptor subfamily (glucoco
mineralocorticoid (MR), estrogen (ER), progesterone (PR) and androgen receptors 
(AR)) and represent the initial group of nuclear receptors cloned in the mid 1980s. 
They harbor the classical structural features that were described before and that have 
defined the family, and seem to act dependent on ligand binding (reviewed in Aranda 
and Pascual, 2001; Chawla et al., 2001). This family also includes receptors with high 
affinity for some dietary components, such as vitamin A and D, as well as the 
receptors for thyroid hormone (retinoic acid receptor (RAR), vitamin D receptor 
(VDR), thyroid hormone receptor (TR)). 
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2) “Metabolic sensors” or “adopted” orphan receptors with low affinity for 
dietary lipids or intermediary metabolites. 
Nuclear receptors of this class are activated by a diverse group of nutrient components 
or intermediary metabolites (e.g. fatty acids, bile acids and others), act as ‘metabolic 
sensors’, and contain the ‘adopted’ members of the orphan receptor family. 
Interestingly, their major role is in metabolism, and in particular the regulation of 
lipid and xenobiotic metabolism. For example, PPARα is expressed in tissues with 
high capacity for fatty acid oxidation, like heart, liver, kidney and brown fat, and is 
activated by fatty acids (Gottlicher et al., 1992). LXRs and FXR are activated by 
oxysterols and bile acids, respectively, and potently regulate cholesterol and bile acid 
metabolism (Repa and Mangelsdorf, 2000). Most receptors here bind DNA as 
heterodimers with RXR (Yu et al., 1991), although formation of heterodimers with 
RXR is not an exclusive characteristic of this class (reviewed in Giguere, 1999). 
 
3) Orphan receptors with unknown ligands 
The third class of nuclear receptors contains the still orphan receptors, which seem 
to be active in the absence of any known ligand. Besides SHP and DAX-1, referred to 
previously, COUP-TFs acts often as repressors of transcription. This repressor 
function may be exerted by competing with other receptors for binding to DNA or for 
heterodimerization with RXR, as well as by having active repression domains that 
recruit corepressor complexes (reviewed in Pereira et al., 2000; Shibata et al., 1997). 
Some of the receptors in this group may “bona fide” orphans. The recent elucidation 
of the crystal structure of the NURR-1 LBD showed the ligand-binding pocket filled 
with hydrophobic residues and thereby, unlikely to be available for binding small 
ligands (Wang et al., 2003). Furthermore, NURR-1 lacks the classical coactivator 
interaction domain, and is very likely regulated through signaling molecules like 
receptor tyrosine kinases kinases (Wang et al., 2003). Similar observations have been 
made for the steroidogenic factor SF-1 (Desclozeaux et al., 2002) and the Rev-ErbA 
subfamily members (Renaud et al., 2000). Other members of this class include LRH-
1, which regulates lipid metabolism in collaboration with the described LXRs and 
FXR, HNF4, which plays a role in gluconeogenesis and the ERR family members, the 
first orphan receptors described (reviewed in Giguere, 1999; Repa and Mangelsdorf, 
2000). 
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The glucocorticoid receptor 
 
Glucocorticoid hormones were already used in the middle of the 20th century, before 
the molecular identification of the glucocorticoid receptor (GR), as anti-inflammatory 
agents. The isolation of the active component and the use as efficient drug against 
rheumatoid arthritis led to the Nobel prize for Tadeus Reichstein, Edward Kendall and 
Philip Hench in 1950 (reviewed in Bonnelye and Aubin, 2002; Neeck, 2002). The 
glucocorticoid receptor (GR), was one of the first steroid receptors to be cloned, in 
1985 (Hollenberg et al., 1985; Weinberger et al., 1985). 
 
Activation pathway of glucocorticoid receptor signaling  
In the absence of hormone, GR is part of a multiprotein complex in the cytoplasm 
(Nathan and Lindquist, 1995; Picard et al., 1990; Sanchez et al., 1985). This large 
complex consists of the two essential heat shock proteins hsp90 and hsp70, and 
several other chaperones and immunophilins. Formation of the complex depends on 
the LBD of the receptor, which interacts with Hsp90 (Pratt and Toft, 2003). The 
multiprotein complex keeps the receptor in a transcriptionally inactive state, while 
allowing ligand binding and even facilitating the folding of the LBD into a high 
affinity binding-pocket for the ligand ligand (Picard et al., 1990). Apparently, this is 
not a rigid situation, and the receptor is dynamically passing in and out of the nuclei 
of hormone-free cells, even though accumulating in the cytoplasm. Upon binding of 
hormone to the receptor, the ligand-bound receptor dissociates from the chaperone 
complex, translocates to the nucleus, and binds to specific DNA sequences, termed 
glucocorticoid response elements (GREs). 
 
Three types of binding sites have been described for GR LBD (reviewed in Almawi 
and Melemedjian, 2002). At these sites, GR can activate or repress transcription, 
depending on the sequence of the GRE, the available coactivators and other non-
receptor DNA-binding transcription factors. 1) A simple GRE consists of an imperfect 
palindrome with two hexamer half-sites separated by 3 base pairs. The recruitment of 
specific coactivators and/or the displacement of other activating transcription factors 
seems to then lead to the activation or repression of transcription (Meyer et al., 1997; 
Rogatsky et al., 2002; Stromstedt et al., 1991).  
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2) A composite GRE was described first for the promoter of the proliferin gene, 
where GR represses transcription. GR binds directly to this composite GRE, but the 
availability of AP-1 factors that bind in the vicinity, or possibly also coactivators, 
determines whether GR represses or activates transcription (Diamond et al., 1990; 
Rogatsky et al., 2002). 3) On tethering response elements, GR does not bind DNA 
directly, but affects transcription through an interaction with other transcription 
factors like NfκB or AP-1. Via this mechanism, GR is proposed to exert its 
immunosuppressive effects and its ability to inhibit NfκB-dependent (Caldenhoven et 
al., 1995; Heck et al., 1997; Ray and Prefontaine, 1994; Scheinman et al., 1995). 
 
 
The role of GR in stress responses 
Glucocorticoids are known for their role in regulating important components of the 
transcriptional response to stress. In the following, some of the better studied effects 
of glucocorticoids in metabolism will be described. At this point, it should be noted, 
that most glucocorticoid responses are exerted by GR. However, the 
mineralocorticoid receptor also posseses a high affinity for glucocorticoids, and some 
of the responses are likely to be mediated by this receptor. Glucocorticoid release is 
controlled by the hypothalamic-pituitary axis, in a diurnal rhythm-dependent manner 
and in response to stress (Jacobson and Sapolsky, 1991). After the first wave of stress 
hormones (catecholamines, glucagons and growth hormone), glucocorticoids conduct, 
as second ‘wave’, part of the metabolic response to stress, exerting effects on glucose, 
lipid, protein and nucleotide metabolism. In addition, they influence the electrolyte 
and calcium homeostasis and the immune system. From an evolutionary perspective, 
stress is usually caused by predators, and the trancriptional response facilitates the 
‘fight or flight’ behavior. The main role of glucocorticoids in metabolism is to raise 
blood glucose levels, by mobilizing existing energy stores, and provide energy to the 
brain. The metabolic actions of glucocorticoids in stress responses are complex and 
have been defined into the following three types responses (Sapolsky et al., 2000).  
1) Permissive actions of glucocorticoids, where the presence of the hormone prior to 
the stressor influences strongly the response to the first wave of “stress hormones” 
(catecholamines, glucagons and growth hormone). An example of this permissive 
action is the increase of glycogenolysis, lipolysis and hepatic gluconeogenesis. 
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2) The stimulating actions of glucocorticoids enhance the response to the first wave 
of “stress hormones”. In this action, GR induces proteolysis in various muscle types, 
inhibits protein synthesis, and keeps lipolysis active in fat cells, thereby providing 
substrates for gluconeogenesis in liver. GR also directly stimulates gluconeogenesis in 
liver. To assure the supply of glucose for the brain, glucocorticoids also inhibit 
glucose uptake in the peripheral tissues. 
 
3) The preparative function of glucocorticoids can often be suppressive and induce 
opposite effects. They are important to prepare for the next stressor. One example of a 
preparative function, which is contradictary to the glycogenolysis at the beginning of 
the stress response, is that glucocorticoids can also induce glycogen storage in the 
liver. 
 
 
Glucocorticoids as therapeutic drugs 
The immunosuppressive function of GR, which is thought of as important for 
protecting the body from the actual stress response, has led to the use of synthetic 
glucocorticoids for the treatment of many different immune diseases, like rheumatic 
arthritis, asthma, collagen vascular diseases and more. GR is expressed and active in 
almost all tissues, affecting many different aspects of metabolism and cell growth, by 
regulating the expression of target genes in a cell-type and physiological state-
dependent manner. Thus, it is not surprising that therapeutic treatment with 
glucocorticoids, particularly when long-term stress, leads to undesired effects, such as 
increases in blood glucose levels (a condition predisposing to diabetes) and 
osteoporosis. Pharmaceutical companies have spent a lot of effort to find synthetic 
ligands that maximize the desired effects (e.g. immunosuppression) while minimizing 
effects on blood glucose levels and the bone. These efforts have been partially 
successful and have generated ligands with preferential effects on GR-mediated 
responses. Interestingly, the underlying mechanism seems to be that these ligands 
encourage the interaction of GR with a specific subset, rather than all coactivators, 
suggesting that distinct coactivators may be utilised at different promoters, pathways, 
or cell types (Miner, 2002). 
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The ERR family  
 
Estrogen-related receptor α (ERRα) and ERRβ represent the first orphan receptors 
identified, based on their sequence similarity with ER (Giguere et al., 1988). The third 
member of this family, ERRγ, exists as multiple tissue-specific, alternatively spliced 
isoforms (Eudy et al., 1998). ERRs are highly similar at the amino acid level, with the 
highest identity being between ERRβ and ERRγ (77%). All three family members 
bind as homodimers to the extended half-site TNAAGGTCA, which is also the 
binding site for the orphan receptor SF-1 (Vanacker et al., 1999a). Heterodimerization 
of ERRs with ERα, and of ERRα with ERRγ has also been proposed (Huppunen and 
Aarnisalo, 2004; Johnston et al., 1997; Yang et al., 1996a). Furthermore, several 
studies have demonstrated that the ERR family members can bind to classical 
estrogen response elements (EREs) and compete with ERα for binding to these sites 
(Johnston et al., 1997; Kraus et al., 2002; Vanacker et al., 1999b; Zhang and Teng, 
2001). The DBDs of the three ERRs are highly identical (around 90 %) and the 
receptors are likely to be co-expressed in some tissues (Bonnelye et al., 1997a; 
Giguere et al., 1988; Heard et al., 2000; Hong et al., 1999; Pettersson et al., 1996). At 
present, it remains unclear whether the three ERRs have overlapping functions, or 
carry distinct biological roles. 
 
 
ERRα 
ERRα is expressed widely, but at different levels in different tissues. During mouse 
embryonic development, high levels of ERRα are detected at sites of ossification 
(Bonnelye et al., 1997a). Furthermore, ERRα transcripts are found in heart, muscle, 
kidney, specific areas of the brain and in the digestive tract, with increasing levels 
during later developmental stages. In adults, ERRα is mainly expressed in tissues 
with high β-fatty acid oxidation activity like heart, kidney and brown fat, but also in 
brain and muscle (Bonnelye et al., 1997b; Sladek et al., 1997). 
The physiological role of ERRα is still debated, although several functions have been 
suggested. In vitro studies have proposed that ERRα modulates estrogen signaling, in 
more than one way: (1) by activating classical estrogen target genes, in the absence of 
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estrogens; (2) by competing with ERα for EREs, and thereby antagonizing ERα 
function, (3) via direct physical interaction with ERα and (4) by regulating the 
expression of the aromatase gene, and hence production of estrogens (Johnston et al., 
1997; Kraus et al., 2002; Vanacker et al., 1999b; Yang et al., 1996a; Zhang and Teng, 
2001). 
 
The high levels of expression of ERRα at ossification sites in developing mouse 
embryos have led to a proposed function in the regulation of bone formation. In 
support of such a role, ERRα induces the expression of osteopontin by binding 
directly to the promoter of this gene (Vanacker et al., 1998), and has been shown to 
induce bone nodule formation in vitro (Bonnelye et al., 2001; Bonnelye et al., 1997a). 
 
The expression pattern of ERRα in adult mice (highest in heart, kidney and brown fat) 
have led to a proposed role in b-fatty acid oxidation. Importantly, ERRα binds the 
promoter of the gene encoding the medium-chain acyl coenzyme A dehydrogenase 
(MCAD), a key enzyme in β-fatty acid oxidation, and regulates its expression (Sladek 
et al., 1997; Vega and Kelly, 1997). 
 
The recent generation of ERRα knockout mice by V. Giguere (Luo et al., 2003), 
supports a role for ERRα in lipid metabolism. The disruption of the ERRα gene leads 
to viable mice that have reduced adipose tissue. Although no differences in the energy 
expenditure, the fasting glucose levels or the serum free fatty acid or triglyceride 
levels have been observed, these mice are resistant to high-fat diet-induced obesity. 
Gene expression profiling of isolated adipocytes have disclosed an altered regulation 
of enzymes involved in fat metabolism. Strikingly, MCAD is upregulated, suggesting 
a repressor function for ERRα at this gene (Luo et al., 2003). The reasons for the 
decreased adipocity and resistance to obesity are, however, currently unclear.  
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ERRβ 
ERRβ expression is highly specific in extra-embryonic tissues during the early 
embryonic development. ERRβ mRNA levels could be detected in a subset of cells in 
the extra-embryonic ectoderm at day 5.5 post-coitum and more prominently after day 
6.5 p.c. in ectodermally derived cells that later on form the chorion. In adults, ERRβ 
expression could be detected only in low levels in the liver, stomach, skeletal muscle, 
heart and kidney (Chen et al., 1999b; Giguere et al., 1988). Disruption of ERRβ in 
mice demonstrated clearly that ERRβ is essential for normal placental formation. 
ERRβ-/- mice show abnormal chorion formation, placental failure and impaired 
trophoblast stem cell differentiation (Luo et al., 1997). 
 
 
ERRγ 
ERRγ transcripts are detected at high levels in both the embryo and adults. During 
development, major sites of expression are the fetal brain, with lower levels in the 
kidney, lung and liver. In human adults, ERRγ mRNA is expressed at high levels in 
the lung, bone marrow, brain and adrenal gland, lower in the thyroid gland, spinal 
cord and trachea (Eudy et al., 1998). The expression pattern in adult mice looks 
different, with high levels in specific areas of the brain brain (Hermans-Borgmeyer et 
al., 2000; Lorke et al., 2000), kidney, testis, spleen and lower levels in lung ((Eudy et 
al., 1998)). In other studies, high levels of ERRγ expression are detected in the adult 
mouse heart, and modest expression is seen in muscle (Hong et al., 1999; Susens et 
al., 2000). The function of the third member of the ERR family of orphan receptors 
remains unclear, even though some target genes, such as the SHP orphan receptor 
gene, have been proposed (Sanyal et al., 2002). 
 
 
Ligands for the orphan receptor family of ERRs 
During the course of identifying new ligands for the family of orphan nuclear 
receptors, a new concept emerged: the "reverse endocrinology". Instead of identifying 
a receptor for a physiologically characterized hormone, as was the case with steroid 
hormones and receptors, orphan receptors were used to search for new hormones 
(Blumberg and Evans, 1998; Giguere, 1999). In the case of ERRα, initial studies 
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reported that it could be activated by a component present in fetal calf serum 
(Vanacker et al., 1999a), while subsequent studies suggest that the three ERRs are 
constitutively active, in the absence of any ligand (Chen et al., 2001; Xie et al., 1999). 
Searches for ligands for the ERRs have been successful in identifying only synthetic 
antagonists. Because of the similarity of ERRs with ERs, ligands with estrogen-like 
activity have been considered. The results are contradictory and differ somewhat from 
group to group, but suggest that toxaphene, chlordane, diethylstilbestrol (DES) and 4-
hydroxytamoxifen (OHT) can act as antagonists of ERRβ and ERRγ, but not of ERRα 
(Coward et al., 2001; Tremblay et al., 2001; Yang and Chen, 1999). Finally, 
elucidation of the crystal structure of the ERRγ ligand-binding domain bound to a 
peptide derived from the SRC-1 coactivator, shows that the ERRγ LBD can adopt an 
active conformation already in the absence of any ligand (Greschik et al., 2002). The 
question is still open, if an agonist ligand can exists for the ERRs. A recent 
publication has proposed that flavones and isoflavone phytoestrogens may enhance 
the activity of ERRs (Suetsugi et al., 2003). 
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Coregulators of transcription 
 
Nuclear receptors are not able to interact directly with RNA polymerase II. Their 
function therefore depends on coregulators, which serve as intermediate factors 
between the nuclear receptors and the basal transcriptional machinery, and which 
determine the activator or repressor function of the receptor. Coregulators can be 
divided into two main classes: coactivators, which activate transcription, and 
corepressors, which lead to transcriptional repression. In the context of this thesis, I 
will focus on the class of coactivators. 
 
 
Coactivators. Coactivators bind to nuclear receptors mostly dependent, but also 
independent of ligand availability, and are able to switch the nuclear receptors from 
an inactive to an active state. The interaction surface of all coactivators is very 
similar. They bind to nuclear receptors via multiple nuclear-receptor interaction 
domains (also called NR boxes) that contain the sequence LXXLL (L=leucine, x=any 
amino acid) located in an amphiphatic a-helix. These motifs have been shown to be 
necessary and sufficient to mediate binding with nuclear receptors (Heery et al., 1997; 
Hu and Lazar, 1999; Nagy et al., 1999; Perissi et al., 1999; Radhakrishnan et al., 
1997; Yamamoto et al., 1998). Whereas most coactivators interact with the AF-2 
domain of the nuclear receptors, some coactivators, such as SRCs and DRIP150 can 
also interact with the AF-1 domain or synergistically with both the AF-1 and the AF-2 
(Benecke et al., 2000; Hittelman et al., 1999). The structural basis for these 
interactions is however not well understood yet. 
 
Corepressors. The two main corepressors are N-CoR and SMRT, which bind to 
nuclear receptors in the absence of ligand or the presence of antagonist ligand (Chen 
and Evans, 1995; Horlein et al., 1995; Lavinsky et al., 1998; Zhang et al., 1998). 
Corepressors harbor conserved NR interacting domains, referred to as CoRNR box, 
with the motif LXXI/HIXXXI/L. This motif seems to represent a prolonged form of 
the coactivator motif LXXLL, with an extended α-helix (Hu and Lazar, 1999; Nagy et 
al., 1999; Perissi et al., 1999; Xu et al., 2002). Disruption of the N-CoR gene blocks 
the development of the CNS, erythrocytes and thymocytes, suggesting that N-CoR 
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repressor activity is essential for organ development (Hermanson et al., 2002). 
Although the available data are contradictory, N-CoR and SMRT seem to execute 
their repression function as complexes with histone deacetylases Sin3, HDAC1, 
HDAC2 and other components (Guenther et al., 2000; Li et al., 2000; Underhill et al., 
2000; Wen et al., 2000). The isolation of additional complexes with varying 
components suggest that N-CoR and SMRT act in a tissue- and promoter-specific 
manner. Furthermore, N-CoR and SMRT conduct short- and long-term repression 
functions not only for nuclear receptors but also many other transcription factors, like 
Mad, and play a role as general repressors of transcription. 
 
Structural data have revealed that most of the coactivators and corepressors bind to an 
overlapping binding surface on the nuclear receptors (Hu and Lazar, 1999; Nagy et 
al., 1999; Xu et al., 2002). This region, also known as AF-2 domain, is located in the 
well-conserved LBD (see figure 3). Helix 12, which is located in the AF-2, seems to 
be the major determinant for the binding of coactivators and to act as a switch. In the 
absence of ligand, the pocket is ‘open’ and corepressors are able to bind (figure 3). 
When an agonist ligand binds, helix 12 moves over the ligand binding pocket; this 
conformational change creates a new pocket that enables coactivator binding 
(Bourguet et al., 1995; Nolte et al., 1998). The actual mechanism may be more 
complex, since several intermediates seem to be possible. Moreover, some 
corepressors, like RIP140, are able to interact with agonist-bound receptor and repress 
transcription (Lee et al., 1998).  
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Figure 3. Model for corepressor and coactivator binding to the nuclear receptor LBD in the 
absence and presence of agonist ligand. (Adapted from Nagy et al., 1999). 
 
 
Types of coactivators  
 
More than 50 nuclear receptor coactivators have been described. With the exception 
of the nuclear receptor interacting motif LXXLL that they have in common, the 
different coactivators are structurally quite diverse proteins. The large number of 
coactivators and coactivator complexes suggests that they carry diverse roles, such as 
integrating distinct signals, conferring tissue and promoter-specific regulation, and/or 
acting via distinct mechanisms. In the following section, the different types of 
coactivators, grouped according to their mechanism of action, will be described: 
1) ATP-dependent chromatin remodeling complexes, 2) histone modifying 
complexes, 3) bridging factors, 4) other coactivators of transcription. (reviewed in 
Glass and Rosenfeld, 2000; McKenna et al., 1999; Naar et al., 2001). 
 
 
1) ATP-dependent chromatin remodeling complexes 
DNA is condensed in chromatin, where the small units, the nucleosomes, consist of 
DNA coiled around an octamer of histone proteins. In the last two decades, it has 
been shown that nucleosomes can repress transcription and be directly linked to 
transcriptional activation (Akey and Luger, 2003; Khorasanizadeh, 2004). A layer at 
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which regulation of transcription can be exerted has been appreciated by the 
identification of a number of coactivators that seem to affect chromatin structure, 
making the DNA accessible to the transcription machinery. Two related remodeling 
complexes have been described in yeast: The SWI/SNF complex, also conserved in 
mammalian cells, and the RSC (remodeling the structure of chromatin) complex 
(Cairns et al., 1994; Peterson et al., 1994; Wang et al., 1996). One of the most 
conserved elements of this complex is the SWI2/SNF2 protein (termed brg-1, or 
brahma-related gene-1 in humans), which contains the ATPase activity that remodels 
the nucleosomes (Khavari et al., 1993; Laurent et al., 1993). The SWI2/SNF2-family 
of DEAD/H ATPases and DNA helicases contains furthermore many members that 
play roles in DNA repair or recombination, chromosome segregation and cell cycle 
progression (Pollard and Peterson, 1998).  
 
 
2) Histone modifying coactivators 
modifying coactivators includes proteins that A different group of chromatin 
enzymatically modify histones. Since the early discovery of histone acetylation 
(Allfrey et al., 1964), the hypothesis has been put forward that the rate of 
transcriptional activity is directly linked to the grade of histone acetylation (Pazin and 
Kadonaga, 1997). Yeast GCN5, the first coactivator identified to exhibit histone 
acetylase (HAT) activity (Brownell et al., 1996), leads to hyperacetylation of lysine 
residues in the short amino-terminal domain of free histones and inhibits the higher 
order folding of nucleosomes. As a consequence, specific promoter areas of genes are 
accessible for the transcription machinery. These findings have received further 
support by the identification of the mammalian ortholog p/CAF (Yang et al., 1996b) 
and other coactivators with HAT activity like CBP, the adenovirus E1A binding 
protein p300 (Bannister and Kouzarides, 1996; Ogryzko et al., 1996) and TAFII250 
(Mizzen et al., 1996). The yeast p/CAF and GCN5 have been shown to exist as big 
multisubunit coactivator complexes named ADA or SAGA complexes (Grant et al., 
1997; Grant et al., 1998). They contain several different components like ADA 
proteins but also TBPs and TAFs, and they connect nuclear receptors to the basal 
transcription machinery. Whereas the mammalian counterpart also contains ADA and 
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TAF proteins (Ogryzko et al., 1998), the interaction to the core machinery has not yet 
been shown. 
The ubiquitously expressed CBP and its functional homolog p300 serve as ligand-
dependent coactivators for several nuclear receptors (Almlof et al., 1998; Smith et al., 
1996) and other transcription factors like CREB (Nakajima et al., 1996). Studies have 
shown that p300/CBP interact with other nuclear receptor coactivators like SRC-1 
(Kamei et al., 1996; Yao et al., 1996) or coactivator complexes like the P/CAF 
(p300/CBP associated factor) mutliprotein complex (Yang et al., 1996b). 
Interestingly, p300/CBP and P/CAF do not only acetylate histones, but also the 
general transcription factors and others (Imhof et al., 1997). 
 
The p160 family of coactivators contains proteins with the molecular mass of about 
160 kDa that interact with nuclear receptors in a ligand-dependent manner (Cavailles 
et al., 1994; Halachmi et al., 1994; Kurokawa et al., 1995). Biochemical and yeast 
two-hybrid assays have led to the identification of three members: SRC-1 (steroid 
receptor coactivator 1), SRC-2 and SRC-3 (Anzick et al., 1997; Chen et al., 1997; 
Hong et al., 1997; Kamei et al., 1996; Onate et al., 1995; Takeshita et al., 1997; 
Torchia et al., 1997). In addition to the highly conserved basic helix-loop-helix 
(bHLH) PAS domain, that can be found in all family members, SRC-1 and SRC-3 
possess a weak intrinsic HAT activity. The importance of this HAT activity is not 
clear, given that SRC-1 also interacts with and recruits other coactivators that posses 
enzymatic activities, like the histone acetylase CBP and the methyltransferase 
CARM1 (Chen et al., 1999a; Kamei et al., 1996; Yao et al., 1996). The p160 family 
members interact not only with the AF-2, but also the AF-1 domain of nuclear 
receptors, as shown for SRC-1 and SRC-2, suggesting that they built a bridge between 
both activation domains (Alen et al., 1999; Bevan et al., 1999; Ma et al., 1999; Webb 
et al., 1998).  
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3) Bridging coactivators- the mediator complex 
One of the best characterized coactivator complexes is the mediator complex, 
identified initially in yeast (Kim et al., 1994). In mammalian cell systems, several 
similar mediator-type complexes have been isolated, also known as TRAP, DRIP, 
ARC complex, two smaller complexes CRSP and PC2 (Malik et al., 2000; Ryu et al., 
1999), and two complexes that may mediate a form of repression, SMCC and NAT 
(Boyer et al., 1999; Fondell et al., 1996; Gu et al., 1999; Naar et al., 1999; Rachez et 
al., 1998). It seems possible, that all of these complexes represent only subcomplexes 
of the same one mediator complex (reviewed in (Glass and Rosenfeld, 2000; Naar et 
al., 2001)). 
The members of the mediator complex do not exert a HAT or any other enzymatic 
activity, but enhance the transcriptional activity of several nuclear receptors like TR 
(Fondell et al., 1999) and VDR (Rachez et al., 1998), as well as of other factors such 
as SREBP-1a and Sp1 (Naar et al., 1999). The ability to interact with the RNA 
polymerase II implements a role as bridging complex to the basal transcription 
machinery (Rachez et al., 1999). Disruption of the common component TRAP220 
leads to embryonic lethality in mice, which suggested that the ligand-dependent 
interaction of the mediator complex with nuclear receptors is dependent on TRAP220 
(Treuter et al., 1999; Yuan et al., 1998).  
 
The reason for the identification of so many different complexes (i.e. ATP remodeling 
complexes, HAT complexes, mediator, and others) is not yet fully understood, but 
Glass and Rosenfeld (Glass and Rosenfeld, 2000) have proposed that the different 
coactivator complexes may act sequentially, combinatorially or in parallel at different 
promoters (see figure 4). 
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Figure 4. Utilization of multiple coactivator complexes. 
(A) Sequential recruitment to the same promotor sequence. In this model, one coactivator 
complex could be necessary to prepare for the next. (B) Combinatorial recruitment of several 
coactivator complexes could be required for physiologic levels of expression on specific 
promotors. (C) Parallel utilization of coactivator complexes describes the recruitment of 
different coactivator complexes in response to distinct signaling pathways or in different 
tissues. (Adapted from Glass and Rosenfeld, 2000). 
 
 
4) Other coactivators of transcription 
Some coactivators cannot be classified in any of the described groups yet. The 
essential yeast gene Rsp5 and its human homolog NEDD4 have been demonstrated to 
enhance GR and PR transcription in yeast and mammalian cells in vitro (Imhof and 
McDonnell, 1996). Subsequent studies have revealed that NEDD4 ubiquitinates the 
largest subunit of RNA polymerase II in vitro and possibly mediates its UV-induced 
proteolytic degradation by the proteosome (Beaudenon et al., 1999). Another 
coactivator with ubiquitination capacity is the E6-associated protein E6-AP 
(Huibregtse et al., 1991), which seems to interact with NEDD4 to regulate 
transcriptional activation of steroid receptors by ubiquitin-ligase complexes 
(McKenna et al., 1998). 
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SRA (steroid receptor RNA activator) represents a nuclear receptor coactivator 
different from all known coregulators (Lanz et al., 1999). It functions as a RNA 
transcript, and interacts with the AF-1 domain of nuclear receptors in the absence of 
ligands. Giguere and coworkers have also suggested a ligand dependent interaction 
with the AF-2 of nuclear receptors, like classical coactivators, and the regulation by 
MAPK pathways (Deblois and Giguere, 2003). Interestingly, SRA seems to be 
recruited by SRC-1 and to furthermore interact with another uncommon family of 
coactivators, the DEAD-box conatining RNA helicases p72 and p68 (Lanz et al., 
1999; Watanabe et al., 2001), to acts as a bridge for the AF-1 and AF-2 domain 
activity of nuclear receptors. 
 
 
The PGC-1 family: inducible, tissue-specific coactivators 
 
Structural features of PGC-1α 
PGC-1 or PGC-1α, as it has been renamed after the identification of its homologues, 
was the founder of a new group of coactivators. It does not posses any enzymatic 
activity, but shows several interesting features (see figure 5). At the N-terminus of 
PGC-1α lies a potent acidic transactivation domain. PGC-1α contains three leucine-
rich LXXLL motifs, L1, L2 and L3 that reside in predicted α-helices. L1 is located in 
the acidic N-terminal transcriptional activation domain and is conserved between the 
PGC-1α family members (Kressler et al., 2002). Interestingly, Mutation of the L1 
motif strongly influenced the transactivation function, which suggested that it is part 
of a region that is important for the interaction with other factors (Kressler et al., 
2002; Puigserver et al., 1999). Leucine motifs L2 and L3 reside in two nuclear 
receptor interaction domains (NIDs). Motif L2 in particular serves as the major 
interaction surface for GR ER, PPARs, RXR, LXR and probably others (Delerive et 
al., 2002; Knutti et al., 2001; Oberkofler et al., 2003; Tcherepanova et al., 2000; Vega 
et al., 2000). Furthermore, mutations in motifs L2 and L3 have been shown to 
increase PGC-1α transcriptional activity possibly by disruption of the interaction with 
a repressor (Knutti, 2001, see later section). Besides the described L2 and L3 motifs, 
PGC-1α harbours other interaction domains, proposed to bind PPARγ, NRF-1 and the 
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muscle-specific transcription factor MEF2C, which are not yet well defined ((Michael 
et al., 2001; Puigserver et al., 1998; Wu et al., 1999), see figure 5). 
 
At the C terminus, PGC-1α harbours two motifs that are atypical for coactivators: a 
serine/arginine-rich (RS) domain and an RNA recognition motif ((RRM); (Knutti et 
al., 2000)). Strikingly, both RRM and RS domains are characteristic features of SR 
splicing factors, components and/or regulators of the spliceosome (reviewed in 
Graveley, 2000; Hastings and Krainer, 2001; Reed and Magni, 2001). RRM motifs 
determine substrate specificity and can interact with RNA as well as other proteins, 
while the RS domains are shown to be important for protein-protein interactions. 
Although the mechanism is not yet understood, PGC-1α has been suggested to be 
involved in RNA processing (Monsalve et al., 2000). Three different observations, 
made by Monsalve and coworkers, support this PGC-1α function: First, PGC-1α, 
through its C-terminal domain, associates with several splicing factors, SRp75, SRp55 
and SRp40 and the elongating form of RNA polymerase II. Second, 
immunofluorescence studies suggest that PGC-1α colocalizes with splicing factors in 
nuclear specles. Third, PGC-1α seems to modulate the processing of a fibronectin 
minigene. The current model for the mechanism by which PGC-1α regulates gene 
expression proposes therefore that PGC-1α couples transcription and pre-mRNA 
splicing: after the recruitment of PGC-1α on a specific target gene by a nuclear 
receptor, PGC-1α seems to bind to SRC-1, CBP, and possibly the mediator complex 
(Puigserver et al., 1999; Surapureddi et al., 2002; Wallberg et al., 2003). Next, it is 
suggested that CBP induces chromatin remodelling, whereas the mediator complex 
bridges to the basic transcription machinery. The N-terminus of PGC-1α possibly also 
binds to polymerase II (CTD; (Monsalve et al., 2000). Finally, PGC-1α is proposed to 
interact with the elongation form of polymerase II, and to regulate mRNA splicing 
(Monsalve et al., 2000). However, it has to be emphasized here, that although the 
interactions between these molecules has been demonstrated, additional experiments 
are still needed to confirm this model. 
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P
In contrast to many coactivators
in a tissue-specific manner and induced by specific metabolic signals. PGC-1α 
expression is highest in tissues with a high density of active mitochondria, like heart, 
skeletal muscle, brown adipose tissue (BAT), kidney, liver and brain (Esterbauer et 
al., 1999; Knutti et al., 2000; Puigserver et al., 1998). In addition, PGC-1α is induced 
in physiologic states that display specific energy demands, such as exposure to cold, 
fasting and physical exercise. (Goto et al., 2000; Herzig et al., 2001; Lehman et al., 
2000; Puigserver et al., 1998)  
 
P
Adaptive thermogenesis is a process tight
and energy expenditure. This programme is switched on in response to exposure to 
cold and overfeeding, and leads to the production of heat instead of energy through 
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the uncoupling of the respiratory chain (reviewed in Puigserver and Spiegelman, 
2003). Interestingly, PGC-1α is strongly induced in the brown fat and muscle (i.e. 
thermogenic tissues) of mice upon exposure of the animals to cold. Overexpression 
studies reveal that PGC-1α is capable of upregulating molecular components of the 
adaptive thermogenesis, e.g. the UCPs (uncoupling proteins), a process likely to 
depend on the interaction of PGC-1α with PPARα , PPARγ, RAR and probably TR 
(Puigserver et al., 1998). 
 
PGC-1α regulates mitochondrial biogenesis in response to specific signals 
al content 
GC-1α function in glucose metabolism 
pregulation has been observed, is in the liver 
Mitochondria provide cellular energy in the form of ATP. The mitochondri
and respiration efficiency vary greatly from cell type to cell type and reflect the 
energy demand defined by the physiological status of the cell (reviewed in Moyes and 
Hood, 2003). The modulation of mitochondrial functions is a complex process, which 
requires the coordinate expression of mitochondrial and nuclear encoded proteins. 
Studies have shown that PGC-1α levels are increased after exercise in muscle, a 
situation with high energy requirements (Goto et al., 2000). Furthermore, PGC-1α 
upregulation is detected in the heart of mice directly after birth, shortly before a 
strong increase of mitochondrial biogenesis and oxidative metabolism (Lehman et al., 
2000). Ectopic expression of PGC-1α in adipocytes, myocytes and cardiomyocytes 
induces the biosynthesis of mitochondria and increases cellular respiration (Goto et 
al., 2000; Lehman et al., 2000; Puigserver et al., 1998; Wu et al., 1999). PGC-1α 
seems to regulate mitochondrial biogenesis in adipocytes and myocytes through the 
induction and coactivation of NRF-1, and possibly NRF-2, which enhance the 
expression of key factors in mitochondrial transcription and replication, such as 
mtTFA (Wu et al., 1999).  
 
P
An additional situation, where PGC-1α u
and heart of fasted animals (Lehman et al., 2000; Yoon et al., 2001). In the fasting 
state, gluconeogenesis is increased in the liver so as to ensure glucose availability to 
tissues like the brain. Overexpression of PGC-1α induces the expression of PEPCK 
and glucose-6-phosphatase, two key enzymes of gluconeogenesis, through the 
coactivation of HNF4, GR and FOXO1 (Herzig et al., 2001; Puigserver and 
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Spiegelman, 2003; Yoon et al., 2001). Additional studies reveal that PGC-1α may 
also control the glucose uptake in peripheral tissues, through the induction of the 
insulin-sensitive glucose transporter GLUT4 in muscle (Michael et al., 2001). This 
induction may be mediated through the interaction with MEF2C, a muscle and heart 
specific transcription factor. The effect of PGC-1a on GLUT4 is however not yet 
clear, as GLUT4 is reported to be down-regulated in the muscle of transgenic mice 
overexpression PGC-1α (Miura et al., 2003). 
 
GC-1α is involved in diabetes 
sing glucose production, PGC-1α levels have been 
egulation of PGC-1α activity 
orally and spatially defined manner. Regulation has 
P
Consistent with PGC-1α increa
reported to be raised in the livers of modeldiabetic mice (Yoon et al., 2001). Genetic 
studies indicate further that mutations in the PGC-1α gene locus may increase the 
susceptibility of patients to diabetes type II (Ek et al., 2001; Hara et al., 2002). The 
contribution of PGC-1α to diabetes seem however to be complex. While increased 
PGC-1α levels and activity in liver may contribute to increased glucose, decreased 
PGC-1α levels and activity in muscle may also contribute to the diabetic phenotype. 
Mootha and coworkers (Mootha et al., 2003) adopted recently a very elegant approach 
with the help of expression profiling and new in silico-techniques, to identify the 
oxidative phosphorylation genes (OXPHOS) as a coordinately downregulated gene 
set in muscle biopsies of diabetes patients. Interestingly, PGC-1α expression seemed 
to be also repressed in these patients, implying a role for PGC-1α in the 
downregulation of mitochondrial biogenesis and the decreased energy expenditure 
during diabetes. (Mootha et al., 2003; Patti et al., 2003). 
 
 
R
PGC-1α is upregulated in a temp
to be tight, since both increased and decreased levels could be contributing to diseases 
like diabetes. This leads to the question, which signalling pathways are involved in 
the regulation of PGC-1α. 
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Regulation during adaptive thermogenesis 
gulated by the β-adrenergic receptor in 
echanisms regulating PGC-1α in mitochondrial biogensis 
 between MEF2 and the 
he regulation of PGC-1α in glucose metabolism 
agon, which is acting through the 
osttranslational mechanisms regulating PGC-1α 
monstrated that PGC-1α is also 
regulated by posttranslational mechanisms (Knutti et al., 2001; Puigserver et al., 
Initial studies showed PGC-1α to be re
response to cold (Boss et al., 1999; Puigserver et al., 1998). PGC-1α levels are also 
regulated by the adipocyte-derived hormone leptin, which regulates food uptake and 
energy expenditure and counts as an important factor controlling adaptive 
thermogenesis (Ahima and Flier, 2000). Interestingly, PGC-1α levels are decreased in 
mice that are leptin-deficient or not responsive to leptin, and upregulated in 
hyperleptinemic rats (Kakuma et al., 2000). 
 
M
Studies in transgenic mice have revealed a complex interplay
histone-deacetylase HDAC5 that lead to the regulation of PGC-1α expression and 
mitochondrial biogenesis in myocytes, possibly in response to CaMK IV (Czubryt et 
al., 2003). In response to exercise, Ca2+ levels rise in muscle cells, inducing 
calcineurin and CaMK IV. Interestingly, PGC-1α levels are induced in transgenic 
mouse lines expressing constitutively active CaMK IV (Wu et al., 2002). Further 
studies have led to the proposal of an autoregulatory loop, in which CREB 
phosphorylated by CaMK IV and MEF2 activated by calcineurin A bind to the PGC-
1α promoter, and in co-operation with PGC-1α itself, lead to an increase in PGC-1α 
expression (Handschin et al., 2003). 
 
T
The main regulators of the fasting state are gluc
cAMP pathway, and glucocorticoids. After cAMP levels rise, protein kinase A (PKA) 
exerts increased activity and activates the cAMP-response element binding protein 
(CREB). The treatment of hepatic cells with cAMP lead to an upregulation of PGC-
1α, which is further potentiated by glucocorticoids (Yoon et al., 2001). The PGC-1α 
promoter harbors binding sites for CREB and seems to be regulated by this factor 
(Herzig et al., 2001).  
 
P
Studies from our lab and from others have de
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2001). Interestingly, the stress-responsive kinase p38 seems to phosphorylate PGC-1α 
on three residues close to the nuclear receptor interaction domains harboring the L2 
and L3 motif. Several findings suggest that this phosphorylation induces the release of 
a molecular repressor of PGC-1α (Knutti et al., 2001): 1) mutation of the L2 and the 
L3 motifs lead to icreased PGC-1α activity; 2) coexpression of a shorter version of 
PGC-1α that has motifs L2 and L3 competes for repressor binding and increases 
PGC-1α activity; 3) a constitutively active upstream kinase of p38 increases the 
activity of wild-type, but not of an L2/3A mutant PGC-1α (Knutti et al., 2001). 
Recent studies by the Spiegelman group have identified the p38-sensitive, L2/3 
interacting repressor as the coregulator p160 myb (Fan et al., 2004). Moroever, 
studies by Ichida et al have proposed the orphan receptor ERRα, which also interacts 
with L2 and L3, to act as a repressor of PGC-1α (Ichida et al., 2002).  
 
 
PGC-1 family members 
GC-1-related coactivator (PRC), the first homologue of PGC-1α, was identified due 
erminus (Andersson and Scarpulla, 2001). Even though the 
 PERC (human) was 
loned by us and others (Kressler et al., 2002; Lin et al., 2002). Sequences of PGC-
P
to its homology in the N-t
overall sequence similarity with PGC-1α is quite low, the domain pattern is highly 
similar. Both coactivators contain the N-terminal acidic transactivation domain, the 
nuclear receptor interaction (LXXLL) motif, the proline rich region, the RS domain 
and the RNA binding domain. Elucidation of the expression levels showed that PRC 
is ubiquitously expressed with higher levels in skeletal muscle and heart (Andersson 
and Scarpulla, 2001). One common function of PGC-1α and PRC is the interaction 
with NRF1 and the induction of mitochondrial biogenesis. A distinctive characteristic 
is that PRC expression is not regulated by exposure to cold, but rather during the cell 
cycle, suggesting a role for PRC distinct from that of PGC-1α. 
 
Recently, a second homologue named PGC-1β (mouse) or
c
1α, β and PRC display around 45 to 46 % (over 450 aa) similarity in the C-terminus; 
whereas all three proteins contain a RNA recognition motif, PGC-1β does not contain 
an RS domain. The N-terminus of all three proteins shows a conserved L1 motif and a 
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conserved nuclear receptor interaction domain (L2). In addition, PGC-1β harbors an 
additional, unique to PGC-1β NID. RNA expression analysis shows PGC-1β to be 
similarly expressed as PGC-1α, with high levels in heart, skeletal muscle, BAT and 
medium levels in liver, brain, WAT, adrenal gland and kidney (Kressler et al., 2002; 
Lin et al., 2002). Strikingly, PGC-1β does not show a specific upregulation in 
response to cold or fasting. 
 
We have observed that PGC-1β, in contrary to PGC-1α, shows much higher 
pecificity in the interaction with nuclear receptors (Kressler et al., 2002). PGC-1β, or 
her oxygen consumption and are resistant to 
s
PERC (PGC-1 related estrogen receptor coactivator) shows a high preference in 
enhancing the activity of ERα, over that of many other nuclear receptors. Moroever, 
PGC-1β converted tamoxifen from an antagonist to an agonist of ERα in osteoblast 
cells in a cell-type and promoter-specific manner. Based on these findings, we have 
proposed a role for PGC-1β in the regulation of estrogen signaling. In disagreement 
with these findings, other labs report that PGC-1β can coactivate PPARγ, TRβ, GR 
and HNF4 (Lin et al., 2002; Meirhaeghe et al., 2003), and more strikingly, NRF-1 
(Lin et al., 2002). Finally, we and others have seen that PGC-1β is an effective 
coactivator of the orphan receptor ERRα ((Kamei et al., 2003), Kressler unpublished). 
Interestingly, ectopically expressed PGC-1β like PGC-1α can also induce 
mitochondrial biogenesis in myoblasts (Meirhaeghe et al., 2003) and hepatocytes (Lin 
et al., 2002). PGC-1α- and PGC-1β-induced mitochondria do however show some 
functional differences, suggesting that the two coactivators have overlapping but not 
identical functions (St-Pierre et al., 2003). Studies in muscle of prediabetic and 
diabetic patients also showed increased levels of PGC-1β, besides PGC-1α and the 
OXPHOS genes (Patti et al., 2003).  
Consistent with a role of PGC-1β in controlling OXPHOS genes, transgenic mice 
overexpressing PGC-1β have a hig
highfat diet-induced, as well as genetically determined obesity. 
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Aim of my thesis 
 
Regulation of transcription is a highly complex process that requires the orchestrated 
collaboration of numerous factors operating at several different levels. Extracellular 
factors like steroid hormones activate nuclear hormone receptors, which are released 
by the chaperone complex, translocate to the nucleus, bind to regulatory DNA 
sequences, interact with chromatin and the basic transcription machinery via 
coactivators, and regulate transcription (reviewed in Aranda and Pascual, 2001). Any 
of the steps in this pathway are potential targets for regulation, by different 
phosphorylation cascades or other mechanisms (reviewed in Weigel, 1996). Nuclear 
receptors like GR are ubiquitously expressed and posses the ability to interact with 
several different coactivators, which themselves are also able to coactivate numerous 
different transcription factors (reviewed in Glass and Rosenfeld, 2000; McKenna et 
al., 1999; Naar et al., 2001). Increasing evidence over the last few years suggests that 
coactivators may provide specificity to the physiological responses mediated by 
nuclear receptors (reviewed in Knutti and Kralli, 2001; Puigserver and Spiegelman, 
2003).  
 
The basic hypothesis of my PhD thesis is that some of the target gene specificity in 
GR signaling, but also in the signaling of other receptors, is determined by the 
interaction with the specific coactivator PGC-1α. To test this hypothesis, we 
established a cell culture model system, where we could activate GR in the absence 
and presence of PGC-1α, and ask if PGC-1α enhances the expression of all GR target 
genes, or if the presence of PGC-1α would reroute GR to the regulation of specific 
cellular programs. Briefly, PGC-1α was introduced into osteoblast progenitor SAOS2 
cells that express no detectable levels of endogenous PGC-1α but have functional GR, 
and responses to glucocorticoids ± PGC-1α were analyzed by gene expression 
profiling on the Affymetrix U133A chips. The results could give information not only 
on how PGC-1α affects GR signaling, but also on potentially new programs regulated 
by PGC-1α in collaboration with other nuclear receptors expressed in these cells. 
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Summary 
 
The estrogen-related receptor alpha (ERRα) is one of the first orphan nuclear 
receptors identified. Still, we know little about the mechanisms that regulate its 
expression and its activity. In this study, we show that the transcriptional coactivator 
PGC-1, which is implicated in the control of energy metabolism, regulates ERRα at 
two levels. Firstly, PGC-1 induces the expression of ERRα. Consistent with this 
induction, levels of ERRα mRNA in vivo are highest in PGC-1 expressing tissues, 
such as heart, kidney, and muscle, and up-regulated in response to signals that induce 
PGC-1, such as exposure to cold. Secondly, PGC-1 interacts physically with ERRα 
and enables it to activate transcription. Strikingly, we find that PGC-1 converts ERRα 
from a factor with little or no transcriptional activity to a potent regulator of gene 
expression, suggesting that ERRα is not a constitutively active nuclear receptor but 
rather one that is regulated by protein ligands, such as PGC-1. Our findings suggest 
that the two proteins act in a common pathway to regulate processes relating to energy 
metabolism. In support of this hypothesis, adenovirus-mediated delivery of small 
interfering RNA for ERRα, or of PGC-1 mutants that interact selectively with 
different types of nuclear receptors, shows that PGC-1 can induce the fatty acid 
oxidation enzyme MCAD in an ERRα-dependent manner. 
 
 
Introduction 
 
The nuclear receptor ERRα was identified in 1988 as a protein that shares significant 
sequence similarity to known steroid receptors, such as the estrogen receptor (Giguere 
et al., 1988). ERRα and its relatives ERRβ and ERRγ form a small family of orphan 
nuclear receptors that are evolutionarily related to the estrogen receptors ERα and 
ERβ, and whose in vivo function is still unclear [(Giguere et al., 1988; Hong et al., 
1999), reviewed in (Giguere, 2002)]. The three ERRs recognize and bind similar 
DNA sequences, which include estrogen response elements (EREs) recognized by 
ERα, as well as extended ERE half-sites that have been termed ERR response 
elements (Johnston et al., 1997; Sladek et al., 1997; Vanacker et al., 1999a; Vanacker 
et al., 1999b). Despite their high similarity to ligand-dependent receptors, ERRs seem 
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to regulate transcription in the absence of known natural lipophilic agonist ligands. 
Searches for ligands have so far identified only synthetic antagonists. 4-
Hydroxytamoxifen, which binds ERRβ and ERRγ but not ERRα, and 
diethylstilbestrol, which binds all three ERRs, inhibit the ability of ERRs to activate 
transcription (Coward et al., 2001; Tremblay et al., 2001). In support of the 
pharmacological data, elucidation of the crystal structure of the ERRγ LBD suggests 
that the ERRs assume the conformation of ligand-activated nuclear receptors in the 
absence of ligand (Greschik et al., 2002), and that agonist ligands may not be 
required. These findings raise the question of how the activity of these nuclear 
receptors is regulated. 
 
One way to control orphan receptor activity is to express the receptors in a 
temporally- and spatially-restricted manner. ERRα is expressed widely, however, 
particularly high ERRα mRNA levels have been noted at sites of ossification during 
development, and in heart, kidney, brown fat, and muscle in adults [(Bonnelye et al., 
1997b; Bonnelye et al., 1997c; Shi et al., 1997; Shigeta et al., 1997; Sladek et al., 
1997; Vanacker et al., 1998; Vega and Kelly, 1997), reviewed in (Giguere, 1999)]. 
Thus, differential expression of ERRα may contribute to the regulation of ERRα-
mediated transcription. The mechanisms and signals that regulate ERRα expression 
are not clear.  
 
The activity of orphan nuclear receptors may also be regulated at the protein level, via 
interactions with specific cofactors. ERRα has been reported variably as an activator, 
a repressor, or a DNA-binding factor with little activity, suggesting that cellular 
factors determine the ability of the ERRα protein to activate transcription (Bonnelye 
et al., 1997b; Johnston et al., 1997; Kraus et al., 2002; Lu et al., 2001; Sladek et al., 
1997; Vanacker et al., 1998; Vanacker et al., 1999b; Xie et al., 1999; Zhang and Teng, 
2000). Possible candidates for exerting such control are coactivators that interact with 
ERRα such as members of the p160 family of coactivators. Overexpression of p160 
coactivators can indeed enhance ERRα mediated transcription at model reporters (Lu 
et al., 2001; Xie et al., 1999; Zhang and Teng, 2000). However, ERRα shows weak 
transcriptional activity in cells that express endogenous p160 coactivators (Lu et al., 
2001; Sladek et al., 1997), suggesting that additional cofactors must be important. 
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PGC-1 is a transcriptional coactivator of many nuclear receptors, as well as specific 
other transcription factors like the nuclear respiratory factor 1 (NRF-1) and members 
of the MEF2 (myocyte enhancer factor 2) family (Knutti et al., 2000; Michael et al., 
2001; Puigserver et al., 1998; Tcherepanova et al., 2000; Vega et al., 2000; Wu et al., 
1999; Yoon et al., 2001). PGC-1 is expressed in a tissue-selective manner, with the 
highest mRNA levels found in heart, kidney, brown fat and muscle (Esterbauer et al., 
1999; Knutti et al., 2000; Larrouy et al., 1999; Puigserver et al., 1998). Moreover, 
PGC-1 expression is induced in a tissue-specific manner by signals that relay 
metabolic needs. Exposure to cold leads to the induction of PGC-1 in brown fat and 
muscle, starvation induces PGC-1 expression in heart and liver, and physical exercise 
increases its expression in muscle (Goto et al., 2000; Herzig et al., 2001; Lehman et 
al., 2000; Puigserver et al., 1998; Yoon et al., 2001). PGC-1 function has been 
implicated in the control of energy metabolism, as PGC-1 expression stimulates 
mitochondrial biogenesis and modulates mitochondrial functions and utilization of 
energy [(Lehman et al., 2000; Vega et al., 2000; Wu et al., 1999), reviewed in (Knutti 
and Kralli, 2001)]. The nuclear receptors PPARγ, TRα, PPARα, HNF4 and GR, and 
the transcription factors NRF-1, MEF2C, and MEF2D interact with, and may recruit 
PGC-1 to the promoters of target genes that execute the metabolic effects of PGC-1. 
Additional transcription factors are likely to contribute to PGC-1 function. 
 
In the study presented here, we show that PGC-1 regulates, first, the expression of 
ERRα mRNA and, second, the transcriptional activity of the ERRα protein. Our 
findings indicate that ERRα by itself is a poor activator of transcription, and that 
PGC-1 fulfils a specific role as a cofactor required for ERRα function. The 
interactions of PGC-1 and ERRα suggest that the two proteins act in a common 
pathway. 
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Experimental procedures 
 
Plasmids and Adenoviral vectors. Expression plasmids for wild-type and mutant 
human PGC-1, and luciferase reporters pGK1, p∆LUC and p∆(cERE)x2-Luc 
(referred in this study as pERE-Luc) have been described (Knutti et al., 2001; 
Kressler et al., 2002). pSG5-mERRα for the expression of full-length mouse ERRα 
was a gift of J.-M. Vanacker (Bonnelye et al., 1997b). The human ERRα ligand 
binding domain (LBD) was amplified by PCR, using HeLa cDNA and primers 
CGAATTCATATGGGGCCCCTGGCAGTCGCT  
and GCTCTAGACTATCAGTCCATCATGGCCTC, and cloned as an Nde I - Xba I 
fragment into pcDNA3/Gal4DBD (Kressler et al., 2002). The plasmid pSiERRα was 
generated by cloning the annealed primers GAT CCC CGA GCA TCC CAG GCT 
TCT CAT TCA AGA GAT GAG AAG CCT GGG ATG CTC TTT TTG GAA A 
(ERRα907/927-s) and AGC TTT TCC AAA AAG AGC ATC CCA GGC TTC TCA 
TCT CTT GAA TGA GAA GCC TGG GAT GCT CGG G (ERRα907/927-a) into 
pSUPER (Brummelkamp et al., 2002).Yeast expression vectors for Gal4-PGC-1 (aa 
91-408, wild type or mutants) were generated by subcloning the PGC-1 cDNA 
fragments encoding aa 91 to 408 in the vector pGBKT7 (Clontech). Plasmid pAS2-
ERRαLBD expresses the ERRαLBD fused to the Gal4 DBD and was generated by 
subcloning the NdeI - XbaI fragment encoding the ERRα LBD into pAS2-1 
(Clontech). pGBKT7/hERα.280C expresses the human ERα LBD (starting at aa 280) 
fused to the Gal4 DBD. Human PPARγ (full-length), RXRα (starting at aa 10) and 
ERRα (starting at aa 221) fused to the Gal4 activation domain (AD) were isolated in a 
yeast two-hybrid screen, and were expressed from the vector pACT2 (Clontech). 
 
Adenoviral vectors were generated by CRE-lox mediated recombination in CRE8 
cells (Hardy et al., 1997). Briefly, CRE8 cells were transfected with 3 µg of purified 
Ψ5 adenovirus DNA and 10 µg of pAdlox DNA shuttle plasmid (Hardy et al., 1997) 
carrying the cDNA for human PGC-1 (wild-type or mutant) downstream of the CMV 
promoter. For the expression of siRNA from adenoviruses, the CMV promoter and 
SV40 polyadenylation sequences of pAdlox were replaced by a DNA fragment 
harboring the expression cassette of pSUPER (Brummelkamp et al., 2002) to generate 
AdSUPER. The viral vector AdSiERRα expresses the same siRNA as pSiERRα. All 
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viruses were plaque-isolated to obtain single clones, titered by serial dilution in CRE8 
cultures that were grown under 0.6% Noble agar overlay, and used as freeze-thaw 
lysates.  
 
Cell lines, Infections, and Transfections. 293, CRE8 (Hardy et al., 1997), HepG2, 
SAOS2-GR(+)(Rogatsky et al., 1997), and HtTA-1 [derived from HeLa; (Knutti et 
al., 2001)] cells were cultured in Dulbecco’s modified Eagle’s medium supplemented 
with 9% fetal calf serum. When measuring ERRα- and GR-mediated transcription, 
cells were grown in medium with charcoal-stripped serum. SAOS2-GR(+) and CRE8 
cultures were supplemented with G418 (400 µg/ml). For infection, cells were plated 
at 2x105 per well in a 6-well dish. The next day, viruses were added at a multiplicity 
of infection (moi) of 40 or 100, as indicated in figure legends, for 2 h. Cells were then 
washed and replenished with fresh medium. For transfections, cells were incubated 
with a calcium phosphate/DNA precipitate. Transfections included 0.2 µg of p6RlacZ 
for normalization of transfection efficiency, and 1 µg of the luciferase reporters 
p∆Luc, pERE-Luc or pGK1. The amounts of expression plasmids per transfection 
were: 0.5-1 µg of pcDNA3 or pcDNA3/HA-PGC-1; 1 µg of pSG5 or pSG5-mERRα; 
1 µg of pcDNA3/Gal4 DBD or pcDNA3/Gal4-ERRαLBD; 1 µg of pSUPER or 
pSiERRα for siRNA. Cell lysates were prepared 40 to 48 h after transfection and 
assayed for luciferase activity as described (Knutti et al., 2000). Luciferase values 
normalized to the β-gal activity are referred to as luciferase units.  
 
RNA analysis. Total RNA was isolated using the Trizol reagent, and checked for its 
integrity by agarose gel electrophoresis and ethidium bromide staining. RNA was 
converted to cDNA and specific transcripts were quantitated by real-time PCR using 
the Light Cycler system (Roche Diagnostics) as described previously (Kressler et al., 
2002). A melting curve from 65 to 95°C (0.05°C/sec) at the end of the reaction was 
used to check the purity and nature of the product. In all cases, a single PCR product 
was detected. The sequences of the primers and the sizes of the PCR products were as 
follows: AAGACAGCAGCCCCAGTGAA (exon 4)  
and ACACCCAGCACCAGCACCT (exon 5) for human ERRα (product 254 bp); 
TGTGGAGGTCTTGGACTTGGA (exon 4/5)  
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and TCCTCAGTCATTCTCCCCAAA (exon 6) for MCAD (product 173 bp); 
CTGTGCCAGCCCAGAACACT (exon 4) and TGACCAGCCCAAAGGAGAAG 
(exon 5) for 36B4/ribosomal protein P0 large (product 201 bp); 
CGGGATGAGTTGGGAGGAG (exon 1)  
and CGGCGTTTGGAGTGGTAGAA (exon 2) for p21 (product 212 bp); 
GGAGGACGGCAGAAGTACAAA (exon 4) and GCGACACCAGAGCGTTCAC 
(exon 5) for mouse ERRα (product 130 bp); primers for mouse PGC-1 and actin have 
been described in (Kressler et al., 2002).  
 
Western analysis. Cells were lysed in 100 mM Tris pH 7.5, 1% NP40, 250 mM NaCl, 
1 mM EDTA buffer. Cell lysates were subjected to western analysis using antibodies 
against the HA epitope (HA.11, BAbCO), ERRα (Johnston et al., 1997), or PGC-1 
(sera from rabbits immunized with a PGC-1 fragment bearing aa 1-293). 
 
Yeast two-hybrid interaction assays. Yeast carrying Gal4-responsive β-gal reporters 
(CG1945xY187, Clontech) were transformed by the lithium acetate transformation 
method with expression plasmids for Gal4 DBD and Gal4-AD fusion proteins. Single 
transformants were grown to stationary phase, diluted 1:20 in selective media, grown 
for an additional 14 h at 30°C in 96-well plates, and assayed for β-gal activity as 
described (Kressler et al., 2002) 
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Results 
 
PGC-1 induces ERRα expression. To identify genes that are induced by PGC-1 and 
that could execute the cellular processes activated by PGC-1, we have compared the 
RNA profiles of SAOS2-GR(+) cells infected with adenoviral vectors expressing 
PGC-1, to those of cells infected with control vectors expressing β-gal or GFP. 
Analysis of the RNA profiles after hybridization to high density oligonucleotide 
arrays (data not shown) identified the orphan nuclear receptor ERRα as a gene that is 
induced strongly by PGC-1. Expression of PGC-1 led to the induction of ERRα at the 
RNA and protein level in SAOS2-GR(+) cells, as well as in HtTA-1, HepG2, and 293 
cells (Fig. 1A, and data not shown). Evaluation of protein levels by immunoblotting 
showed that the increase in the levels of ERRα protein followed closely the 
appearance of PGC-1 protein at different times after infection, suggesting that ERRα 
induction is an early event upon PGC-1 expression (Fig. 1B).  
 
ERRα mRNA levels have been reported to be high in PGC-1 expressing tissues, such 
as kidney, heart, muscle and brown adipose tissue (Esterbauer et al., 1999; Knutti et 
al., 2000; Larrouy et al., 1999; Puigserver et al., 1998; Shi et al., 1997; Shigeta et al., 
1997; Sladek et al., 1997; Vanacker et al., 1998; Vega and Kelly, 1997). Analysis of 
mRNA expression levels in tissues of adult mice shows that indeed ERRα levels 
correlate with PGC-1 mRNA levels (Fig. 1C). PGC-1 expression in some of these 
tissues is known to be induced in response to physiological signals, such as exposure 
to cold (Puigserver et al., 1998). Thus, to test the ability of PGC-1 to induce ERRα in 
vivo, we determined PGC-1 and ERRα mRNA levels in the brown fat and muscle of 
mice that were exposed to cold for 6 hours. As seen in Fig. 1D, the increase in PGC-1 
expression was accompanied by an increase in ERRα mRNA levels, suggesting that 
PGC-1 can also induce ERRα expression in vivo.  
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Figure 1. PGC-1 induces ERRα at the mRNA and protein level.  
(A, B) Cells were infected with either GFP (control) or PGC-1 expressing adenoviruses at a 
moi of 40 [SAOS2-GR(+)] or 100 (HtTA-1). (A) RNA was isolated 24 h (HtTA-1) or 48 h 
[SAOS2-GR(+)] after infection. Levels of ERRα mRNA were determined by quantitative 
RT-PCR, normalized to 36B4 levels, and expressed relative to levels in control cells. Data 
represent the mean ± standard deviation of four experiments performed in duplicates. Cell 
extracts prepared 24 h after infection were analyzed by immunoblotting with antibodies 
against PGC-1 (upper panel) or ERRα (lower panel). (B) Cell extracts prepared at the 
indicated times after infection of HtTA-1 cells with a PGC-1 expressing adenovirus were 
analyzed by immunoblotting with antibodies against PGC-1 (upper panel) or ERRα (lower 
panel). (-), extracts from uninfected HtTA-1 cells. (C, D) Levels of PGC-1 and ERRα mRNA 
in the indicated mouse tissues were determined by quantitative RT-PCR, and normalized to β-
actin levels. (C) Relative mRNA levels in tissues of a ~ 6 week-old female mouse. Levels in 
heart were set equal to 100 for each transcript. Data represent mRNA levels relative to 
expression in heart, and are the mean ± range of duplicate PCR reactions. SKM, skeletal 
muscle; ADG, adrenal gland. (D) Relative mRNA levels in brown fat and soleus muscle of 
four ~8-week-old male siblings, kept at 23 oC (M1, M2; control) or exposed to 4 oC for 6 
hours (M3, M4; cold). Data shown are the mean ± range of PGC-1 and ERRα mRNA levels 
normalized to β-actin levels in each RNA sample. 
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PGC-1 induces strongly ERRα-mediated transcription. The finding that PGC-1 
induces the expression of ERRα suggests that PGC-1 enhances also the activity of 
ERRα-regulated promoters. To test this, we transfected 293 cells with a PGC-1 
expression vector and a reporter that carries the luciferase gene under the control of 
the minimal ADH promoter with or without binding sites for ERRα (pERE-Luc and 
p∆Luc, respectively). PGC-1 enhanced strongly expression from the pERE-Luc 
reporter, in a manner dependent on the presence of the binding sites for ERRα (Fig. 
2A). Estradiol, tamoxifen or hydroxytamoxifen did not affect the enhancement by 
PGC-1 (data not shown), suggesting that it was not mediated by receptors that are 
regulated by these ligands and can recognize the same DNA binding site (e.g. ERα, 
ERβ, ERRβ or ERRγ). To confirm that endogenous, PGC-1-induced ERRα was 
mediating the effect of PGC-1 on the pERE-Luc reporter, we determined the effect of 
inhibiting the expression of ERRα. For this, cells were transfected with a vector 
expressing a small interfering (si) RNA specific for ERRα (pSiERRα) 
(Brummelkamp et al., 2002). Expression of the ERRα-specific siRNA led to a 
decrease in ERRα mRNA levels (Fig. 2B), and a decrease in the PGC-1 – mediated 
induction of the luciferase reporter, demonstrating that endogenous ERRα was 
required for the PGC-1 effect (Fig. 2C). In the absence of PGC-1, pSiERRα decreased 
ERRα expression (Fig. 2B) but had no effect on the pERE-Luc reporter (Fig. 2C), 
suggesting that in this context ERRα was not transcriptionally active.  
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Figure 2. PGC-1 induces ERRα-mediated transcription.  
(A) 293 cells were transfected with a luciferase reporter driven by either just the minimal 
ADH promoter (p∆Luc) or 2 EREs upstream of the minimal ADH promoter (pERE-Luc), and 
either the control vector pcDNA3 or a PGC-1 expression vector. Data are the mean ± standard 
deviation of luciferase activities from three experiments performed in duplicates. (B) 293 
cells were transfected with the empty vector pSUPER (Brummelkamp et al., 2002) or the 
vector expressing siRNA for ERRα (pSiERRα), and either pcDNA3 (+vector) or the PGC-1 
expression vector pcDNA3/HA-PGC-1 (+PGC-1). Transfection efficiency was 40-50%. RNA 
was prepared 48 h later. ERRα mRNA levels were determined by quantitative RT-PCR and 
normalized to levels of 36B4. Data are the average of two experiments performed in 
duplicates. (C) 293 cells were transfected with the pERE-Luc reporter, a control or PGC-1 
expression vector as indicated, and either the control pSUPER or the siRNA expressing 
pSiERRα. Data represent the mean ± standard deviation of luciferase activities from two 
experiments performed in duplicates. 
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PGC-1 activates ERRα at the protein level. PGC-1 interacts physically with many 
nuclear receptors and enhances their transcriptional activity [reviewed in (Knutti and 
Kralli, 2001)]. Thus, PGC-1 could also interact with ERRα. In this case, the increased 
ERRα-mediated transcription could be the combined result of PGC-1 inducing ERRα 
levels, and enhancing ERRα activity. To address this, we first asked if overexpression 
of ERRα would lead to the same phenotype as PGC-1 expression. If the only function 
of PGC-1 were to increase ERRα levels, we would expect that exogenous ERRα 
expression would mimic the PGC-1 effect. Surprisingly, overexpression of ERRα had 
very little effect on pERE-Luc (< 2-fold), suggesting that ERRα alone was not 
sufficient for the transcriptional activation of this reporter (Fig. 3A). Coexpression of 
PGC-1 with ERRα led to an increase in luciferase expression that was stronger than 
that seen with just endogenous ERRα, indicating that PGC-1 activated the 
exogenously introduced ERRα (Fig. 3A). 
 
To determine the effect of PGC-1 on the activity of ERRα directly, we evaluated the 
consequence of PGC-1 expression on the activity of a Gal4 DNA binding domain 
(DBD) - ERRα LBD chimera, using a Gal4-responsive luciferase reporter. In this 
context, endogenous ERRα does not interfere with the luciferase readout. As seen in 
Fig. 3B, Gal4-ERRα LBD by itself activated transcription modestly, ~2-fold, 
suggesting that the LBD of ERRα carries only a weak transcriptional activation 
function. Addition of PGC-1 converted the Gal4-ERRαLBD fusion to a strong 
activator of transcription, indicating that PGC-1 enables the transcriptional function of 
ERRα (Fig. 3B).  
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Figure 3. PGC-1 activates ERRα, which by itself is a weak activator of transcription.  
(A) 293 cells were transfected with the pERE-Luc reporter, a control or PGC-1 expression 
vector as indicated, and either the pSG5 vector (endogenous) or the pSG5-mERRα expression 
vector (+ERRα) (Vanacker et al., 1999b). Data are the mean ± standard deviation of 
luciferase activities from three experiments performed in duplicates. (B) 293 cells were 
transfected with the Gal4 responsive luciferase reporter pGK1, an expression vector for either 
the Gal4 DBD or a fusion of the ERRα LBD to the Gal4 DBD, and either vector alone or 
PGC-1 expression vector. Data are from one representative experiment performed in 
triplicates, and are expressed relative to the activity of Gal4-ERRαLBD in the absence of 
PGC-1.  
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ERRα interacts with PGC-1 via an atypical Leu-rich box. PGC-1 harbors three 
Leu-rich motifs, (L1, L2, and L3), one of which, (L2), bears the consensus LxxLL 
sequence present in many proteins that interact with the LBD of nuclear receptors. 
The L2 motif serves as the major binding site for many nuclear receptors, and 
mutations in L2 disrupt the interactions of PGC-1 with nuclear receptors tested so far 
(Knutti et al., 2001; Tcherepanova et al., 2000; Vega et al., 2000). Surprisingly, PGC-
1 harboring a mutant L2 (L2A) was still capable of interacting with ERRα in a yeast 
two-hybrid assay; in the same context, the L2A mutant was severely compromised for 
interaction with PPARγ, RXRα, and ERα (Fig. 4A,B). In previous studies, we had 
noted that the L3 site can mediate a weak interaction with the glucocorticoid receptor 
(Knutti et al., 2001). We thus tested the contribution of the L3 site to the PGC-
1/ERRα interaction. As seen in Fig. 4A and B, PGC-1 bearing a disruption of just L3 
(L3A) was also capable of interacting with ERRα, while the double L2/3A mutation 
abolished the interaction. Mutations in motif L1, alone or in combination with L2, had 
no effect on the physical interaction of PGC-1 with ERRα (data not shown). Thus, we 
concluded that motifs L2 and L3 can be used equivalently for physical interactions 
between PGC-1 and ERRα, while L2 is the preferred site for most other receptors 
(Fig. 4A & B).  
 
Next, we determined the requirement of the physical interaction between PGC-1 and 
ERRα for the activation of the ERRα LBD in mammalian cells, using the context of 
the Gal4-ERRαLBD chimera. Single mutations in either L2 or L3 did not compromise 
the PGC-1 effect (Fig. 4C), suggesting that interaction via either site is sufficient for 
activation of ERRα by PGC-1. The double L2/3A mutation abolished the activation, 
indicating that the physical interaction between the two proteins is necessary for the 
effect of PGC-1 on the ERRα LBD (Fig. 4C).  
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Figure 4. ERRα interacts with the L3 as well as the L2 site of PGC-1. 
 (A, B) Yeast two-hybrid assay. (A) Interactions between the L2/L3 containing PGC-1 
fragment (aa 91-408) fused to the Gal4 DBD, and the indicated receptors fused to the Gal4 
AD. Data are the mean ± standard deviation of βgal activities from four independent 
transformants. (B) Interactions between the LBD of ERRα or ERαto the Gal4 DBD (Gal4-
ERRα and Gal4-ERα), and full-length PGC-1 [wild type (wt) or L2/L3 mutants] fused to the 
Gal4 AD. Interaction with ERα was assayed in the presence of 10 µM 17β-estradiol. Data are 
the mean ± standard deviation of βgal activities from twelve yeast transformants. (C) 
Activation of the ERRα LBD in mammalian cells. 293 cells were transfected with the Gal4 
responsive luciferase reporter pGK1, the vector expressing the Gal4-ERRα LBD fusion, and 
either vector alone (−), PGC-1 wild type (wt), or the indicated PGC-1 mutants. Data are the 
mean ± standard deviation of luciferase activities from at least four experiments performed in 
duplicates. 
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PGC-1 can induce the expression of the endogenous gene MCAD in an ERRα - 
dependent manner. The ability of PGC-1 to induce ERRα expression and activity 
predicts that PGC-1 should also induce the expression of ERRα target genes. To test 
this, we determined the effect of PGC-1 on the RNA levels of a proposed ERRα 
target, the medium chain acyl-coenzyme A dehydrogenase (MCAD), an enzyme in 
fatty acid oxidation (Sladek et al., 1997; Vega and Kelly, 1997). As seen in Fig. 5, 
PGC-1 expression led to the induction of MCAD in HtTA-1 and SAOS2-GR(+) cells. 
To address whether the induction was mediated by ERRα, we asked if suppression of 
ERRα expression affected the response of MCAD to PGC-1. Infection of HtTA-1 
cells with adenoviruses that express ERRα-specific siRNA led to a decrease in ERRα 
mRNA levels (Fig. 5A), and a reduced induction of MCAD (Fig. 5B), consistent with 
ERRα mediating the PGC-1 effect at the MCAD promoter.  
 
The distinct utilization of the L3 site of PGC-1 for interaction with ERRα and not 
other receptors like GR, suggests that mutations in the L2 and L3 sites could be used 
to diagnose the type of nuclear receptors that mediate specific functions of PGC-1. 
Functions that are mediated by receptors utilizing the L2 site should be abrogated by 
the single PGC-1 mutation L2A, while functions that rely on ERRα should be 
disrupted only by the double L2/3A and not the single L2A mutation. To test this, we 
infected SAOS2-GR(+) cells that express GR from a stably-integrated locus, with 
adenoviruses expressing PGC-1, wild-type or mutant variants. As predicted, the 
glucocorticoid-dependent induction of the endogenous GR target p21 (Rogatsky et al., 
1997) was enhanced by both wild-type PGC-1 and the L3A mutant, but not by the 
L2A mutant (Fig. 5C). In contrast, induction of MCAD in the same cells was not 
affected by the L2A mutation and was only abolished by the double L2/3A mutation 
(Fig. 5D). These findings indicate that the L2 and L3 sites of PGC-1 are indeed used 
selectively by different nuclear receptors to recruit PGC-1 at their respective 
endogenous target genes. 
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Figure 5. PGC-1 induces the endogenous MCAD gene in an ERRα. 
(A, B) HtTA-1 cells were infected with either control (AdSUPER) or siERRα expressing 
(AdSiERRα) adenoviruses on day 1, and either GFP- or PGC-1-expressing adenoviruses on 
day 2. RNA was harvested on day 3, and mRNA levels for ERRα and MCAD were analyzed 
by quantitative RT-PCR, normalized to 36B4 levels, and expressed relative to levels in cells 
infected with AdSUPER/GFP viruses. Data represent the mean ± standard deviation of three 
experiments performed in duplicates. (C, D) SAOS2-GR(+) cells were infected with 
adenoviruses expressing either GFP or PGC-1 [wild type (wt) or mutants L2A, L3A, or 
double L2/3A]. (C) 24 h after infection cells were treated with either 50 nM corticosterone 
(+H) or just vehicle ethanol (−). RNA was harvested 8 h after hormone addition, and p21 
mRNA levels were determined by quantitative RT-PCR, normalized to 36B4 levels, and 
expressed relative to levels in cells infected with GFP virus and treated with just ethanol. Data 
represent the mean ± range of duplicates of one experiment. (D) RNA was harvested 48 h 
after infection, and MCAD mRNA levels were determined by quantitative RT-PCR, 
normalized to 36B4 levels, and expressed relative to levels in cells infected with GFP virus. 
Data represent the mean ± standard deviation of two experiments performed in duplicates. 
Wild-type, L2A, L3A and L2/3A mutants were expressed at similar levels, as determined by 
western blot analysis. 
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Discussion 
 
Many members of the nuclear receptor superfamily are still orphan receptors, with no 
known physiological ligands. The mechanisms that regulate the activity of these 
receptors are not fully understood. The results presented here provide evidence that 
the transcriptional coactivator PGC-1 is a key regulator of the orphan nuclear receptor 
ERRα. PGC-1 acts at two levels. First, it induces ERRα expression; second, it 
associates with ERRα and enables the transcriptional activation of ERRα target genes. 
PGC-1 expression is known to be regulated in a tissue-selective manner by 
physiological signals that relay metabolic needs (Goto et al., 2000; Herzig et al., 
2001; Lehman et al., 2000; Puigserver et al., 1998; Yoon et al., 2001). Accordingly, 
PGC-1 function has been implicated in the regulation of energy metabolism [(Lehman 
et al., 2000; Vega et al., 2000; Wu et al., 1999), reviewed in (Knutti and Kralli, 
2001)]. Our findings suggest that ERRα functions in PGC-1 - regulated pathways, 
where it may contribute to the transcriptional activation of genes important for energy 
homeostasis.  
 
The activity of several orphan nuclear receptors is restricted by expression of the 
receptors in specific tissues or at particular times [reviewed in (Giguere, 1999)].The 
mechanisms that control the selective expression of these receptors are often not clear. 
The observation that PGC-1 induces ERRα mRNA levels, provides a molecular 
explanation for the high ERRα expression in heart, kidney, muscle and brown fat, i.e. 
tissues that express PGC-1. Moreover, it suggests physiological signals that are likely 
to control ERRα expression, as shown here for exposure to cold in brown fat and 
muscle. In support of these findings, Ichida et al. have recently shown that fasting, 
which is known to induce PGC-1 expression in the liver (Herzig et al., 2001; Yoon et 
al., 2001), also increases ERRα mRNA levels (Ichida et al., 2002).The spatial and 
temporal correlation of PGC-1 and ERRα expression implies that ERRα induction is 
an early, and possibly direct outcome of PGC-1 action. Future studies must address if 
PGC-1 acts directly at the ERRα promoter. Additional regulatory mechanisms may 
restrict or enhance ERRα induction by PGC-1, in a tissue- or physiological state-
dependent manner. 
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Interestingly, we find that in the absence of PGC-1, ERRα is a very weak activator of 
transcription. Coexpression of PGC-1 enables potent transcriptional activation by 
ERRα. These findings suggest that ERRα is not a constitutively active receptor, and 
that transformation into an active form is favored by binding to protein ligands, such 
as PGC-1, rather than to small lipophilic ligands. Expression levels of PGC-1 may 
explain why ERRα has been reported as an efficient transcriptional activator in some 
cells (e.g. ROS 17.2/8) and a poor activator in others (Bonnelye et al., 1997b; 
Johnston et al., 1997; Kraus et al., 2002; Lu et al., 2001; Sladek et al., 1997; Vanacker 
et al., 1998; Vanacker et al., 1999b; Xie et al., 1999; Zhang and Teng, 2000). Many 
established cell lines express very low, if any, levels of PGC-1. Importantly, the 
ability of PGC-1 to activate ERRα at the protein level predicts that physiological 
signals that induce PGC-1 are likely to activate ERRα-mediated transcription, even in 
the absence of increased ERRα expression.  
 
The activation of ERRα at the protein level requires the physical interaction of PGC-1 
with ERRα. Surprisingly, this interaction differs from that of PGC-1 with other 
nuclear receptors. While PGC-1 recognizes most receptors tested until now (GR, 
ERα, TRα, RXRα, RARα, PPARα, PPARγ, HNF4) via the canonical LxxLL motif 
L2, it can interact with ERRα equally well via the L2 or the L3 site. Similar to our 
findings, Huss et al. have recently shown that ERRα, as well as the related receptor 
ERRγ, bind the L3 site of PGC-1 (Huss et al., 2002), suggesting that the L3-mediated 
interaction is characteristic of the ERR subfamily of receptors. Interestingly, the 
differential utilization of the Leu-rich motifs can be used to dissect the receptors that 
mediate specific PGC-1 functions, as shown by the fact that L2A mutations disrupt 
GR- but not ERRα-dependent effects of PGC-1. Thus, the L2 and L3 mutants of 
PGC-1 may provide useful tools for elucidating the types of receptors that recruit 
PGC-1 at distinct promoters. 
 
The in vivo functions of ERRα are not yet defined. Based on its ability to bind EREs 
and modulate some estrogen-responsive genes, ERRα has been proposed to modulate 
ER signaling and possibly play a role in ER-dependent tumors (Kraus et al., 2002; Lu 
et al., 2001; Vanacker et al., 1999b). A function of ERRα in bone development is 
supported by the high levels of ERRα at sites of ossification during embryogenesis, 
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and the ability of ERRα to promote osteoblast differentiation in vitro and to activate 
the promoter of the bone matrix protein osteopontin (Bonnelye et al., 2001; Bonnelye 
et al., 1997b). Finally, the strong expression of ERRα in tissues with high capacity for 
fatty acid oxidation, and its ability to bind the promoter of the MCAD gene, suggest a 
role in the mitochondrial β-oxidation of fatty acids (Sladek et al., 1997; Vega and 
Kelly, 1997). Our findings support a function of ERRα in PGC-1 – stimulated cellular 
processes, such as fatty acid oxidation (Vega et al., 2000), and possibly other aspects 
of energy homeostasis. Interestingly, the close relationship of PGC-1 and ERRα 
activity may reflect not only an involvement of ERRα in known PGC-1-regulated 
functions, but also of PGC-1 in processes where ERRα roles have been suggested, 
such as bone development and homeostasis, or breast cancer.  
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Results and Discussion 
 
 
Mechanism of ERRα induction 
 
In our published study, we demonstrated that the mRNA and protein levels of ERRα 
were induced by PGC-1α. Since coactivators do not bind DNA directly, we wanted 
also to determine which transcription factor mediates the PGC-1α effect on the 
expression of the ERRα gene. As described earlier, PGC-1α interacts with most 
nuclear receptors via the L2 motif, but with ERRs via either the L2 or the L3 motif. 
To find if a nuclear receptor with characteristic of either of ERRs or of other NRs was 
required for the PGC-1α mediated induction, we tested what effect mutations in the 
L2/L3 motifs of PGC-1α would have on the induction of ERRα expression. As seen 
in figure 6 A, mutation of the L2 motif had no effect, while mutation of the L3 motif 
caused a small drop in ERRα induction. When both motifs were mutated, the 
upregulation of ERRα expression levels by PGC-1α was mostly abolished, 
suggesting that it was mediated by a nuclear receptor that could recruit PGC-1α via 
L2 as well as L3 (as predicted for ERRα, ERRβ, and ERRγ).  
 
To further address the hypothesis that ERRα is involved in the regulation of its own 
expression, we used a dominant negative version of ERRα. Nuclear receptor activity 
depends on the integrity of the AF-2 domain in the LBD (reviewed in Warnmark et 
al., 2003). Deletion of the AF-2 domain of ERRα abolishes the ability of ERRα to 
recruit PGC-1α, and to activate transcription (Bonnelye et al., 1997a), but does not 
affect its ability to bind DNA. Consequently, this mutant is able to compete with the 
endogenous ERRα for binding to DNA, and blocks ERRα signaling (Bonnelye et al., 
1997a). Therefore, we constructed adenoviral vectors expressing the dominant 
negative ERRα. As shown in figure 6 B, expression of the dominant negative ERRα 
decreased the levels of ERRα in the absence of PGC-1α similar to the effect of 
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specific siRNA for ERRα . Furthermore, PGC-1α induced the expression of ERRα in 
the absence, but not anymore in the presence of the dominant negative ERRα.∆AF2, 
consistent with the idea that endogenous ERRα is required for the induction.  
 
To further address the mechanism by which PGC-1α and ERRα regulate ERRα 
expression, we analyzed the sequence of the ERRα promoter and identified three 
putative ERREs (figure 6 C). These results strongly suggested us to analyze the 
ERRα effect on the ERRα promoter. We therefore cloned base pairs –537 to –829 of 
the ERRα upstream regulatory sequence in a luciferase reporter construct, and tested 
its response to PGC-1α and ERRα in transient transfection assays. Figure 6 D shows 
that expression of PGC-1α led to the induction of the ERRα promoter reporter 
construct activity. This induction required the expression of endogenous ERRα, since 
specific siRNA for ERRα completely inhibited the effect of PGC-1α. Inhibition of 
ERRα expression had no influence on the basal activity of the promoter, in the 
absence of PGC-1α. To confirm that the decrease in activity caused by the siRNA 
resulted from the specific loss of ERRα, we cotransfected a plasmid expressing 
ERRα to overcome the effect of the siRNA. As seen in figure 6 E, we detected a 
dose-dependent increase in the ability of PGC-1α to induce the ERRα promoter, with 
1-20 ng of DNA of the plasmid expressing ERRα. Interestingly, higher levels of 
ERRα expression showed an inhibitory effect. 
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Figure 6. ERR α induces its own expression by acting at the ERR α promoter. 
(A) SAOS2 cells were infected with adenoviruses expressing GFP (control), wt PGC-1 α or 
mutants L2A, L3A and L2/3A (MOI 40); RNA was isolated at 46 h after infection, and 
analyzed by quantitative RT-PCR. Values for ERR α mRNA were normalized to values of 
36B4 mRNA and expressed in relation to the control, which was set as 1. Values represent the 
mean ± SEM of two experiments with duplicates. (B) Cells were infected with adenoviruses 
expressing control (pSuper), siRNA for ERR α, or the dominant negative ERR α.∆AF-2 
mutant. After three days, cells were re-infected with control (GFP) or PGC-1 α adenoviruses. 
Cell extracts were isolated 24 hours later and analyzed with polyclonal PGC-1 α or ERRa 
antibodies. (C) Promoter sequence of ERR α with three putative ERR α binding sites. (D, E) 
SAOS2 cells were infected with adenoviruses expressing siRNA for ERR α on day 1. On day 
4, cells were transfected with the ERR α -promoter luciferase reporter and either pcDNA3 
(control vector) or the expression plasmid pcDNA3-PGC-1 α. Data are from duplicates of 1 
of 2 representative experiments. In (D), increasing amounts of the ERR α expression vector 
pcDNA3.ERR α (as indicated) were cotransfected with the PGC-1 α expression plasmid. 
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Our results imply that the induction of ERRα by PGC-1α is executed by a positive 
feedback-loop. The fact that high expression levels of ERRα have an inhibitory 
effect, suggests that the role of ERRα in the regulation of its own promoter may be 
more complex than a simple activation mechanism. While low levels of ERRα are 
required for the induction of its expression by PGC-1α, at high levels ERRα may 
represses its promoter. The physiological significance of this finding is currently not 
clear. Figure 7 shows a possible model for the positive feedback loop. Physiological 
signals induce the expression of PGC-1α. PGC-1α and ERRα proteins bind to the 
promoter of ERRα and induce the expression of more ERRα. After the synthesis of 
new ERRα protein, PGC-1α and ERRα act as a transcriptional couple to activate 
other genes in response to the physiological signals. 
 
PGC-1
PGC-1
ERRα
ERRα
promoter  
ERRα
PGC-1
ERRα
target promotor
physiological stress:
cold, exercise, fasting...
 
Figure 7. Model of the positive feedback loop by which PGC-1α induces ERRα 
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Summary 
 
ERRα is one of the first orphan nuclear receptors to be identified, yet its physiological 
functions are still unclear. We show here that ERRα is an effector of the 
transcriptional coactivator PGC-1α, and that it regulates the expression of genes 
involved in oxidative phosphorylation and mitochondrial biogenesis. Inhibition of 
ERRα compromises the ability of PGC-1α to induce the expression of genes encoding 
mitochondrial proteins, and to increase mitochondrial DNA content. A constitutively 
active form of ERRα is sufficient to elicit both responses. ERRα binding sites are 
present in the transcriptional control regions of ERRα/PGC-1α-induced genes, and 
contribute to the transcriptional response to PGC-1α. The ERRα regulated genes 
described here have been reported to be expressed at reduced levels in humans that 
are insulin-resistant. Thus, changes in ERRα activity could be linked to pathological 
changes in metabolic disease, such as diabetes. 
 
 
Introduction 
 
Estrogen-related receptor alpha (ERRα, NR3B1) was identified on the basis of its 
sequence similarity to classical, hormone-regulated steroid receptors (Giguere et al., 
1988). Based on its ability to recognize similar DNA sequences as the estrogen 
receptors, ERRα has been proposed to modulate estrogen signaling (Giguere, 2002; 
Johnston et al., 1997; Vanacker et al., 1999; Yang et al., 1996). ERRα may also 
regulate bone formation, as it is highly expressed at ossification sites, promotes 
osteoblast differentiation in vitro, and activates the promoter of the bone matrix 
protein osteopontin (Bonnelye et al., 2001; Bonnelye et al., 1997). Finally, ERRα may 
regulate fatty acid oxidation. Consistent with this function, ERRα is prominently 
expressed in tissues with high capacity for β-oxidation of fatty acids, such as brown 
fat, heart, muscle and kidney, and induces the expression of the medium chain acyl-
coenzyme A dehydrogenase gene (Sladek et al., 1997; Vega and Kelly, 1997).  
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A better understanding of the transcriptional programs and cellular pathways that 
depend on ERRα has been hampered by the lack of tools to regulate the activity of 
this receptor. Despite the high similarity between ERRα and other ligand-dependent 
nuclear receptors, it is not clear if ERRα activity is regulated by small lipophilic 
ligands. Compounds that inhibit ERRα-dependent transcription, such as toxaphene, 
chlordane and diethylstilbestrol, have been described (Tremblay et al., 2001; Yang 
and Chen, 1999). However, these compounds are not specific enough for ERRα to 
facilitate studies of its cellular function. Recently, we demonstrated that the 
transcriptional coactivator PGC-1α regulates ERRα function (Schreiber et al., 2003). 
PGC-1α induces the expression of ERRα and interacts physically with ERRα, 
enabling it to activate transcription (Huss et al., 2002; Schreiber et al., 2003). These 
findings suggest that PGC-1α can be used as a protein ‘ligand’ to regulate ERRα-
dependent transcription, and study ERRα function.  
 
PGC-1α has been identified as a tissue-specific coactivator of nuclear receptors 
(Knutti and Kralli, 2001; Puigserver and Spiegelman, 2003; Puigserver et al., 1998). 
Its expression is most prominent in tissues with high energy demands, similar to the 
expression pattern of ERRα (Puigserver and Spiegelman, 2003; Schreiber et al., 
2003). PGC-1α mRNA levels are induced in response to signals that relay metabolic 
needs, such as exposure to cold, fasting, and physical exercise [reviewed in (Knutti 
and Kralli, 2001; Puigserver and Spiegelman, 2003)]. Strikingly, increases in PGC-1α 
levels seem sufficient to induce cellular pathways important for energy metabolism, 
including adaptive thermogenesis, mitochondrial biogenesis, and fatty acid oxidation 
(Lehman et al., 2000; Puigserver et al., 1998; Vega et al., 2000; Wu et al., 1999). This 
is accomplished via the interaction of PGC-1α with transcription factors, which 
recruit PGC-1α to target DNA regulatory sequences and enable the induction of genes 
important in energy metabolism pathways. Transcription factors that guide PGC-1α 
action to specific genes include nuclear receptors, as well as members of other 
transcription factor families, such as NRF-1, which controls the expression of 
mitochondrial proteins, and MEF2C/D (Knutti and Kralli, 2001; Puigserver and 
Spiegelman, 2003). 
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The recent identification of ERRα as a protein that is coexpressed with, as well as 
induced and activated by PGC-1α, suggests that ERRα plays a role in some of the 
known PGC-1α regulated pathways. Consistent with this hypothesis, we show here 
that ERRα and PGC-1α cooperate to induce mitochondrial biogenesis. 
 
 
Materials and Methods 
 
Adenoviruses and plasmids. Adenoviral vectors expressing GFP, PGC-1α, siRNA 
for ERRα, and control AdSUPER have been described (Schreiber et al., 2003). 
Adenoviruses expressing ERRα or VP16-ERRα were constructed using the insert of 
pSG5-mERRα or pSG5-m∆AB.ERRα respectively (Bonnelye et al., 1997). For the 
reporter plasmids, human genomic DNA and gene-specific oligonucleotides 
(Supplement 2) were used to amplify the sequences -385 to +90 and -686 to +55 
(relative to transcription initiation site) of the ATPsynβ and Cyt c genes, respectively. 
The PCR products were cloned upstream of the luciferase coding sequences of pGL3-
Basic (Promega). Mutations and deletions were introduced by fusion PCR (Knutti et 
al., 2001). The ERREs at ATPsynβ/-338 (CCAAGGACA), Cyt c/-596 
(ACAAGGTCA), and Cyt c/-9 (CCAAGGACA) were changed to CCAgatctt, 
ACAgatctA and CCAgatctA, respectively. The NRF-2 binding sites of ATPsynβ were 
deleted by removing sequences -300 to -270; the NRF-1 binding site of Cyt c 
(CCAGCATGCGCG) was changed to CCAGgATcCaac.  
 
Cell culture and Transfections. Cells were cultured in DMEM supplemented with 
9% charcoal-stripped FCS. SAOS2 [SAOS2-GR(+) in (Schreiber et al., 2003)] cells 
were infected with adenoviruses at a multiplicity of infection (moi) of 20-100. COS7 
cells were transfected by calcium phosphate precipitation and analyzed as described 
(Knutti et al., 2000). The amounts of plasmids per transfection were 100 ng of the 
reporters pCytc/-686Luc or pATPsynβ/-385Luc, 100 ng pcDNA3/HA-PGC-1α 
(Knutti et al., 2000), and 50 ng pcDNA3/ERRα(Coward et al., 2001). 
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cRNA preparation and Array hybridization. Total RNA (10 µg) was reverse 
transcribed using the SuperScript Choice system (Life Technologies). The cDNA (1 
µg) was in vitro transcribed using the Enzo BioArray High Yield RNA system (Enzo 
Diagnostics). The cRNA (10 µg) was fragmented and hybridized to a HG-U133A 
GeneChip (Affymetrix) using standard procedure (45°C, 16 h). Washing and staining 
were performed in a Fluidics Station 400 (Affymetrix) using the protocol EukGE-
WS2v4 and scanned in an Affymetrix GeneChip 2500 scanner. 
 
Microarray analysis. Data from 3 experiments were analysed using the Affymetrix 
Microarray Suite v5 and GeneSpring 5.1 (Silicon Genetics). Changes in gene 
expression were assessed by looking for concordant changes between replicates using 
a signed Wilcoxon rank test. The “change” p-value threshold was <0.003. Genes 
whose detection p-value was >0.05 in all experimental conditions were excluded from 
the analysis. Genes that reproducibly changed in the same direction were subjected to 
a 1-way ANOVA test (p<0.05) using a Benjamini and Hochberg multiple testing 
correction. Classification into genes encoding mitochondrial proteins was based on 
annotations of the Affymetrix NetAffx Analysis Center, SOURCE and NCBI 
PubMed, and the OXPHOS and human_mitoDB_6_2002 lists curated at WICGR 
(Mootha et al., 2003b). 
 
DNA isolation and quantification. Total DNA was prepared according to standard 
procedures and digested with 100 µg/ml RNase A for 30 min at 37˚C. The relative 
copy numbers of mitochondrial and nuclear DNA were determined by real-time PCR, 
using primers specific to the COX II (mitochondrial) and β actin (nuclear) genes 
(Supplement 2), 1 ng DNA, and the Light Cycler system (Roche Diagnostics). Serial 
dilutions of DNA from uninfected cells were analyzed in parallel to establish a 
standard curve. Quantification was as described (Kressler et al., 2002).  
 
RNA analysis. Isolation of RNA, conversion to cDNA and quantification of 
transcripts by real-time PCR using the Light Cycler system (Roche Diagnostics) and 
gene-specific primers (Supplement 2) have been described (Kressler et al., 2002).  
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Western analysis. Cell lysates were subjected to western analysis using antibodies 
against PGC-1α (Schreiber et al., 2003) and ERRα (Johnston et al., 1997). 
 
Labeling of mitochondria and Flow cytometry. Cells were incubated, first, with 
500 nM CM-H2XRos or 500 nM MitoFluor Red 594 (Molecular Probes) in culture 
medium for 30 min, and then in fresh, dye-free medium for 30 min at 37˚C. CM-
H2XRos labeled mitochondria were visualized by fluorescence microscopy. 
MitoFluor Red 594 labeled cells were analyzed by flow cytometry (FACSCalibur, 
Beckton Dickinson), using the software WinMDI 2.8.  
 
In silico analysis for ERREs. 35 sequences reported to bind ERRα (Johnston et al., 
1997; Sladek et al., 1997; Vanacker et al., 1998; Vanacker et al., 1999) were aligned 
using ClustalW and used to compile a position-weighted nucleotide distribution 
matrix. Cross-validation of the matrix revealed a mean and median score for the 35 
sequences of 0.915 and 0.946, with a maximum at 0.994 and a minimum of 0.695, the 
best possible score being 1. For candidate genes, 5 kb of 5’ upstream region sequence 
were searched for matches to the matrix, using a variant of the NUBIScan algorithm 
(Podvinec et al., 2002).  
 
Electrophoretic mobility shift assay. 0.5 µl of in vitro translated ERRα [T7 Coupled 
Reticulocyte system (Promega)] or of unprogrammed lysate was incubated in 20 µl 
buffer (10 mM Hepes pH 7.5, 2.5 mM MgCl2, 50 mM EDTA, 1mM DTT, 6% 
glycerol) with 1ng 32P end-labeled oligonucleotide probe and 1 µg poly dI:dC, in the 
absence or presence of 100 ng unlabeled oligonucleotide competitor (Supplement 2). 
Complexes were resolved in 6% native polyacrylamide gels.  
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Results 
 
PGC-1α induces mitochondrial biogenesis in SAOS2 cells, via a pathway that 
requires interaction with nuclear receptors. To identify the cellular programs that 
are regulated by PGC-1α in SAOS2 cells and where ERRα could play a role, we used 
high density oligonucleotide arrays and compared the RNA profiles of cells 
expressing PGC-1α to those of control cells. 17 hours after infection with a PGC-1 
expressing adenovirus, 151 of the upregulated transcripts were classified as nuclear 
genes encoding mitochondrial proteins (Supplement 1, Lists A, B). These genes 
define “mitochondrial functions” that are upregulated in the early phase of the PGC-
1α-induced response (~12 hours after PGC-1α protein becomes detectable), and 
encode proteins with roles in many facets of mitochondrial biogenesis and function, 
including mitochondrial protein synthesis (20 genes), transport across the 
mitochondrial membrane (17 genes), fatty acid oxidation (8 genes), the tricarboxylic 
acid (TCA) cycle (17 genes), and oxidative phosphorylation (55 genes) (Supplement 
1). An additional 23 of the upregulated transcripts represent genes that do not encode 
known mitochondrial proteins but have been reported as co-regulated with 
“mitochondrial genes”, and proposed to carry functions relevant to mitochondrial 
biology (Mootha et al., 2003a) (Supplement 1). PGC-1α also induced the expression 
of the mitochondrial transcription and translation factor mtTFA. Interestingly, it did 
not affect the expression of NRF-1 or NRF-2 (Supplement 1), the transcription factors 
that regulate the expression of many nuclear genes encoding mitochondrial proteins, 
and that are induced by PGC-1α in C2C12 cells (Wu et al., 1999). We concluded that 
PGC-1α induces the gene expression program of mitochondrial biogenesis in SAOS2 
cells, in a manner that differs from the NRF-1 pathway described in C2C12 cells (Wu 
et al., 1999). 
 
To determine whether the PGC-1α-mediated induction of mitochondrial proteins led 
to an increase in mitochondrial content, SAOS2 cells were stained with MitoTracker, 
a dye that accumulates specifically in respiring mitochondria. Mitochondria in control 
cells infected with a GFP-expressing adenovirus had a characteristic tubular 
appearance and were concentrated around the nuclei, similar to mitochondria in non-
infected cells (Fig. 1A and data not shown). Expression of PGC-1α led to a distinct 
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mitochondrial reticulum, which filled the cytoplasm. The increased mean 
fluorescence intensity in PGC-1α expressing cells (Gm 151) compared to control cells 
(Gm 90) was consistent with an increase in mitochondrial content (Fig. 1B). To 
measure mitochondrial DNA directly, we isolated total DNA and determined the 
relative copy number of mitochondrial DNA by quantitative PCR. PGC-1α expression 
led to an increase in mitochondrial DNA content per cell, by 1.7- and 2-fold, at 48 and 
60 hrs, respectively (Fig. 1C). 
 
PGC-1α interacts with nuclear receptors via two leucine rich motifs. Leucine motif 2 
(L2) mediates interaction with most nuclear receptors, including ERRα, while motif 3 
(L3) recognizes specifically ERRα and the related receptors ERRβ and ERRγ (Huss et 
al., 2002; Ichida et al., 2002; Schreiber et al., 2003). Mutation of motifs L2 and L3 
(L2/3A) disrupts interactions with nuclear receptors, without affecting the interaction 
domains for other factors like NRF-1 and MEF2C (Knutti and Kralli, 2001; 
Puigserver and Spiegelman, 2003). To determine the role of nuclear receptors in 
PGC-1α induced mitochondrial biogenesis, we tested the effect of the L2/3A 
mutation. As seen in Fig. 1A-C, the PGC-1α variant L2/3A showed a reduced ability 
to induce mitochondria, when compared to wild type PGC-1α. The L2/3A PGC-1α 
was also deficient in inducing the expression of nuclear genes encoding mitochondrial 
proteins, and of ERRα (Fig. 1D,E). The single L2A mutant, which is defective for 
interactions with PPARs, GR, and TR but retains interactions with ERRα (Huss et al., 
2002; Schreiber et al., 2003; Vega et al., 2000; Wang et al., 2003; Wu et al., 2003), 
was as active as wt PGC-1 in inducing the expression of target genes (Fig. 1D and 
data not shown). We concluded that interactions of PGC-1α with nuclear receptors, 
and potentially ERRα, are important for PGC-1α to induce the program of 
mitochondrial biogenesis.  
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Figure 1. PGC-1α induces mitochondrial biogenesis in SAOS2 cells, dependent on 
interaction with nuclear receptors.  
(A-E) Cells were infected with GFP- or PGC-1α- [wild type (wt) or mutant L2/3A] 
expressing adenoviruses at an moi of 40. (A) Mitochondria in cells labelled with CM-H2Xros 
were imaged 48 h after infection. (B) Accumulation of MitoFluor Red 594 in cells was 
measured by flow cytometry, 48 h after infection. Gm represents the mean fluorescence 
intensity of 20,000 cells. (C) Mitochondrial (COX2) DNA levels, normalised to nuclear (β 
actin) DNA levels, are expressed relative to levels in control cells expressing GFP, which 
were set to 1, at 48 h and 60 h after infection. Data are the mean ± SEM of three experiments 
performed in duplicates. *, p < 0.0001 vs. PGC-1α wt at 48 h; **, p < 0.001 vs. PGC-1α wt at 
60 h, as determined by the Students t-test. (D) mRNA levels of ATPsynβ, Cyt c and COXIV 
at 48 h after infection were determined by quantitative RT-PCR, normalised to the mRNA 
levels of 36B4 and expressed relative to levels in GFP infected cells. (E) Protein levels of 
PGC-1α and ERRα were determined by western analysis at 48 h after infection. 
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ERRα expression is required for the PGC-1α-induced mitochondrial 
biogenesis.To address the involvement of ERRα specifically, we compared the ability 
of PGC-1α to induce genes encoding mitochondrial proteins in cells that express 
endogenous ERRα, and in cells where ERRα expression was inhibited by small 
interfering RNAs (siRNA). As seen in Fig. 2A, siRNA specific for ERRα abolished 
the basal expression of ERRα in the absence of PGC-1α, and reduced strongly the 
induction of ERRα by PGC-1α. Under these conditions, we determined the mRNA 
levels of PGC-1α up-regulated genes that carry important roles in different aspects of 
mitochodrial biogenesis and function: mtTFA (mitochondrial DNA replication and 
transcription), Tim22 (protein import into mitochondria), isocitrate dehydrogenase 
alpha (IDH3A, TCA cycle), carnitine/acylcarnitine translocase (CACT, fatty acid 
oxidation), and cytochrome c, somatic and ATP synthase β (Cyt c, synβ, oxidative 
phosphorylation). For all six genes, PGC-1α expression led to increases in their 
mRNA levels when endogenous ERRα levels were not perturbed, confirming results 
from the arrays. Inhibition of ERRα expression by siRNA reduced significantly the 
ability of PGC-1α to induce these genes, without affecting basal levels in the absence 
of PGC-1α (Fig. 2B). Since the siRNA diminished but did not abolish ERRα 
expression, the remaining induction by PGC-1α could still be mediated by the low 
levels of ERRα (Fig. 2A), as well as by other pathways. Inhibition of ERRα did not 
prevent PGC-1α from inducing GR targets such as p21 (data not shown) nor affect the 
mRNA levels of the transcription factors NRF-1 and NRF-2 (Fig. 2B). 
 
The requirement of ERRα for the induction of genes such as mtTFA and Tim22 
suggests that ERRα is required for PGC-1α-dependent mitochondrial biogenesis. 
Indeed, inhibition of ERRα expression significantly diminished the ability of PGC-1α 
to increase mitochondrial DNA content (Fig. 2C). Inhibition of ERRα had no effect 
on mitochondrial DNA in the absence of PGC-1α, leading us to conclude that ERRα 
contributes to the PGC-1α mediated induction, but not the basal expression of genes 
important in mitochondrial biogenesis. 
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Figure 2. Inhibition of ERRα expression impairs the induction of mitochondrial biogenesis 
by PGC-1α.  
SAOS2 cells were infected with control- (AdSUPER) or an adenovirus expressing siRNA for 
ERRα (siERRα) at a moi of 100, and two days later with GFP- or PGC-1α- expressing 
adenoviruses at a moi of 20 (A,B) or 40 (C). Cells were harvested 24 h (A,B) or 48 h (C) 
later. (A) ERRα mRNA levels were determined by quantitative RT-PCR and normalized to 
36B4 levels. Data shown are the mean ± SEM of three experiments performed in duplicates. 
(B) mRNA levels for mtTFA, Tim22, IDH3A, synβ, carnitine/acylcarnitine translocase 
(CACT), Cyt c, NRF-1, and NRF-2, were determined by quantitative RT-PCR, normalised to 
the mRNA levels of 36B4 and expressed relative to levels in AdSUPER/GFP infected cells. 
Data are the mean ± SEM of three experiments performed in duplicates. *, p < 0.02; **, p < 
0.003; ***, p < 0.0005 vs. PGC-1α expressing cells in the absence of siERRα. (C) 
Mitochondrial (COX2) DNA levels were normalised to nuclear (β actin) DNA levels, and 
expressed relative to levels in control (AdSUPER and GFP) infected cells, which were set to 
1. Data are the mean ± SEM of two experiments performed in duplicates. *, p < 0.008 vs. 
PGC-1α expressing cells in the absence of siERRα. 
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A constitutive form of ERRα induces mitochondrial biogenesis in the absence of 
PGC-1α. The lack of effect of ERRα on the basal expression of genes encoding 
mitochondrial proteins could reflect the low levels of ERRα in the absence of PGC-
1α (Fig. 2A), the low transcriptional activity of ERRα in the absence of PGC-1α, 
and/or the requirement for other PGC-1α dependent pathways that enable the 
induction of these genes. To address these possibilities, we determined the effect of 
overexpression of ERRα or of ERRα endowed with a heterologous strong 
transcriptional activation domain, in the absence of PGC-1α. ERRα fused to the VP16 
activation domain (VP16-ERRα) and, as control, the VP16 activation domain alone, 
were expressed in SAOS2 cells using adenoviral vectors. As seen in Fig. 3, neither 
ERRα nor VP16 by itself induced the expression of mtTFA, ATPsynβ, Cyt c, or 
IDH3A. In contrast, VP16-ERRα induced all four genes, to ~50% of the PGC-1α - 
induced levels (Fig. 3A). VP16-ERRα also led to a significant increase in the amount 
of cellular mitochondrial DNA (Fig. 3B), indicating that ERRα is capable of inducing 
mitochondrial biogenesis in the absence of PGC-1α, if activated by other means.  
 
 90
Chapter III: ERRα functions in PGC-1α induced mitochondrial biogenesis 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. A constitutively active ERRα induces mitochondrial biogenesis.  
SAOS2 cells were infected with adenoviruses expressing GFP, PGC-1α, ERRα, VP16 or 
VP16/ERRα (moi 40), and analyzed 24 h (A) or 60 h (B) later. (A) mRNA levels for the 
indicates genes were determined by quantitative RT-PCR, as in Fig. 1D. Data are the mean ± 
SEM of three experiments performed in duplicates. *, p< 0.002; **, p≤ 0.0001; ***, p< 
0.0004 vs. GFP infected cells. (B) Mitochondrial DNA content was determined as in Fig. 1C. 
Data are the mean ± SEM of two experiments performed in triplicates. *, p< 0.0001 vs. GFP 
infected cells. 
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ERRα binds to regulatory sites in the promoters of ATP synthase β and 
cytochrome c. We next asked whether ERRα acts directly at the promoters of genes 
encoding mitochondrial proteins. ERRα binds to DNA sites with the consensus 
sequence TCAAGGTCA, termed ERREs (Bonnelye et al., 1997; Johnston et al., 
1997; Sladek et al., 1997; Vanacker et al., 1999). Analysis of the promoter and 
upstream regulatory sequences of 18 genes that are induced by PGC-1α indicated the 
presence of putative ERREs in most of them (not shown). We focused on ATPsynβ 
and Cyt c, whose promoters have been studied (Evans and Scarpulla, 1989; Haraguchi 
et al., 1994; Villena et al., 1994) and where the putative ERREs are within 1 kb of the 
characterized transcription initiation sites (Fig. 4A). First, we tested whether ERRα 
binds to these sites in a gel mobility shift assay. In vitro-translated ERRα formed a 
specific complex with an oligonucleotide representing the putative ERRE at –596 bp 
of the Cyt c promoter (Fig. 4B). The complex was inhibited by a 100-fold excess of 
an oligonucleotide bearing a known ERRE from the TRα promoter (Vanacker et al., 
1998), and oligonucleotides representing the candidate ERREs from the Cyt c/-9, 
ATPsynβ/-338, and IDH3A/-4023, but not by oligonucleotides harboring a mutated 
TRα ERRE (M4), a random sequence, or another site of the IDH3A gene.  
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Figure 4. ERRα recognizes sites in ATPsynβ and Cyt c regulatory sequences. 
 (A) Sequences of candidate ERREs identified by in silico analysis. The TRα. ERRE has been 
described previously (Vanacker et al., 1998). (B) Electrophoretic mobility shift assay. ERRα 
was incubated with a 32P-labeled oligonucleotide containing the ERRE of Cyt c/-596, in the 
presence of unlabeled oligonucleotides as indicated. M4 oligonucleotide has the TRα/-443 
sequence with a two bp subsitution in the core ERRE (Vanacker et al., 1998). 
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To test the significance of the ERRα binding sites for the induction of ATPsynβ and 
Cyt c, we measured the response of these two promoters to PGC-1α/ERRα in COS7 
cells. PGC-1α induced the ATPsynβ and Cyt c promoters driving the expression of 
luciferase by 2.7 and 2.6-fold (Fig. 5). Coexpression of ERRα enhanced further the 
induction, to 7.6 and 7.3-fold. Mutations in the ERREs decreased the response to 
PGC-1α and to PGC-1α/ERRα by 40-50% (Fig. 4C), without affecting the basal 
levels of expression in the absence of PGC-1α (not shown). The ATPsynβ and Cyt c 
promoters harbor also binding sites for NRF-2 and NRF-1, respectively (Evans and 
Scarpulla, 1989; Villena et al., 1994). Deletion of the NRF-2 site in the ATPsynβ 
promoter caused a drop in basal expression levels (by 40%) and a small decrease in 
the response to PGC-1α, but did not affect the response to ERRα. Mutations in the 
NRF-1 site of Cyt c also reduced basal levels of expression by 40%, but did not 
decrease the response to PGC-1α or PGC-1α/ERRα. Taken together, our results 
indicate that the promoters of the two genes are responsive to ERRα, and that the 
identified ERREs contribute to, but are not solely responsible for, the induction by 
PGC-1α and ERRα. 
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Figure 5. The ERRE  of ATPsynβ and Cyt c contribute to the transcriptional response to 
PGC-1α.  
COS7 cells were transfected with reporters pATPsynβ/-385Luc or pCytc/-686Luc, [wild type 
(wt) and bearing mutations (mt) or deletions (∆) at the ERREs and NRF-1/-2 binding sites] 
and control vector (-), PGC-1α-, and/or ERRα-expressing plasmids, as indicated. Data are 
expressed as fold activation by PGC-1α, or PGC-1α/ERRα, with the basal activity of each 
construct (white bars) set to 1, and are the mean ± SEM of at least three experiments 
performed in duplicates.  
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Discussion 
 
PGC-1α has been shown previously to induce mitochondrial biogenesis and oxidative 
metabolism in muscle cells, adipocytes and cardiomyocytes (Lehman et al., 2000; 
Puigserver et al., 1998; Wu et al., 1999). These studies also provided evidence that the 
transcription factors NRF-1 and NRF-2 mediate the effects of PGC-1α on the 
expression of nuclear genes encoding mitochondrial proteins (Wu et al., 1999). We 
now show that PGC-1α expression in SAOS2 cells, osteoblast progenitors with 
adipocyte differentiation capacity (Diascro et al., 1998), also induces mitochondrial 
biogenesis. Interestingly, this PGC-1α driven program depends on the induction and 
activation of the orphan nuclear receptor ERRα. Moreover, in the absence of PGC-1α, 
a constitutively active ERRα induces mitochondrial biogenesis and the expression of 
genes essential for oxidative phosphorylation. Our findings demonstrate a role for 
ERRα in the control of mitochondrial biogenesis and function, and suggest that, 
depending on the cell type, ERRα activity is necessary and sufficient for 
mitochondrial biogenesis. Consistent with these findings, RNA profiling studies have 
recently shown a tight correlation of the expression of ERRα with that of genes 
encoding mitochondrial proteins (Mootha et al., 2003a).  
 
 
Mitochondrial abundance and oxidative capacity are cell type-specific and regulated 
by energy demand. For example, physical exercise and chronic exposure to cold lead 
to the biogenesis of mitochondria in muscle and brown fat, respectively (Harper and 
Himms-Hagen, 2001; Moyes and Hood, 2003). This adaptive response requires the 
coordinated induction of a large set of nuclear genes, accomplished, at least in part, by 
PGC-1α and the transcription factors NRF-1 and NRF-2 (Moyes and Hood, 2003; 
Scarpulla, 2002). Since not all genes encoding mitochondrial proteins have binding 
sites for NRF-1 and NRF-2, additional factors must contribute to the response (Lenka 
et al., 1998; Scarpulla, 2002). Possibly, the different factors contribute selectively to 
mitochondrial biogenesis in different cellular contexts; e.g., the levels of NRF-1 are 
induced during PGC-1α -mediated mitochondrial biogenesis in muscle but decreased 
when PGC-1α and mitochondrial levels rise during brown fat development (Baar et 
al., 2002; Villena et al., 2002). NRF-1, NRF-2 and ERRα may act synergistically in 
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some cell types, and operate independently in others. The presence of multiple factors 
may serve to integrate diverse signals into mitochondrial biogenesis. Furthermore, the 
different factors may enhance differentially the expression of specific genes, thereby 
enabling the newly made mitochondria to be selectively endowed with cell type- or 
signal- specific functions. Interestingly, ERRα alone, i.e. in the absence of PGC-1α or 
other activating signals, had no effect on “mitochondrial” genes, suggesting a function 
in the tissue-specific or signal-dependent regulation, rather than basal expression of 
genes encoding mitochondrial proteins.  
 
 
Consistent with our findings, expression of Cyt c is downregulated in mice that carry 
a targeted null mutation in the ERRα gene (Luo et al., 2003). Further studies will be 
necessary to define mitochondrial defects, and to determine if other factors may 
partially compensate for the loss of ERRα function in these mice. One such candidate 
factor is the related receptor ERRγ, which is not expressed in the SAOS2 cells used in 
our study (data not shown). The ERRα null mice display also altered expression of 
many genes involved in lipid metabolism (Luo et al., 2003). Together with our 
findings that ERRα is important for the PGC-1α-driven induction of the 
carnitine/acylcarnitine translocase and MCAD genes (Schreiber et al., 2003), these 
observations suggest that ERRα function contributes to other PGC-1α-induced 
pathways, such as fatty acid β-oxidation (Sladek et al., 1997; Vega et al., 2000; Vega 
and Kelly, 1997). Finally, while our study demonstrates a role for ERRα as an 
important effector of PGC-1α, it is still possible that ERRα carries additional roles in 
regulating PGC-1α activity, as previously suggested (Ichida et al., 2002).  
 
 
Mitochondrial dysfunction and in particular decreases in oxidative capacity have been 
linked to insulin resistance and type 2 diabetes (Bjorntorp et al., 1967; Petersen et al., 
2003). Recent studies also suggest that decreases in the levels of PGC-1α and the 
related coactivator PGC-1β contribute to the reduced oxidative capacity in diabetic 
subjects (Mootha et al., 2003b; Patti et al., 2003). Supporting this notion, 
polymorphisms in the PGC-1α gene have been associated to an increased risk of 
diabetes (Ek et al., 2001; Hara et al., 2002), while mice overexpressing PGC-1β show 
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increased levels of ERRα and resistance to high-fat induced obesity (Kamei et al., 
2003). Strategies aiming in enhancing ERRα activity may thus have therapeutic 
applications in diseases associated with reduced mitochondrial function, such as 
diabetes.  
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A. Oligonucleotides used to determine gene-specific mRNA levels by quantitative real-time PCR.  
 
Gene Forward primer 5’-3 Reverse primer 5’-3’ NCBI no. exons 
ATPsynβ GCAAGGCAGGGAGACCAGA CCCAAAGTCTCAGGACCAACA NM_001686 2/3 
β actin TCACCCACACTGTGCCCATCTACGA CAGCGGAACCGCTCATTGCCAATGG NM_001101 3 
CACT CTGGAGAACGGATCAAGTGCT CCCTTTGTAGATGCCTCGGAT NM_000387 4/5 
COX II CCTGCGACTCCTTGACGTTG AGCGGTGAAAGTGGTTTGGTT NM_173705 --- 
COX4i1 CAAGCGAGCAATTTCCACCT GGTCACGCCGATCCATATAAG NM_001861 2/3 
Cyt c CCAGTGCCACACCGTTGAA TCCCCAGATGATGCCTTTGTT NM_018947 2/3 
ERRα AAGACAGCAGCCCCAGTGAA ACACCCAGCACCAGCACCT NM_004451 4/6 
IDH3A ATTGATCGGAGGTCTCGGTGT CAGGAGGGCTGTGGGATTC NM_005530 9/10 
mtTFA GATGCTTATAGGGCGGAGTGG GCTGAACGAGGTCTTTTTGGT NM_003201 5/6 
NRF-1 CAGCAGGTCCATGTGGCTACT GCCGTTTCCGTTTCTTTCC NM_005011 3/4 
NRF-2 CAAGGCAACAGATGAAACGG GACTTGCTGACCCCCTGAACT NM_005254 7/9 
36B4 CTGTGCCAGCCCAGAACACT TGACCAGCCCAAAGGAGAAG NM_001002 3/4 
Tim22 CCAAGTCCAGCCAAGAGTGAG CAGCGGTAAACACCCCAAAT NM_013337 1/2 
 
 
 
B. Oligonucleotides used in gel mobility shift assays. 
(the core sequence of an ERRα recognition site is in bold) 
 
Gene/position Sequence 5’-3 
TRα/-443 GCGATTTGTCAAGGTCACACAGCGC 
TRα M4 GCGATTTGTCAAGtgCACACAGCGC 
random GCGCTAGACTCGGGCTTGCGGACGC 
ATPsynβ/-338 GCGAAAGCCCAAGGACAGGCAACGC 
Cyt c/-596 CGCCTAGAACAAGGTCACGAGCCGC 
Cytc/-9 GCGTAAGTCCAAGGACACGCCGCGC 
IDH3A/-4023 GCGAGATCACAAGGTCAGGAGGCGC 
IDH3A/-282 GCGCGCTGTTAAGGTAAGACGTCGC 
 
 
 
C. Oligonucleotides used to clone the ATPsynB and Cyt C promoter sequences.  
(gene-specific sequences are in bold)  
 
Gene Forward primer 5’-3 Reverse primer 5’-3’ 
ATPsynβ (-385/+90) GGACTCGAGGCCCCTATGGCTGTCACCTAG GCCAAGCTTGCGACGCTGAAGGGGTGAGT 
Cyt c (-686/+55) GGAGTCGACAAATGCAGCACCTTCCTCAGT GCCAAGCTTCGCTGGCACAACGAACACT 
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Regulation of mitochondrial biogenesis by PGC-1β 
 
PGC-1β has a similar expression pattern as PGC-1α (Kressler et al., 2002), and has 
also been reported to induce mitochondrial biogenesis (Meirhaeghe et al., 2003; St-
Pierre et al., 2003). Given that our work established a role for ERRα in mediating the 
PGC-1α effects in mitochondrial biogenesis, we were interested to test if ERRα could 
be acting also downstream of PGC-1β to increase the mitochondrial content in 
SAOS2 cells. To answer this question, we first infected SAOS2 cells with 
adenoviruses expressing GFP or PGC-1β and analyzed the mitochondrial DNA 
content of the cells (figure 6A). We observed that PGC-1β induced mitochondrial 
biogenesis as potently as PGC-1α, around 2 fold after 48 and 60 hours. 
 
PGC-1β can interact with and coactivate ERRα (Kressler, unpublished data; (Kamei 
et al, 2003)). We would therefore expect that PGC-1β, like PGC-1α, induces the 
expression of endogenous ERRα in SAOS2 cells. As can be seen in figure 6 B, PGC-
1β upregulates ERRα mRNA levels strongly. Both basal and PGC-1β-induced 
expression of ERRα could be suppressed by siRNA specific for ERRα, enabling us to 
ask whether the induction and expression of ERRα is important for the effects of 
PGC-1β on mitochondrial functions. First, we looked at the expression of mtTFA, the 
mitochondrial replication and transcription factor, and isocitrate dehydrogenase 3, a 
key enzyme of the TCA cycle. As results in figure 6 C show, PGC-1β induces both 
genes, and this induction depends on endogenous ERRα, as it is not seen when ERRα 
expression is blocked via siRNA. Nevertheless, when we tested the importance of 
ERRα on the induction of mitochondrial density by PGC-1β (figure 6 D), we 
observed only a small, not significant inhibition of the effect of PGC-1β. Although 
these data are very preliminary and more work should be done, our results suggest 
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that PGC-1β requires the function of the endogenous ERRα to induce at least some 
genes important for mitochondrial biogenesis. It seems as though ERRα is not as 
important for PGC-1β as for PGC-1α for the final increase of the mitochondrial 
content in the cell, although more careful analysis would be required to conclude this. 
It would be interesting to test, if the PGC-1α homologues and ERRα act as a 
complex, or if PGC-1β induces mitochondrial biogenesis under different 
physiological conditions distinct from PGC-1α. In particular the role of ERRα in 
PGC-1β signaling should be further studied. 
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Figure 6. PGC-1β induces mitochondrial biogenesis through ERRα. 
(A) SAOS2 cells were infected with adenoviruses expressing GFP, PGC-1α or PGC-1β 
(MOI40). 48 and 60 hours later, total cellular DNA was isolated and analyzed by quantitative 
real-time PCR. Levels for COX2 (mitochondrial DNA) were normalized to β-actin (nuclear 
DNA) levels and expressed relative to the GFP control with was set as one. Equal expression 
levels for PGC-1α and PGC-1β were controlled by western blot analysis (not shown). Values 
are the mean ± SEM of two experiments with duplicates. Asterisks indicate that values with 
PGC-1α or PGC-1β are significantly induced compared to GFP infected cells. *< 0.02, **< 
0.003, ***< 0.005. (B, C, D) Cells were infected with adenoviruses expressing control 
(pSUPER) or siRNA for ERRα, and 3 days later re-infected with adenoviruses expressing 
GFP or PGC-1β at an MOI of 20 (B,C), or 40 (D). (B,C) RNA was isolated at 24 hours after 
infection with PGC-1α viruses, and analyzed by real-time RT-PCR. Data shown here 
represent the mean ± SEM of two experiments with duplicates. The mRNA levels of ERRα, 
mtTFA and IDH3 were normalized to the levels of 36B4 and expressed as fold induction 
compared to control (GFP and pSUPER infected cells). Asterisks show that values of the 
PGC-1β infected cells with siRNA are significantly reduced compared to PGC-1β without 
siRNA (*< 0.0001, **< 0.005, *< 0.0002) and values for mtTFA are also significantly 
induced by PGC-1β without siRNA compared to cells without PGC-1β (*< 0.0001), as 
determined by students t-test. (D) DNA was harvested at 60 hours after GFP or PGC-
1β expression, and analysed as in A. Data represent mean ± SEM from two experiments with 
duplicates. Asterisks indicate that values with PGC-1β are significantly induced compared to 
values without (no siRNA) *< 0.0002; values with PGC-1β and siRNA are not significantly 
reduced compared to no siRNA. **p= 0.054. 
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Results and discussion 
 
PGC-1α is a coactivator that is expressed in an inducible, tissue-specific manner, and 
that regulates metabolism in response to stressors, such as cold, fasting or exercise. As 
discussed earlier, PGC-1α exerts its effects via interactions with many different 
nuclear receptors and other transcription factors like HNF4, PPARγ, GR, NRF1, 
MEF2C (Knutti et al., 2000; Michael et al., 2001; Puigserver et al., 1998) and ERRα. 
Furthermore, PGC-1α acts as a strong activator of GR-mediated transcription in 
transient transfection assays (Knutti et al., 2000). GR is activated by glucocorticoids, 
whose levels also increase in response to stressors, including cold, fasting or exercise, 
and is known to contribute to the mobilization of energy during stress. Interestingly, 
glucocorticoids may regulate the expression of PGC-1α in liver (Yoon et al., 2001), 
suggesting a complex regulatory interaction. Since the two proteins can be viewed as 
acting in response to stressors, it seems likely that they collaborate, at least partially, 
to regulate genes important in stress responses. Our goal was therefore to analyze how 
PGC-1α and GR would influence each other’s effects on gene expression. At the 
same time, we could analyze how PGC-1α impacts gene expression in collaboration 
with other transcription factors (i.e. absence of hormone), and identify gene targets for 
GR, since only a few direct targets were known when this study started. The previous 
two chapters focused on genes induced by PGC-1α in an ERRα-dependent manner. 
In this chapter we will discuss the preliminary analysis of expression profiling of 
genes responsive to PGC-1α and/or GR:  
 
Part 1: Introduction into the experimental settings and the in silico analysis method 
 
Part 2: Genes or programs that are regulated by PGC-1α independent of GR 
 
Part 3: The effect of activated GR on PGC-1α regulated expression profiles  
 A) genes that are induced by PGC-1α and repressed by GR 
 B) genes that are activated by PGC-1α in a GR-dependent manner 
Part 4: Genes that are regulated by GR independent of PGC-1α 
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Part 1: Introduction 
 
The cell culture system chosen should fulfill two major requirements: cells should, 
first, express wild type GR that can be activated by glucocorticoids, and, second, have 
low or possibly no detectable levels of PGC-1α expression, so that we could compare 
GR responses in the absence and presence of PGC-1 α. Because many established cell 
lines express inactive GR, we decided to test SAOS2 cells that stably express GR and 
that were recently characterized (Rogatsky et al., 1997). Furthermore, the osteoblast 
progenitor nature of SAOS2 cells was interesting, given that glucocorticoids can 
induce bone loss. To introduce the coactivator PGC-1α with high efficiency, we 
constructed adenoviral expression vectors for PGC-1α. These vectors could deliver 
efficient expression of PGC-1α in ~70 % of the cells, when used at a multiplicity of 
infection (MOI) of 50 (figure 1 A).  
 
First, we used transient transfection assays to determine if the adenovirally expressed 
PGC-1α was transcriptionally active. Figure 1 B shows that adenovirally expressed 
PGC-1α was able to enhance GR activity at a model reporter luciferase construct, by 
5- to 6-fold. Next, we analyzed if adenovirally expressed PGC-1α was able to induce 
endogenous target genes. For a PGC-1α target, we assayed the expression of 
cytochrome c (Wu et al., 1999). As seen in figure 1 C, cytochrome c was induced by 
the PGC-1α adenovirus already at an MOI of 5; an MOI of 50 showed a stronger 
induction. For a GR target, we chose the cell cycle-dependent kinase-inhibitor p21, a 
known target gene for GR in SAOS2 cells (Rogatsky et al., 1997), and asked how 
many hours of glucocorticoid treatment were required to detect its induction. Figure 1 
D shows that p21 mRNA levels were already increased after ~1 hour of treatment 
with 50 nM corticosterone, and reached a plateau after 3 hours. Finally, we 
determined the expression levels of PGC-1α at different times after infection. PGC-
1α expression was detectable at 4-6 hours after infection, and reached steady levels at 
~ 10 hours (see figure 1B chapter 2). Based on these findings, we decided on a 
protocol where cells were infected with either control or PGC- 1α expressing viruses 
(MOI 50) for 14 hrs, and treated with either vehicle (ethanol) or hormone (50 nM 
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corticosterone in ethanol) for the next 3 hours. At 17 hours after infection, cells were 
harvested and RNA was prepared. 
After RNA isolation of the following four conditions, the expression profiles were 
analyzed on the Affymetrix U133A arrays: 
Cells infected with control βgal adenovirus, treated with vehicle  (1) 
control βgal adenovirus, treated with glucocorticoids (2) 
PGC-1α expressing adenovirus, incubated with vehicle (3) 
PGC-1α, incubated with glucocorticoids (4) 
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igure 1. Titration of the experimental settings. 
clonal antibody against PGC-1α after the 
α
 
 
F
(A) Immunofluorescence staining with a poly
infection with an adenovirus expressing PGC-1  a for around 48 hours. Left picture 
represents a nuclear DAPI staining. (B) SAOS2 cells were infected with adenoviruses 
expressing control (βgal) or PGC-1 α for 48 hours. Transfection of an MMTV-Luc reporter 
was performed at the same time and then luciferase activity was measured. (C) Cells were 
infected with different amounts of PGC-1α expressing adenovirus for around 48 hours. RNA 
was harvested and analyzed by quantitative RT-PCR. Cytochrome c mRNA levels were 
normalized to 36B4 levels and expressed relative to the control levels without PGC-1α and in 
the absence of glucocorticoids. One representative experiment with duplicates. (D) After 
infection with the PGC1α expessing adenovirus for around 48 hours, cells were treated with 
50 nM corticosterole for the indicated amount of time. Isolated RNA was analyzed by 
quantitative RT-PCR and values for p21 were normalized to levels of 36B4 and expressed as 
fold of the control. Data show one experiment with duplicates. The same results were 
obtained with another GR target gene. 
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To determine the genes that were differentially regulated from one condition to the 
other, we used the Microarray Suite program v5 (Affymetrix). Comparison of the 
genes expressed under the different conditions led us to generate four groups of lists, 
each with a list of up- and a list of down-regulated genes (figure 2). These lists served 
as the starting point for the subsequent analysis. In the following chapters, we will 
present some first validations of these results and furthermore discuss some functional 
groups with respect on their relevance for PGC-1α or GR signaling, followed by the 
discussion of selective interesting examples of genes that were regulated on the gene 
chips (examples marked in bold). At the current state of the analysis, we have 
verified that PGC-1α regulates the program of mitochondrial biogenesis, and the 
expression of many ‘mitochondrial genes’ in an ERRα -dependent manner (Chapter 
3). Furthermore, we have verified by real-time PCR the expresion levels of 23 
additional genes that are regulated by PGC-1α and/or GR. 
 
The human U133A array contains approximately 22,500 probe sets, representing 
around 14,500 well-characterized genes or 18,400 transcripts and variants. As the 
numbers suggest, some genes are represented more than once on the gene chip array. 
Only a small percentage of the genes are represented several times, whereas most 
genes appear only once on the U133A chip. Due to this fact, in the subsequent 
analysis I will use the terms ‘probe set’, when genes represented multiple times have 
not been eliminated, and “genes”, when the actual number of genes has been 
determined. Our experience from the analyzed lists suggests that the number of 
regulated genes is around 10 to 20 % less than the number of probe sets.  
 
Several different layers of statistical analysis have been incorporated into the analysis. 
Besides the cutoff lines set by the Affymetrix software, the data was normalized with 
the robust multichip analysis (Irizarry et al., 2003), and only genes that were 
consistently regulated in all three experiments were taken into account. Notably, the 
three repeats of the experiments were done on different days, as far as more than 6 
months from each other. Further statistical analysis was provided using the 1-way 
anova test, and setting a threshold of significance of 0.05. All values above were 
designated as “not significantly regulated”. While the use of this cutoff has reduced 
the large number of genes to be analyzed, it has also excluded some genes that fell 
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below the significance level, using these stringent conditions, but were found to be 
significantly regulated by quantitative RT-PCR analysis. In the following sections, 
only “significantly regulated” genes will be presented or discussed. 
 
Figure 2B presents the numbers of probe sets that were differentially regulated by 
PGC-1α and GR, classified into four groups. Two points appeared to be interesting at 
first glance: 
 
First, more probe sets were induced by PGC-1α than by GR. This could be explained 
by the fact that PGC-1α exerts its transcriptional coactivator function with several 
different endogenous nuclear receptors and other transcription factors. Furthermore, 
PGC-1α expression could be detected after around 4-6 hours (figure 1 B chapter 2). 
Around eleven hours of PGC-1α expression could possibly lead to indirect effects on 
the expression of some genes. The conditions for GR were more stringent (3 hrs of 
activation) and could have led to fewer indirect effects. 
 
The second point was that a smaller percentage of probe sets was significantly 
repressed by PGC-1α alone compared to with GR alone (group A and C). Whereas 
PGC-1α a repressed significantly 40 % of the probe sets in the absence of GR, the 
latter repressed 74 % significantly. These findings indicate that the role of PGC-1α in 
transcriptional repression is smaller than in activation. This observation is supported 
by the absence of any data for PGC-1α as a negative regulator of transcription. 
Even more striking is the situation if both factors are present and activated (group B 
and D). PGC-1α only represses 6 out of 340 probe sets significantly, but GR represses 
47 % significantly. This clearly demonstrates that PGC-1α does not exert a function 
in GR mediated repression and even influences GR signaling positively, since a lower 
percentage of GR targets were significantly repressed in the presence of PGC-1α. 
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Figure 2. Transcriptional profiles of PGC-1α and GR in SAOS2 cells 
(A) The comparison of genes expressed in the different conditions, using the Microarray Suite 
program, led to four groups of probe sets, each with two lists: one of up- and one of down-
regulated genes. (B) Numbers of probe sets that were regulated, in each of the 8 lists. The 
“significantly” regulated probe sets were determined using the 1-way anova test and a cut-off 
value of 0.05. 
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Part 2: Genes that are regulated by PGC-1α in the absence of 
glucocorticoids 
 
PGC-1α exerts its functions in metabolism by interacting with several different 
nuclear receptors and other transcripton factors (reviewed in Knutti and Kralli, 2001; 
Puigserver and Spiegelman, 2003). Importantly, PGC-1α is expressed at significant 
levels in some tissues, such as heart and muscle, in the absence of any stress, i.e. at a 
state when glucocorticoid levels are low (Knutti and Kralli, 2001; Puigserver and 
Spiegelman, 2003). It is therefore expected that many of the effects of PGC-1α on 
gene expression are GR-independent. Our first goal was therefore to identify genes 
and pathways that were regulated by PGC-1α in the absence of any glucocorticoids. 
 
 
Classification of all genes significantly induced by PGC-1α 
 
The classification of all genes induced significantly by PGC-1α in the absence of 
glucocorticoids shows an interesting picture (figure 3). As discussed in chapter 3, 
around 28 % of all induced genes are nuclear encoded with a function in 
mitochondrial biogenesis. Assuming that there are around 700 to 800 genes with 
functions in mitochondria, as proposed recently by Mootha and coworkers (Mootha et 
al., 2003), ~23-26 % of all ‘mitochondrial genes’ are induced by PGC-1α, already at 
17 hours after infection with the PGC-1α adenovirus. Since this function of PGC-1α 
was already discussed extensively, the main focus of this chapter will be on the genes 
that have no predicted function in mitochondrial biogenesis.  
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As can be seen in figure 3 and table 1 of the Appendix I, all PGC-1α induced genes 
were classified into functional groups. Interestingly, the second largest group of genes 
seems to be involved in cell signaling processes, such as cytoskeletal organization, 
cell growth and viability, and others. Followed by this, there is a group of genes 
involved in protein homeostasis, with roles in protein synthesis, transport, and 
ubiquitination, and, next, a group of genes encoding transcriptional regulators, 
including ERRα. The wide variety of genes regulated by PGC-1α suggests that PGC-
1α expression influences many cellular processes; some of them will be discussed in 
the following paragraphs. 
 
 
 
 
 
Figure 3. Classification of all genes that were significantly induced by PGC-1α in the 
absence of glucocorticoids (475 genes, represented by 547 probe sets).  
 
The graph illustrates the portion of each functional group. The most prominent function was 
chosen for the classification. Cell signaling includes: cytoskeleton organization, cell adhesion, 
apoptosis, cell cycle, differentiation, immune response and signaling pathways. Protein 
homeostasis includes protein synthesis, posttranslational modification, protein folding, 
trafficking and ubiquitination. The group of metabolism includes genes involved in energy 
homeostasis, oxidative stress, lipid, cholesterol, nucleotide metabolism and some others. (The 
list of the gene, together with their classification, can be found in table 1 of the Appendix I) 
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RNA processing 
 
Monsalve and coworkers have proposed a function for PGC-1α in the regulation of 
RNA processing (Monsalve et al., 2000). In their study, PGC-1α was able to interact 
with different splicing factors, and influence the splicing pattern of a fibronectin 
minigene, presumably as a result of the interaction between the C-terminus of PGC-
1α (RS and RRM domains) with the splicing factors. Interestingly, PGC-1α 
expression in SAOS2 cells led to the induction of six proteins involved in mRNA 
splicing (one cdk-like kinase known to affect splicing, two RNA-binding motif 
factors, a homologue of a drosophila splicing factor and more importantly, a 
component of the spliceosome), as well as ribonuclease P, which is involved in 
tRNA splicing, Although we have not tested yet the significance of these factors, 
these observations raise the possibility that the reported effect of PGC-1α on splicing 
are due not to direct interactions with splicing regulators, but rather to indirect effects 
of PGC-1α on the expression of some splicing components. It would be interesting to 
test if PGC-1α influences splicing in general or perhaps only the processing of some 
specific mRNAs. 
 
 
Transcription 
 
Several transcription factors and coregulators were induced by PGC-1α, suggesting 
that some of the genes regulated in the arrays may be indirect, rather than direct 
targets of PGC-1α.  
 
EAR-2 (erb A related 2, NR2F6) is a member of the orphan nuclear receptor family 
that was identified as TRα -related gene in 1988 (Miyajima et al., 1988). The function 
of EAR-2 is not fully understood, though it seems to act as a transcriptional repressor. 
High expression levels in the liver have suggested a role in the repression of 
apolipoproteins, lipid transporters with an important role in lipid and cholesterol 
metabolism (Ladias et al., 1992; Vorgia et al., 1998). Other studies have suggested a 
role for EAR-2 together with COUP-TFII in the repression of the estrogen activity on 
the oxytocin gene promoter (Chu et al., 1998; Chu and Zingg, 1997). Interestingly, 
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ERRα and EAR-2 were identified in the same study to both regulate aromatase, the 
key enzyme of estrogen synthesis, albeit in opposite directions (Chen et al., 2001; 
Yang et al., 2002; Yang et al., 1998).  
 
Interestingly, we also detected the regulation of other orphan nuclear receptors by 
PGC-1α, such as LXRβ and LRH-1, two receptors involved in the regulation of lipid 
metabolism. Furthermore, PGC-1α expression led to the repression of COUP-TF II, a 
nuclear receptor with repressor activities, (Pereira, 2000) and RXRα, the common 
heterodimer partner for many nuclear receptors (reviewed in Rastinejad, 2001). Since 
not all of these genes were regulated significantly, they will not be discussed further, 
though, it could be important to verify their regulation by PGC-1α, and to test a 
potential role of PGC-1α in the regulation of lipid metabolism.  
 
SRC-1 was the first nuclear receptor coactivator identified (Kamei et al., 1996; Onate 
et al., 1995) and belongs to the class of histone modifying coactivators. Early studies 
showed the assembly of SRC-1 together with PGC-1α and CBP (Puigserver et al., 
1999) in a complex that exerts HAT activity. Later studies by Surapureddi et al 
(Surapureddi et al., 2002) confirmed these data by the identification of a putative 
PPARα -interacting cofactor complex (PRIC) from rat liver, which contained CBP, 
SRC-1, PGC-1α and others. Besides SRC-1, several other coactivators were induced 
by PGC-1α, for example TRAP80, a member of the mediator complex, which was 
also proposed to interact with PGC-1α (Surapureddi et al., 2002; Wallberg et al., 
2003). Interestingly, the regulation of these genes by PGC-1α suggests a much higher 
complexity in transcriptional regulation than expected. It could imply that increases in 
levels of PGC-1α in response to specific metabolic signals alter the expression of 
specific coactivators, as well as recruit them to PGC- 1α complexes. Such complex 
mechanisms may explain the potency with which PGC-1α induces specific pathways. 
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Cell signaling  
 
Our early studies, before the gene expression profiling experiments, had already 
suggested that PGC-1α expression in SAOS2 cells influences cell shape, cytoskeleton 
organization and possibly cell growth or viability. As can be seen in figure 4, both the 
actin (A) and the tubulin staining (B) change dramatically after PGC-1α expression 
for around 48 hours. Interestingly, one of the PGC-1α repressed genes was a member 
of the tubulin family, suggesting that changes in the pattern of cytoskeletal proteins 
expressed could underlie the observed changes in cell shape. 
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Figure 4. PGC-1α expression changes the morphology of SAOS2 cells. 
SAOS2 cells were infected with an adenovirus expressing PGC-1α or the control βgal for 
around 48 hours (MOI 50). The GFP expressing cells represent PGC-1α positive cells, since 
PGC-1α and GFP were expressed from the same bicistronic message of this vector. (A) Actin 
staining. (B) Tubulin staining. 
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The role of PGC-1α in differentiation. The regulation of many genes involved in 
cell signaling, cytoskeleton organization, cell growth, but also the influcence of PGC-
1α on the cell shape, suggested to us that PGC-1α might alter the differentiation state 
of the cells. SAOS2 cells are osteoprogenitor cells that posses the ability to 
differentiate into osteoblasts or adipocytes, (Diascro et al., 1998). While ERRα has 
been shown to promote bone formation and induce osteopontin, ERRα expression 
also parallels adipocyte differentiation and leads to the induction of the β-fatty acid 
oxidation enzyme MCAD (Bonnelye et al., 2001; Bonnelye et al., 1997; Sladek et al., 
1997; Vanacker et al., 1998; Vega and Kelly, 1997). Interestingly, neither 
osteopontin, nor alkaline phosphatase, osteocalcin, collagens or other classical 
osteoblast markers were upregulated by PGC-1α. However, these may be genes 
induced in later stages of development. PGC-1α did induce the expression of 
C/EBPδ, a transcription factor carrying roles in both adipocyte and osteoblast 
differentiation (Guerra et al., 1994; Gutierrez et al., 2002; Lane et al., 1999).  
 
Three more differentiation factors, BMP-2, VEGF and lipin were upregulated by 
PGC-1α. BMP-2 induces the differentiation of mesenchymal cells into osteoblasts, 
chondrocytes or adipocytes (Ahrens et al., 1993). VEGF was identified as a BMP-2 
target and could also be involved in myoblast, osteoblast or adipocyte differentiation 
(Claffey et al., 1992; Marrony et al., 2003; Midy and Plouet, 1994). Finally, lipin was 
suggested as an important factor for adipocyte differentiation, and mutations in its 
gene cause lipodistrophy (Peterfy, 2001). However, it has also been identified as a 
marker of muscle atrophy in fasted mice and rats with renal failure, cancer or diabetes 
(Lecker et al., 2004).  
 
The induction of these factors by PGC-1α could imply that SAOS2 cells differentiate 
into adipocytes, rather than osteoblasts. This would be consistent with the induction of 
other genes in these cells, such as the ones encoding enzymes of the fatty acid 
oxidation pathway. However, it is not possible at this state of analysis to tell which, if 
any, differentiation program is induced by PGC-1α. Differentiation studies over a 
longer period of time, and possibly in different cell types, could give some insight into 
the role of PGC-1α and possibly ERR α in driving differentiation programs. 
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Metabolism 
 
Oxidative stress. ROS (reactive oxygen species) are byproducts of several metabolic 
reactions in the cell and primarily in mitochondria. An excess of ROS in mitochondria 
is able to cause oxidative stress. To prevent the oxidative damage of cellular 
machineries and in particular of the DNA, cells have developed a complex antioxidant 
defense system consisting of superoxide dismutases and glutathione transferring 
enzymes. PGC-1α, a potent regulator of mitochondrial biogenesis has been proposed 
to be involved in the cellular response to oxidative stress. The significant induction of 
three glutathione transferases, as seen in our gene chip experiment, and of SOD2 
(verified by real time RT-PCR), is consistent with this theory. Interestingly, at 17 
hours after infection with the PGC-1α adenovirus, cells have not yet made new 
mitochondria. Thus, the enhancement of enzymes fighting oxidative stress seems to 
fit a program induced by PGC-1α in preparation for the oxidative stress that is 
expected from the increased mitochondrial activity at later times, rather than as a 
response to the upregulated oxidative phosphorylation and oxidative stress. 
 
Glucose catabolism in SAOS2 cells. During fasting, in the fasting hyperglycemia 
situation of diabetes type II and during physiological exercise, glycogen serves as the 
major energy storage for the body. By the time glycogen reserves are exhausted, the 
body has to seek for new alternatives. Non-carbohydrates like lipids, provided from 
adipocytes and mainly muscle proteins are catabolized and glycerol, lactate and amino 
acids can be used for gluconeogenesis in the liver, which is regulated by PGC-1α 
(Yoon et al., 2001). Peripheral tissues as adipocytes, bone or muscle are not 
gluconeogenic, and therefore depend on glycogenolysis, uptake of glucose from the 
circulation, and glycolysis.  
The following metabolic enzymes were induced in our experiments (see figure 5): 
1) We detected an increase in the amylo-1, 6-glucosidase, 4-α-glucanotransferase, 
the glycogen debranching enzyme, which is activated during glycogenolysis. 
2) An increase in phosphoglucomutase, could convert the resulting glucose 1-
phosphate into glucose 6-phosphate, thereby making it accessible for glycolysis. 
3) Furthermore, we saw an upregulation of phosphofructokinase, the key enzymatic 
step in glycolysis.  
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4) The glycerol 3-phosphate dehydrogenase reaction in glycolysis forms NADH+H+, 
which is not able to enter the mitochondria to be oxidized by the respiratory chain. 
Therefore, upregulation of the malate-aspartate shuttle tries to overcome this by 
reducing oxaloactetate to malate and transporting the latter into the mitochondrion. 
There, malate is oxidized back to oxaloacetate, “producing” one NADH+H+, which 
can then be used by the respiratory chain.  
 
In conclusion, assuming that the increased expression of genes also leads to an 
increased production of the enzymes described here, PGC-1α seems to induce 
catabolic pathways in the SAOS2 cells, by activating glycogenolysis and glycolysis. 
These processes could provide the necessary substrates for entry into the 
mitochondrial oxidative pathways, and the production of ATP.  
 
 
 
Figure 5. PGC-1α influences glycogen breakdown and glycolysis in SAOS2 cells. 
Catabolic glucose pathway, numbers indicate proteins that were induced in our gene chip 
experiments. (Adapted from Moller, 2001). 
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Part 3: Genes regulated by PGC-1α and glucocorticoids 
 
GR exerts at least two types of effects on stress responses: 1) suppressive functions 
that either protect the cells from a metabolic overshoot or help prepare for new stress 
responses, and 2) permissive and stimulating effects that are part of the stress 
response (reviewed in Sapolsky et al., 2000). Based on this, we decided to analyze:  
A) if any of the PGC-1α induced genes in the absence of glucoorticoids were 
inhibited by glucocorticoids, suggesting a suppressive function for GR in PGC-1α 
signaling, and B) genes whose induction was dependent on both PGC-1α and 
glucocorticoids 
 
 
A) Genes that were induced by PGC-1α but repressed by GR 
 
24 probe sets (21 genes) were significantly induced by PGC-1α and repressed by GR 
(figure 6). To examine the possible programs that could be induced by PGC-1α and 
repressed by GR, we classified the genes according to their proposed functions (Table 
2 of Appendix I). 
 
igure 6. Venn Diagrams were genereated using GeneSpring. 24 probe sets were 
α .  
 
 
F
significantly induced by PGC-1  but repressed by GR
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Strikingly, only 3 genes with mitochondrial function were repressed by GR, 
suggesting that GR does not play a role in mitochondrial biogenesis in our system, as 
will be discussed later. A few of the other genes could be classified into one 
functional group, the BMP-2 signaling pathway: BMP-2, VEGF and G0/G1. The 
TGFβ superfamily member BMP-2 and VEGF, and their possible function in 
osteoblast or adipocyte differentiation were discussed before. The putative 
lymphocyte G0/G1 switch gene is highly expressed in adipocytes and stimulated by 
BMP-2 in late adipogenic differentiation (Bachner et al., 1998; Russell and Forsdyke, 
1991). Our data could suggest that PGC-1α induces a differentiation program in 
SAOS2 cells, but GR inhibits it. This is of course speculative, since it is not clear at 
this point if BMP-2 induces adipocyte or osteoblast differentiation in SAOS2 cells. 
 
 
Metabolism 
 
GR suppresses the metabolic function of PGC-1α in SAOS2 cells in two ways. 
Phosphoenolpyruvate carboxykinase 1 (PEPCK1) is known as a key enzyme for 
gluconeogenesis in liver and kidney. In adipocytes, PEPCK is important not for 
gluconeogenesis, but rather for glyceroneogenesis, which leads to the reesterification 
of fatty acids and to lipid synthesis (reviewed in Hanson and Reshef, 2003). 
Glyceroneogensis seems to be essential for storing the fatty acids, when they are not 
required for energy. PGC-1α induced the expression of PEPCK1, suggesting that it 
could promote glyceroneogenesis in our cell system. GR repressed PEPCK1, as it has 
been shown before to do in adipocytes, in vivo and in vitro, and consistent with its 
role in promoting lipolysis and inhibiting lipid synthesis in adipose tissue 
(Nechushtan et al., 1987). Interestingly, this regulation of PEPCK1 would further 
suggest that the SAOS2 cells display adipocyte-like characteristics. 
 
An interesting question arises, which transcription factor mediates the PGC-1α 
upregulation of PEPCK1. In liver, HNF4, GR and FOXO1 have been implicated in 
the PGC-1α induction of PEPCK1 (Herzig et al., 2001; Yoon et al., 2001). In 
adipocytes, PPARγ has been proposed to play an important role in the regulation of 
PEPCK1 expression (Tontonoz et al., 1995). Furthermore, PPARγ is a major regulator 
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of adipocyte differentiation and was proposed to be upregulated by BMP-2 (Grimaldi, 
2001; Hata et al., 2003). Although, PPARγ expression was not altered in our 
experiments profiles, it could be activated by fatty acids and coactivated by PGC-1α 
in our cell system. 
 
Pyruvate dehydrogenase kinase 4 (PDK4) was induced, not repressed by 
glucocorticoids. However, because this regulation may fit the suppressive effects of 
glucocorticoids on PGC-1α induced pathways, it is discussed here. PDK4 inhibits the 
activity of the pyruvate dehydrogenase complex by phosphorylation and prevents 
pyruvate from entering the TCA cycle. The induction of PDK4 by GR has been 
reported earlier. Interestingly, it seems to be dependent on binding to FOXO1, a factor 
also shown to be required for PGC-1α and HNF4 regulation of PEPCK1 in liver 
(Furuyama et al., 2003; Puigserver et al., 2003). As figure 7 A shows, the expression 
values of the gene chips suggested that the induction of PDK4 was stimulated by 
PGC-1α. However, analysis of the mRNA levels by quantitative real-time PCR in 
figure 7 B suggests no role for PGC-1α. Further analysis is necessary to determine if 
PGC-1α coactivates GR on the PDK4 promoter. The physiological implications of the 
PDK4 regulation by GR is that it would block the entry of energy substrates (whose 
levels would be increased by PGC-1α -induced glycogenolysis and glycolysis), into 
the TCA cycle and the respiratory chain. This suppressive effect on the PGC-1α 
induced program could be to protect cells from an overload with energy in form of 
ATP, or, quite likely, to divert energy substrates away from the cell’s oxidative 
system and back to the liver, where they could be used for gluconeogenesis.  
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Figure 7. Pyruvate dehydrogenase kinase 4 is induced by GR 
(A) Expression values represent the mean ± SEM from the three experiments analyzed on the 
U133A chip. (B) SAOS2 cells were infected with adenoviruses expressing βgal or PGC-1α 
(MOI 50). At 14 hours, cells were treated with 50 nM of corticosterone or vehicle for 3 hours. 
RNA was then isolated and analyzed by real-time RT-PCR. The mRNA levels for pyruvate 
dehydrogenase 4 were normalized to the mRNA levels of 36B4 and expressed relative to the 
βgal infected cells treated with vehicle. Results shown are the mean ± SEM of 4 experiments 
with one value. Asterisks indicate that values with and without PGC-1α are significantly 
induced by glucocorticoids, *< 0.02 
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B) Genes that were induced by PGC-1α dependent on GR 
 
We compared the PGC-1α -induced probe sets, in the absence and presence of 
glucocorticoids. As we show in figure 8 A, many new genes appeared to be regulated 
by PGC-1α in the presence of hormone. In addition, more than half of the PGC-1α 
induced probe sets in the absence of glucocorticoids were also regulated in their 
presence. This represents a group (319 probe sets) that seems to be induced 
independently of GR (although, as exception, 6 of these probe sets may also be 
responsive to glucocorticoids). More interestingly, 171 probe sets responded to PGC-
1α only in the presence of glucocorticoids. As this represented around a third of all 
PGC-1α upregulated genes in both conditions, it would suggest an important function 
for GR in PGC-1α signaling. To obtain a subgroup of these probe sets that were 
induced significantly by both PGC-1α and GR, we compared the lists of probe sets 
induced in response to PGC-1α in presence of glucocorticoids, and GR-induced genes 
in the presence of PGC-1α (figure 8 B). This revealed a consistent group of 55 probe 
sets (49 genes) that were induced by PGC-1α and GR (shown as Table 3 in Appendix 
I). Strikingly, this represented only a small subgoup of the 171 probe sets that were 
induced by PGC-1α only in the presence of glucocorticoids. We do not exclude that 
the rest are not dependent on both PGC-1α and GR. Experimental validation of 
members from the different groups will be required to gain some insights on the 
significance of the regulated genes. Our current analysis focused on the group of the 
55 probe sets. 
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Figure 8. Comparison of the probe sets that were regulated by PGC-1α and GR. (A) GR 
activation shifts the PGC-1α responsive probe sets. (B) Overlap of PGC-1α and GR induced 
genes. 
 
 
To validate some of our findings, we analyzed the mRNA levels of three examples by 
quantitative real-time PCR. Figure 9 A and B shows the U133A expression values 
next to the results of the quantitative real-time PCR for Bardet Biedl syndrome 1 
(BBS1), solute carrier 19 member 2 (thiamine transporter) and interleukin receptor 22 
(IL22R). As could be observed, all three were upregulated by GR, with an additional 
effect of PGC-1α. 
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Figure 9. Genes that are regulated by PGC-1α and GR 
(A) Values represent the mean ± SEM of three different expression profile experiments with 
the human 133A chips. (B) Cells were infected with either the controls (βgal) or PGC-1α 
expressing adenovirus for 14 hours. Then, cells were treated with glucocorticoids for 3 
additional hours and RNA was isolated. The mRNA levels were analyzed by quantitative 
PCR. Values for Bardet Biedl syndrome 1, the thiamine transporter and interleukin receptor 
22 were normalized to the levels of 36B4 and expressed relative to the βgal control and 
vehicle. Results represent the mean ± SEM of four to five different experiments. Asterisks 
indicate that values with glucocorticoids and without PGC-1α were significantly induced (*< 
0.05, ** < 0.006, *** < 0.0001) or values with PGC-1α and glucocorticoids showed a 
significant enhancement to the ones without PGC-1α (* < 0.05, ** < 0.006). 
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These results showed that both GR and PGC-1α regulate the expression of these 
genes. We cannot yet tell if this is due to direct regulation by PGC-1α and GR. 
Further studies are necessary to determine if GR binds directly the promoters of 
IL22R, thiamine transporter and BBS1 and if PGC-1α coactivates GR on these genes. 
 
Classification of genes in this group according to proposed functions, implied a 
regulation of the cell cycle and cell viability by GR and PGC-1α, since we detected 
an induction of the cycle inhibitor p21, which was already identified as GR target in 
SAOS2 cells and used as a control for the experimental design ((Rogatsky et al., 
1997), figure 1), and a few more genes involved in cell cycle arrest or apoptosis 
(Appendix I table 3). We also observed the induction of transcriptional regulators, 
signaling molecules and several other cellular pathways. More experiments are 
necessary to verify these preliminary data. In the following, some examples will be 
discussed. 
 
 
Metabolism 
 
PGC-1α and GR regulate together important metabolic factors. Bardet Biedl 
syndrome (BBS) is a heterogeneous, autosomal recessive disorder, which is 
characterised by mental retardation, obesity, hypogonadism, short stature, retinitis 
pigmentosa and polydactyly, and secondary disorders like diabetes, hypertension and 
renal and cardiac anomalies (reviewed in Katsanis et al., 2001). At least five gene loci 
seem to be involved in the manifestation of this syndrome, but the most important was 
allocated to BBS1. BBS4 could play a role in signaling, and BBS6 seems to act as 
molecular chaperone; the function of BBS1 is not yet known. Interestingly, not only 
BBS1 was induced in our experiments, but also BBS6, also known as McKusick-
Kaufman gene (MKKS), which was significantly upregulated by PGC-1α with some 
GR responsiveness (see Appendix I table 1 and 3 respectively).  
 
Humans lack biosynthesis pathways for several micro-nutrients like thiamine, also 
known as vitamine B1. Uptake through nutrients and in particular the transport of 
those vitamins via the thiamine transporter are essential. The active form of 
 135
Chapter IV: Analysis of PGC-1α and GR expression profiles 
 
thiamine serves as cofactor for several metabolic enzymes involved in carbohydrate 
catabolism (reviewed in Schorken and Sprenger, 1998), the biosynthesis of 
neurotransmitters, and the production of reducing equivalents used in the oxidative 
stress defenses (Gibson and Zhang, 2002). For example, thiamine is essential for the 
pyruvate dehydrogenase complex, the key enzyme in glucose metabolism that 
provides acetyl-CoA and NADH for the TCA cycle. Defects in the thiamine 
transporter THTR1 lead to diabetes mellitus, sensoneural deafness, cardiovascular 
diseases, neurosensory defects and defects in the haematopoietic system (Beri-beri, 
Wernicke encephalopathy (Singleton and Martin, 2001)).  
 
We have verified the regulation of BBS1 and the thiamine transporter by PGC-1α and 
GR, as seen in figure 9. It remains to be further analyzed if GR directly binds to the 
promoters of those genes and what could be the function of BBS1. Regulation of 
these target genes supports previous findings that defects in PGC-1α signaling, but 
also prolonged glucocorticoid levels, could be involved in insulin-resistance, 
hyperglycaemia and diabetes (Ek et al., 2001; Hammarstedt et al., 2003; Hara et al., 
2002; Lane et al., 1999; Rosmond, 2002). 
 
 
Signaling 
 
GR possibly regulates PGC-1α activity. The MAP kinases p38 and the stress-
activated protein kinase/c-Jun N-terminal kinases (SAPK/JNK) are activated by stress 
generators such as toxins, proinflammatory cytokines and also by reactive oxygen 
species (ROS) during oxidative stress. Work of our and other labs have shown that the 
activity of PGC-1α is induced through p38 phosphorylation, in response to cytokines, 
and through the displacement of a repressor (Fan et al., 2004; Knutti et al., 2001; 
Puigserver et al., 2001). PGC-1α and GR induced the kinase MAP3K7, better known 
as TAK1. Strikingly, TAK1 is the upstream MAP kinase for MKK6, which in turn 
phosphorylates and activates p38 (Moriguchi et al., 1996). These data would suggest a 
feedback mechanism of PGC-1α for its own activation and more importantly, another 
mechanism by which GR could regulate PGC-1α activity.  
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Although MAP kinases show some specificity, they exert influence on many different 
functions in cell signaling. TAK1 was also shown to act in response to the PGC-1α 
target BMP-2, a growth factor involved in differentiation and discussed before 
(Shibuya et al., 1998). However, the fact that GR repressed BMP-2 but induced 
TAK1, would suggest that TAK1 does not respond to BMP-2 in this system. Promoter 
binding studies with TAK1 and phosphorylation studies with PGC-1α in the absence 
and presence of glucocorticoids could provide support for this theory. 
 
PGC-1α regulates GR through a negative feedback mechanism. “Prereceptor” or 
“intracrine” regulatory mechanisms have been described for several steroid hormones 
and involve target tissue activation or inactivation of the circulating hormone. 
Glucocorticoid metabolism is regulated by two isoenzymes of 11ß-hydroxysteroid 
dehydrogenase 11ß-HSD (Stewart and Krozowski, 1999). The type 1 isozyme (11ß-
HSD1) is involved in the generation of the active glucocorticoid, cortisol, in tissues 
with high GR expression like liver, gonads or adipose tissue (Tannin et al., 1991). In 
contrast, 11ß-HSD2 converts active cortisol to inactive cortisone. In tissues with high 
MR expression, like kidney and colon, 11ß-HSD2 acts to protect the MR from 
cortisol, which binds to GR and MR (Albiston et al., 1995). Deficiency of 11ß-HSD2 
leads to hyperactive MR, natrium retention and hypertension (reviewed in Stewart, 
1999; Wilson et al., 2001). Surprisingly, studies have also suggested a high expression 
for 11ß-HSD2 in osteoblast cells (Bland et al., 1999; Eyre et al., 2001), not known to 
have functional MR, suggesting an alternative role for this enzyme in the regulation of 
bone homeostasis or cell proliferation. Experiments revealed insensitivity to 
glucocorticoids in cells that show a high 11ß-HSD2 activity (Bland et al., 1999; Eyre 
et al., 2001). This suggests an important role for 11ß-HSD2 in modulating ligand 
availability for GR. The regulation of 11ß-HSD2 by GR and PGC-1α implies an 
interesting, up to date unidentified negative feedback regulation of GR activity. 
Interestingly, the expression levels were not altered in the presence of one factor 
alone, but induced around 1.8 fold in the presence of both. This could imply an 
essential function for PGC-1α in this regulation. Further studies should address 
whether GR acts on 11ß-HSD2 directly, and the requirement of PGC-1α instead of 
other coactivators. 
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PGC-1α and GR influence the expression of the vitamin D receptor. Vitamin D 
receptor (VDR) functions as a ligand-induced nuclear receptor regulating the 
expression of genes involved not only in the control of calcium homeostasis, 
phosphate homeostasis and bone remodeling, but also in immunomodulation, 
inhibition of cell growth and induction of cell differentiation (Lin and White, 2004). 
Polymorphisms in the VDR gene, besides the ERα gene, were proposed by many 
studies as candidates in contributing to osteoporosis in menopausal women. 
Strikingly, osteoporosis appears as a negative side effect of long-term glucocorticoid 
treatment in patients with autoimmune diseases. In our cell system, VDR was one of 
the GR targets, where PGC-1α was definitively required for the induction. 
Interestingly, the cytochrome P450 enzyme (CYP24A1), which inactivates cycling 
vitamine D, was significantly upregulated by PGC-1α and repressed by GR. Although 
many other examples that were discussed before implied a non-osteoblast phenotype 
for the SAOS2 cells and VDR does not exclusively function in bone, the regulation of 
the VDR could imply a role for PGC-1α as a coactivator for GR in the bone. 
Consistent with this J. Miner and his group recently identified a new synthetic 
compound, which activates GR and reduces the ability to interact with PGC-1α, but 
still allows to interact with other coactivators (Coghlan et al., 2003). Interestingly, this 
compound showed similar antiinflamatory effects as glucocorticoids, but less side 
effects in bone.  
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Part 4: Genes that were regulated by GR independent of PGC-1α 
 
Our data suggested that PGC-1α and GR could exert some collaborative functions in 
SAOS2 cells. However, not all GR -induced genes were regulated by PGC-1α. This 
led us to further analyze the GR induced expression profiles. Figure 10 shows that the 
expression of PGC-1α dramatically influenced the expression profiles of GR. 
Interestingly, three times more probe sets were induced by GR only in the presence 
than only in the absence of PGC-1α, supporting the idea that PGC-1α plays an 
important role in the regulation of GR activity. Still, 139 probe sets were significantly 
induced irrespective of PGC-1α expression. We focused on this group of genes in our 
first analysis. As can be noted in table 4 of the Appendix I, assignment of proposed 
functions to this group of induced genes suggests an effect of glucocorticoids on 
many cellular processes, including effects on a large number of transcriptional 
regulators.  
 
 
 
 
Figure 10. Ven Diagragram compares all probe sets significantly induced by GR, in the 
absence and presence of PGC-1α. 
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Furthermore, only three probe sets were induced by GR independent on PGC-1α and 
significantly repressed by latter. One example will be discussed later. 
 
To verify that the regulation of some of these genes does not depend on PGC-1α, we 
analyzed the mRNA levels of two examples: lipase protein and zinc finger protein 
145. Lipase is a protein with unknown function, but sequence analysis revealed some 
similarity with acetyltransferases, which could suggest a function in metabolism. The 
zinc finger protein 145 or promyelocytic leukemia zinc finger (PLZF) protein gene is 
disrupted in therapy-resistant acute promyelocytic leukemia (APL) (Chen et al., 
1993). This Kruppel-like transcription factor seems to be involved in apoptosis, 
growth suppression (Shaknovich et al., 1998) and differentiation of different tissues, 
for example in adipocyte differentiation (Sekiya, 2004). As seen on the U133A 
expression values and the mRNA levels tested by quantitative RT-PCR in figure 11, 
both genes responded to glucocorticoids, whereas expression of PGC-1α did not show 
any effect. 
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Figure 11. Genes induced by GR independent of PGC-1α 
(A) Affymetrix U133A expression values represent the mean ± SEM from three experiments. 
(B) SAOS2 cells were infected with adenoviruses expressing βgal or PGC-1α (MOI 50) for 
14 hours, followed by a 3 hour treatment with 50 nM of corticosterone or vehicle. Then, RNA 
was isolated and analyzed by quantitiative RT-PCR. The mRNA levels for lipase and the zinc 
finger protein 145 were normalized to the mRNA levels of 36B4 and expressed relative to the 
βgal infected cells treated with vehicle. Results shown are the mean ± SEM from 4 
experiments with one value. As the asterisks show, were the values with glucocorticoids 
significantly induced to the values without. *< 0.02, ** 0.0004, *** < 0.005 
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Role of GR in mitochondrial biogenesis. Since early results suggested a regulation 
of mitochondrial biogenesis by glucocorticoids, several studies have provided support 
for these findings (Allan et al., 1983; Wakat and Haynes, 1977). Characteristics of 
long-term stress situations are enhanced catabolism of muscle protein and stimulation 
of hepatic gluconeogenesis. Eventually, insulin resistance followed by diabetes and 
increased energy expenditure can occur. Several studies have shown an increased 
expression of genes with functions in mitochondria after glucocorticoid treatment in 
liver (Kadowaki and Kitagawa, 1988; Morris and Kepka-Lenhart, 2002), colon 
(Rachamim et al., 1995) and in muscle (Weber et al., 2002). In contrary, the decrease 
of several mitochondrial enzymes was observed after glucocorticoid treatment in 
kidney and pancreas (Fabregat et al., 1999; Simon et al., 1998). Finally some evidence 
exists for the localization of GR in mitochondria (Demonacos et al., 1995; 
Demonacos et al., 1993; Demonacos et al., 1996; Moutsatsou et al., 2001; Tsiriyotis et 
al., 1997) or for the association with the mitochondrial outer membrane (Koufali et 
al., 2003). However, the mechanism of this glucocorticoid action, is still not clear, 
since no regulation of the mitochondrial transcription and replication factor mtTFA 
could be seen (Weber et al., 2002). 
 
Based on the parallel activation of PGC-1α and GR by some stressors, the role of 
both proteins in the regulation of energy pathways, and the ability of PGC-1α to 
regulate GR activity, it appeared possible that PGC-1α and GR regulate 
mitochondrial biogenesis coordinately. However, the analysis of glucocorticoid 
induced or repressed genes revealed only a small percentage of genes with 
mitochondrial function. This does not rule out the potential collaboration between GR 
and PGC-1α in mitochondrial biogenesis completely, since glucocorticoids may 
function in this program in a cell-type specific manner, and not in SAOS2 cells. 
Recent results suggested an important role for the regulation of mitochondrial 
biogenesis by glucococrticoids in muscle (Weber et al., 2002). It would be therefore 
interesting to establish a muscle cell system to study the role of GR/PGC-1α in 
mitochondrial biogenesis. 
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Transcription 
 
GR might affect DNA repair through the regulation of forhead box transcription 
factor 3A. In the following, one example will be discussed, which is one of the three 
genes that were induced by GR but repressed by PGC-1α. 
Forkhead box O 3A (FOXO3A) was represented by four probe sets on the U133A 
chip, and three of them were significantly induced in all three experiments by 
glucocorticoids. PGC-1α significantly repressed FOXO3A expression in the absence 
of hormone, whereas it did not show an effect in the presence. FOXO transcription 
factors are regulated by protein kinase B in response to insulin signaling (Kops et al., 
1999). Studies have implicated a role for them in the regulation of cell cycle and cell 
viability (Dijkers et al., 2000a; Dijkers et al., 2000b; Medema et al., 2000). Insulin 
activates PI3kinase, which in response activates PKB by phosphorylation. The 
subsequent phosphorylation of FOXO3A by PKB leads to the shuttling of FOXO3A 
out of the nucleus, and to its inactivation (Brunet et al., 2002). FOXO3A possibly 
regulates cyclin-dependent-kinase inhibitor p27 expression through the regulation of 
ubiquitin-mediated degradation and causes cell cycle arrest in the G1 phase (Medema 
et al., 2000). Since the insulin-PI3K pathway seems to be involved in the regulation of 
life span in Caenorhabditis elegans (Lin et al., 1997; Ogg et al., 1997), Greenberg and 
colleagues were wondering if a similar mechanism could be identified in mammals. 
Interestingly, their studies suggested a FOXO3A dependent induction of G2-M cell 
cycle arrest and DNA repair (Tran et al., 2002). Their DNA microarray analysis 
identified two factors that were induced by FOXO3A and involved in DNA repair, 
GADD45 and PA26. Strikingly, both of these genes were also induced by GR, 
independent of PGC-1α in our experiments. 
PGC-1α influenced the cell morphology of SAOS2 cells (figure 4), and also induced 
several genes involved in the induction of cell cycle arrest and apoptosis. Some 
factors, which generate cell cycle arrest, like p21, were induced by both PGC-1α and 
GR. However, whereas PGC-1α overexpression seems to induce stress to the cells, 
GR might counteract this effect and tries to protect the cells from DNA damage 
through the regulation of FOXO3A. 
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Chapter V: Discussion 
 
 
Numerous different coactivators and coactivator complexes have been identified to 
modulate nuclear receptor signaling. Increasing amount of evidence gained with many 
studies in the last years have proposed that coactivators define the specificity of 
transcriptional regulation in a promoter- and tissue-specific manner. The goal of my 
thesis was to analyze if the tissue-specific and signal-inducible coactivator PGC-1α 
would provide specificity to GR signaling and the signaling of other nuclear receptors. 
We designed a cellular model system with either undetectable levels of PGC-1α or 
overexpressed PGC-1α, and with inactive or actived GR. Our results gave us new 
information about the role of the orphan nuclear receptor ERR α in PGC-1α 
signaling. Furthermore, we asked if PGC-1α would be able to redirect GR signaling 
to a specific subset of genes, thereby altering the specificity of gluccocorticoid 
signaling. 
 
 
Part 1: The function of ERRα in PGC-1α signaling 
 
PGC-1α regulates the orphan nuclear receptor ERRα. 
The identification of ligands for orphan nuclear receptors in the last years opened a 
new view on the regulation of metabolism by nuclear receptors, which can function as 
direct metabolite sensors, and respond immediately and specifically to the metabolic 
requirement of the cell (reviewed in (Giguere, 1999). Still, some receptors like ERRα 
remain ‘orphan’. ERRα expression is high in tissues with high β-fatty acid oxidation 
and seems to regulate a key enzyme in this program, MCAD (Luo et al., 1997; Sladek 
et al., 1997; Vega and Kelly, 1997). Interestingly, ERRα knockout mice show 
reduced adipose tissue and the altered expression of several enzymes involved in lipid 
metabolism (Luo et al., 2003). We demonstrated that the expression of ERRα 
paralleledd the specific expression of PGC-1α, a sensor and integrator of metabolic 
signals, in tissues with high energy demands (Schreiber et al., 2003). Moreover, our 
data suggested that PGC-1α is important for ERα function, by regulating both its 
expression and activity, thereby serving as a protein ligand for this orphan receptor. 
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Finally, we have shown that PGC-1α induces the expression of ERRα through an 
autoregulatory loop, in which low levels of ERRα enable PGC-1α to induce the 
ERRα promoter.  
 
 
PGC-1α as a regulator of several orphan nuclear receptors. 
Our expression analysis revealed that PGC-1α also induced other orphan nuclear 
receptors, like LXRβ and LRH-1, which seem to play an important role in the 
regulation of lipid metabolism (Francis et al., 2003; Repa and Mangelsdorf, 2000) and 
EAR-2 (erb A like 2), a less known family member with proposed functions in lipid 
metabolism and estrogen signalling (Ladias et al., 1992; Yang et al., 1998). Strikingly, 
besides ERRα, also other orphan nuclear receptors like LXRα or RAR are regulated 
through autoregulatory loops (Laffitte et al., 2003; Leroy et al., 1991; Li et al., 2002). 
Interestingly, PGC-1α was recently reported to induce FXR expression in liver, in 
response to fasting (Zhang et al., 2004). PGC-1α coactivates PPARγ or HNF4 at the 
FXR promoter, leading to enhanced FXR levels and the regulation of lipid 
metabolism. Our findings, together with these recent studies, suggest that PGC-1α 
may serve as a regulator of several orphan nuclear receptors, orchestrating the 
regulation of metabolism in response to metabolic demands. 
 
 
PGC-1α regulates mitochondrial biogenesis in collaboration with ERRα. 
Mitochondrial biogenesis describes the processes required for the formation and 
homeostasis of mitochondria. The efficiency of mitochondrial respiration is under the 
strict control of physiological activity, temperature changes, hormones, growth 
factors, cell cycle or developmental aspects (Moyes and Hood, 2003; Scarpulla, 
2002). One of the key factors controlling the rapid adaptation to enhanced respiratory 
demands seems to be PGC-1α, which is regulated by exercise, fasting or thermogenic 
processes (reviewed in Knutti and Kralli, 2001; Puigserver and Spiegelman, 2003). 
Ectopic expression of PGC-1α led to the induction of mitochondrial biogenesis in 
muscle, heart and adipose tissue. In adipocytes and perhaps myocytes, PGC-1α seems 
to regulate the expression of genes encoding mitochondrial proteins, especially the 
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mitochondrial replication and transcription factor mtTFA through the induction and 
interaction with NRF-1 and NRF-2 (Baar et al., 2002; Wu et al., 1999). In SAOS2 
cells, we observed that the increase in the mitochondrial content by PGC-1α was 
highly dependent on ERRα, and that NRF-1 and NRF-2 levels did not change. Our 
results suggest that ERRα does not influence the basic, constitutive activity of 
mitochondria, which could be exerted by NRF-1, NRF-2, Sp1, YY1, CREB, MEF-2 
proteins and others that have been proposed before (reviewed Scarpulla, 2002). In 
contrast, PGC-1α modulates mitochondrial activity in collaboration with ERRα, 
possibly in response to physiological signals like exposure to cold or fasting. Our 
findings are supported by an integrative genomic and proteomic approach by Mootha 
and coworkers, who recently identified ERRα as a transcription factor that is 
coregulated with mitochondrial biogenesis (Mootha et al., 2003). Furthermore, ERRα 
knockout mice show reduced cytochrome c levels (Luo et al., 2003). Since we 
propose that ERRα regulates the mitochondrial content of the cell in response to 
metabolic requirements, it would be interesting to analyze the response of ERRα-
deficient mice to exercise or cold, and determine the effects on mitochondrial 
functions. Experiments with isolated primary tissues like adipose cells or muscle 
could also test if PGC-1α is still able to induce mitochondrial biogenesis in ERRα-
deficient cells. 
 
 
The possible role for ERRγ in PGC-1α regulated pathways. 
Interestingly, PGC-1α has also been shown to coactivate the other two members of 
the ERR family, ERRβ and ERRγ (Hentschke et al., 2002; Huss et al., 2002; Kamei et 
al., 2003) Although ERRβ is mainly expressd during early embryonic development 
with only low levels in the adult, ERRγ seems likely to be coexrpessed with ERRα in 
several tissues (Bonnelye et al., 1997b; Heard et al., 2000; Hong et al., 1999; Sladek 
et al., 1997; Susens et al., 2000). All three family members show high similarities in 
the DBD and seem capable of binding the same response elements; still they may 
exert different specificities in the regulation of target promoters, as for example SHP 
(Sanyal et al., 2002). Our lab furthermore observed that all three receptors bind to the 
same interaction surface in PGC-1α (Knutti, unpublished). These data suggest some 
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potentially overlapping functions for ERRα, ERRβ and ERRγ. Some differences must 
exist, since the ERRβ knockout mouse is embryonic lethal (Luo et al., 1997), while 
disruption of ERRα leads to viable mice (Luo et al., 2003).  
Interestingly, ERRα mice displayed decreased ERRβ expression, which could suggest 
the regulation of ERRβ by ERRα. Recent studies also proposed a regulation of ERRα 
by ERRγ or vice versa, since the interaction of both family members in vitro inhibited 
their transcriptional activity (Huppunen and Aarnisalo, 2004). Although this 
interaction remains to be verified in vivo, these observations suggest that some 
regulatory network exists between ERRα, ERRβ and ERRγ. We did not detect any 
ERRγ in our system, suggesting that even if ERRγ could compensate for the loss of 
ERRα function, this would not be evident in the SAOS2 cells. Analysis of ERRγ 
overexpression or disruption by siRNA and the effects on mitochondrial biogenesis in 
another cell line could address the question of the involvement of ERRγ in ERRα 
pathways, and in particular mitochondrial biogenesis. At least four scenarios seem 
possible: (1) ERRα and ERRγ could bind as heterodimers to the promoters of 
mitochondrial genes and play a role in PGC-1α pathways. (2) ERRγ could replace 
ERRα and mediates PGC-1α programs in different tissues or in response to different 
physiological requirements. (3) ERRγ regulates ERRα activity through competition 
for binding sites or by direct protein-protein interaction, or by binding to the ERRα 
promoter. (4) ERRγ cannot replace ERRα; instead it mediates distinct PGC-1α 
functions. 
 
As observed before, ERRα is able to not only activate, but also inhibit transcription 
(Sladek et al., 1997; Zuo and Mertz, 1995). Our experiments with the ERRα promoter 
suggested a dependency on the concentration: in low amounts ERRα activates 
transcription from its own promoter, and at high levels it represses it. The effect of the 
cellular concentration on ERRα function was already described for the interaction 
with ERα (Kraus et al., 2002). Interestingly, overexpression studies have proposed 
that ERRα acts as a repressor of PGC-1α function on the PEPCK promoter (Ichida et 
al., 2002). Given our findings that ERRα can activate and repress at the same time the 
ERRα promoter, it seems important that any conclusion on the role of ERRα at any 
promoter are based on loss of function, as well as gain of function experiments. Our 
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findings demonstrate that ERRα functions are complex, and imply that ERRα 
function may depends on the cell type, promoter and especially the available 
cofactors. 
 
 
Role of PGC-1β in mitochondrial biogenesis. 
Our results suggest that both PGC-1α and PGC-1β require the transcriptional activity 
of ERRα to induce the expression of ‘mitochondrial function’ genes. Although our 
data are still preliminary, PGC-1β shows less dependency on ERRα to increase 
mitochonddrial density. Strikingly, also PRC, the third PGC-1α homologue, increased 
the cellular content of mitochondria, although the role of ERRα in this function has 
not yet been analyzed. Whereas PGC-1α and ERRα were induced by metabolic 
signals, PGC-1β and PRC are not. In contrast, PRC was regulated during proliferation 
(Andersson and Scarpulla, 2001), whereas PGC-1β is possibly controlled by the 
differentiating state of the cell (Kamei et al., 2003; Lin et al., 2002). It is still an open 
question, whether there is a redundancy among the three PGC-1 family members, and 
if so, why. In particular the structural differences of the three family members suggest 
that they should carry distinct functions. It is possible that PGC-1α, PGC-1β and PRC 
regulate mitochondrial biogenesis through the integration of different cellular 
requirements like cell cycle, differentiation, proliferation and metabolism. The 
question remains, which place is taken by ERRα in the induction of mitochondrial 
biogenesis by PGC-1β. As suggested by others, PGC-1β shows some differences in 
the regulation of mitochondrial processes to PGC-1α. Studies observed that PGC-1β, 
but not PGC-1α expression led to the regulation of specific enzymes that protect from 
oxidative stress (St-Pierre et al., 2003). This could propose that ERRα together with 
PGC-1α regulates different mitochondrial pathways than with PGC-1β. However, our 
data is still preliminary and more experiments are necessary to define the role of 
ERRα in PGC-1β signalling.  
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Part 2: Analysis of the PGC-1α and GR expression profiles 
 
PGC-1α induced specific metabolic pathways in SAOS2 cells. 
GR plays an important role in bone homeostasis and long-term treatment with 
glucocorticoids leads to osteoporosis. Although no studies with PGC-1α function in 
bone are available, an interesting study identified a new GR ligand, which prevented 
the interaction with PGC-1α and were proposed to have less side effects on glucose 
metabolism and bone homeostasis (Coghlan et al., 2003). These findings suggest that 
PGC-1α may play a role in regulating GR functions in bone.  
 
In the osteoprogenitor SAOS2 cell line, PGC-1α activated specific metabolic 
programs. We saw the promotion of catabolic pathways as the glycogenolysis and 
glycolysis, the induction of new mitochondria and the upregulation of enzymatic 
pathways in mitochondria like the β-fatty acid oxidation, the TCA cycle and the 
respiratory chain. Furthermore, our results demonstrated the induction of several 
transcription factors like ERRα, EAR-2, CEBPδ and others, which possibly mediate a 
part of the PGC-1α response. Interestingly, we found that a significant group of the 
PGC-1α induced genes, which were exclusively regulated by PGC-1α and not by GR, 
were dependent on ERRα, namely genes involved in the regulation of mitochondrial 
pathways. We also provided some evidence that at least some of those genes were 
regulated directly by ERRα, through binding to the promoters of these genes. This 
implies ERR α as an important mediator of PGC-1α functions. Further studies with 
overexpressed or reduced levels of ERRα could provide more indications about the 
participation of ERRα to other PGC-1α regulated pathways in SAOS2 cells. 
 
 
PGC-1α function was strongly altered by glucocorticoids. 
PGC-1α regulates cellular metabolism and energy balance in response to several 
stressors and glucocorticoids could possibly modulate PGC-1α action. Furthermore, 
both PGC-1α and GR are involved in diseases like diabetes. We observed that PGC-
1α dramatically influenced the profile of genes induced by glucocorticoids, and vice 
versa. The major difference between the PGC-1α regulated pathways that were 
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independent of, and dependent on GR was seen in the mitochondrial biogenesis, 
which was induced by PGC-1α alone, and was only minimally influenced by GR. The 
role of glucocorticoids in PGC-1α mediated programs appeared to be both 
“permissive/stimulative” and “suppressive”. On the one hand, we observed the 
collaborate induction of interesting metabolic factors involved in diabetes and obesity, 
such as the thiamine transporter or the Bardet Biedl syndrome 1. On the other hand, 
GR repressed the activity of the pyruvate dehydrogenase complex (via PDK4) and the 
expression of PEPCK1, which were induced by PGC-1α. These results suggest that 
PGC-1α does not act as a general transcriptional coactivator of GR, which would 
enhance the activity of GR on all target genes. To the contrary, PGC-1α seems to play 
a specific role in GR signaling, inducing specific cellular programs. However, at this 
state of the analysis and with not much experimental validation of the array results, 
not many conclusions can be drawn about the common or opposing cellular programs. 
The quantitative analysis of mRNA levels of more genes, coupled to in silico 
promoter studies, cellular assays, and experimental validation of the resulting data 
could give more information. 
 
 
The nature of SAOS2 cells. 
Myocytes, adipocytes, chondrocytes and osteoblasts all derive from the same 
mesenchymal progenitor cell. Previous studies mostly referred to SAOS2 cells as 
osteoblast cells. In contrast, our analysis of the PGC-1α expression profiles suggested 
that SAOS2 cells are osteoprogenitor cells rather that osteoblast cells. These findings 
are supported by the previous observation that SAOS2 cells are able to differentiate 
into adipocytes (Diascro et al., 1998). We could not detect a regulation of osteopontin 
by PGC-1α, although it has been proposed as an ERRα target gene (Bonnelye et al., 
1997a; Vanacker et al., 1998), or of any other bone marker. In contrast, we observed 
adipocyte features, such as the induction of the β-fatty acid oxidation genes by PGC-
1α. Surprisingly, we also observed the induction of myocyte-specific genes, such as 
the genes encoding myoglobin and the cardiac specific Hsp27, which were induced by 
PGC-1α. The induction of BMP-2 and CEBPδ, which are able to promote both 
osteoblast and adipocyte differentiation, suggest that PGC-1α and GR could play a 
role in the differeniation of the SAOS2 cells. Furthermore, PGC-1α and GR seem to 
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exert antiproliferative effects in our system by the induction of p21 and other factors, 
which could be involved in differentiation. On account of these observations it would 
be interesting to perform differentiation studies in the SAOS2 cells with 
overexpressed PGC-1α, and in particular analyse the possible role of ERRα. 
 
Can PGC-1α be replaced by other coactivators? 
Our results suggest that PGC-1α exerts distinct programs with ERRα and influences 
the activity of GR on specific target genes. However, the question arises, if only PGC-
1α can exert these functions, or if other coactivators like SRC-1 could induce similar 
responses, for example mitochondrial biogenesis. In principle, this was one question I 
would have liked to answer during my thesis. Due to several reasons I decided to 
focus on other aspects. Therefore I would like to discuss this possibility at this point.  
 
If the induction of SRC-1 levels by PGC-1α can be verified, it would be indeed 
interesting to test the activity of SRC-1 on some of the identified targets. Furthermore, 
I would suggest an experiment with specific downregulation of SRC-1 by siRNA to 
reveal if PGC-1α is still able to induce mitochondrial biogenesis or if SRC-1 is 
required for PGC-1α functions. The disruption of SRC-1 (Picard et al., 2002) 
suggested at least some dependency in the regulation of energy metabolism by PGC-
1α. However, the function of PGC-1α shows high complexity and several 
requirements would have to be fulfilled by SRC-1. For example, PGC-1α induced the 
expression of other coactivators, like TRIP 80, a component of the mediator complex. 
Earlier studies suggested already that PGC-1α interacts with SRC-1 to recruit 
chromatin-modifying coactivators like CBP and with the mediator complex as bridge 
to the basal transcription machinery. Interestingly, SRC-1 was also shown to interact 
with the mediator and may therefore replace PGC-1α. Importantly, PGC-1α seems to 
represent the regulatory element in this complex, responding to several signals like the 
cAMP cascade activated by glucagon, glucocorticoids or phosphorylation by p38. 
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An important argument against SRC-1 being able to substiture PGC-1α function may 
stem from studies on the orphan receptor ERRα. Expression and activation of ERRα 
seems important for the induction of the mitochondrial biogenesis program. 
Unpublished work from our group shows that coactivators like SRC-1 are very poor 
in activating ERRα, suggesting that they could not substitute for all PGC-1α 
functions.  
 
In conclusion, the specific function of PGC-1α seems to be a sum of several pieces, 
such as the expression at the right time and the right place, the ability to interact with 
specific nuclear receptors like ERRα, the induction of specific target genes, and 
finally the post-translational regulation by specific signaling pathways.  
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Summary and conclusions 
 
 
In the last years, increasing numbers of coactivators that regulate the transcriptional 
activity of nuclear receptors have been identified. Many of the coactivators seem to 
act as complexes, although redundancy has also been observed. Coactivators exert 
different functions like bridging to the basal transcription machinery or modification 
of chromatin structures. PGC-1α seems to take a special place in this scenery of 
transcriptional regulation. It was observed that PGC-1α levels were induced under 
certain physiological conditions, which signal increased metabolic demands. Ectopic 
expression of PGC-1α is sufficient to increase the mitochondrial density of cells 
representing different tissues, thereby leading to the proposal that PGC-1α is a key 
regulator of mitochondrial biogenesis. Furthermore, PGC-1α expression was 
connected to the misregulation of metabolism in obesity and diabetes. It is astonishing 
that the overexpression of only one component leads to the induction of so many 
programs; one would think that this makes the system vulnerable. To execute its 
metabolic functions, PGC-1α interacts with several different nuclear receptors like 
HNF4, PPARγ, ERRα, GR and more. Interestingly, also the expression of these 
receptors is controlled by metabolic means, as observed for HNF4, PPARγ, and 
ERRα for example, which respond to fasting. Possibly, it is the induction of both the 
specific coactivator and the nuclear receptor, controlled by different systems, that 
leads to the activation of the specific downstream programs. 
 
We observed that PGC-1α is controlling the expression of the orphan nuclear receptor 
ERRα by an autoregulatory loop. This induction of ERRα seems to be essential for 
PGC-1α to regulate mitochondrial biogenesis, (as shown by siRNA for ERRα 
experiments), and ERRα fused to the VP16 activation domain is sufficient to induce 
this program. The identification of binding sites for ERRα in genes encoding 
mitochondrial proteins and our in vitro studies suggest that ERRα regulates these 
genes directly, coactivated by PGC-1α. However, although PGC-1α and ERRα were 
induced by the same physiological programs, it remains to be determined if ERRα 
and PGC-1α regulate mitochondrial biogenesis in response to specific metabolic 
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signals in vivo. Moreover, the question remains if ERRα is required for the induction 
of mitochondrial biogenesis by PGC-1α in all tissues and situations. The analysis of 
ERRα levels during exercise and muscle could give more information. In particular, it 
would be interesting to determine ERRα levels in liver and muscle of diabetes 
patients, since the increase of PGC-1α expression in the one and the decrease in the 
other tissue seems to be connected to the misregulation of metabolic processes. In this 
case, ERRα could possibly provide a starting point for the development of new drugs 
against diabetes. 
 
Glucocorticoid levels are increased during organismal stress situations, similar to 
PGC-1α expression levels. Upon fasting, GR even regulates the expression of PGC-
1α. Whereas GR does not play a role in the regulation of mitochondrial processes by 
PGC-1α in SAOS2 cells, in remains to be further analysed in other tissues. However, 
as the previous studies suggested and our data supported, PGC-1α could play a role in 
several GR regulated pathways in vivo, besides the gluconeogenesis in liver. We 
observed a high number of genes that was regulated by PGC-1α only in the presence 
of glucocorticoids. The data also suggest that GR regulates PGC-1α function in 
metabolism positively and negatively. Furthermore, both influenced the cell growth 
and the expression of “differentiation-inducing” genes in SAOS2 cells. At this state of 
the analysis it is not clear, if PGC-1α induces adipocyte differentiation in SAOS2 
cells and if GR could influence this program. Finally and importantly, our data 
provide further support to the hypothesis that PGC-1α serves as a key component that 
confers specificity to nuclear receptor signaling. 
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Appendix I 
 
 
Table 1: Genes induced by PGC-1α without glucocorticoids 
 
Table 2: Genes induced by PGC-1α and repressed by GR 
 
Table 3: Genes induced by PGC-1α and GR 
 
Table 4: Genes induced by GR in the absence and presence of PGC-1α 
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Peroxisome proliferator-activated receptor  coacti-
vator-1 (PGC-1) is a tissue-specific coactivator that en-
hances the activity of many nuclear receptors and coor-
dinates transcriptional programs important for energy
metabolism. We describe here a novel PGC-1-related co-
activator that is expressed in a similar tissue-specific
manner as PGC-1, with the highest levels in heart and
skeletal muscle. In contrast to PGC-1, the new coactiva-
tor shows high receptor specificity. It enhances potently
the activity of estrogen receptor (ER) , while having
only small effects on other receptors. Because of its nu-
clear receptor selectivity, we have termed the new pro-
tein PERC (PGC-1 related Estrogen Receptor Coactiva-
tor). We show here that the coactivation function of
PERC relies on a bipartite transcriptional activation
domain and two LXXLL motifs that interact with the
AF2 domain of ER in an estrogen-dependent manner.
PERC and PGC-1 are likely to have different functions
in ER signaling. Whereas PERC acts selectively on ER
and not on the second estrogen receptor ER, PGC-1
coactivates strongly both ERs. Moreover, PERC and
PGC-1 show distinct preferences for enhancing ER in
different promoter contexts. Finally, PERC enhances
the ER-mediated response to the partial agonist tamox-
ifen, while PGC-1 modestly represses it. The two coacti-
vators are likely to mediate distinct, tissue-specific re-
sponses to estrogens.
Nuclear receptors are ligand-regulated transcription factors
with a broad range of functions in development, physiology,
and behavior. They include steroid hormone receptors for glu-
cocorticoids, mineralocorticoids, progestins, estrogens, and an-
drogens, as well as receptors for thyroid hormone, retinoids,
vitamin D, and intermediary metabolites (1). They use a con-
served DNA binding domain (DBD)1 to interact with specific
sites in the genome, termed hormone response elements
(HREs). DNA-bound receptors can activate the expression of
genes in the vicinity of HREs, via two transcriptional activation
functions, denoted AF1 and AF2. AF1 lies in the N-terminal
part of the receptors and varies significantly from one receptor
to another. AF2 is located at the conserved ligand binding
domain (LBD) and relies on an agonist ligand-induced protein
conformation (2–5). Depending on cellular and promoter con-
text, AF1 and AF2 act independently or synergistically to reg-
ulate gene expression.
A large number of proteins that interact with the AF2 do-
main and enhance the activity of nuclear receptors have been
identified (reviewed in Refs. 6–8). They include the three mem-
bers of the p160 steroid receptor coactivator (SRC) family
(SRC-1/NcoA-1, TIF2/GRIP1/NcoA-2, AIB1/pCIP/ACTR/RAC3/
SRC-3), the cointegrators CBP and p300, components of the
Mediator complex, individual coactivators such as PGC-1,
NRIF3, ASC-2/RAP250, PELP1, and CAPER, and the family of
CITED proteins (6–12). Most of these coactivators harbor one
or multiple LXXLL motifs (L being leucine and X any amino
acid) within short amphipathic helices (13, 14). These LXXLL
motifs, also called NR boxes, interact with a hydrophobic
pocket of the ligand-activated LBD of the receptors, thereby
recruiting the coactivators to target DNA sites (15–17). The
diverse coactivators are then thought to regulate transcription
via enzymatic modification of chromatin or other transcription
proteins, and/or physical recruitment of components of the
transcriptional machinery (reviewed in Refs. 6–8). The multi-
tude of nuclear receptor coactivators suggests that at least
some of them carry distinct and specific functions. They may do
so by interacting with specific subsets of receptors, acting in
selective cell types, directing receptor function to subsets of
target genes or conferring regulation by other signals.
Of the so far identified AF2 coactivators, most interact with
many, if not all, nuclear receptors. Although particular LXXLL
motifs of SRC-1, TIF2, and SRC-3 display preferences for spe-
cific receptors, the three p160 coactivators can enhance the
activity of most nuclear receptors (18, 19). CBP and p300 are
general coactivators, not only of nuclear receptors but also of
many nonreceptor transcription factors (7). AF2 coactivators
that display receptor specificity include NRIF3, PELP1, CA-
PER, and CITED1. NRIF3 enhances selectively the activity of
the thyroid hormone receptor (TR) and retinoid X receptor
(RXR), without affecting the glucocorticoid (GR), estrogen (ER)
or vitamin D receptors (9). The other three receptor-selective
coactivators potentiate preferentially the activity of the two
ERs, ER and ER (10–12). None of the ER-specific AF2 coac-
tivators described so far distinguish between ER and ER,
* This work was supported by the Swiss National Science Founda-
tion, the University of Basel, Novartis Stiftung (to S. N. S.), and the
Max Cloe¨tta Foundation. The costs of publication of this article were
defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
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receptors that bind similar ligands and carry distinct biological
functions (20, 21).
Few coactivators show tissue-specific expression. One of
them is PGC-1, which is expressed at high levels in tissues such
as heart, skeletal muscle, kidney, and brown fat (22–24).
PGC-1 expression is induced also in a tissue-specific manner, in
response to particular physiological states such as exposure to
cold or fasting (22, 25, 26). Induction of PGC-1 in response to
signals indicating metabolic needs of an organism can then
lead to the activation of pathways important for energy home-
ostasis, such as adaptive thermogenesis, mitochondrial biogen-
esis, fatty acid oxidation, and gluconeogenesis (22, 25–29).
PGC-1 interacts with and enhances the activity of many nu-
clear receptors, like the peroxisome proliferator-activated re-
ceptors (PPAR)  and , TR, GR, ER, hepatocyte nuclear
factor 4 (HNF4), as well as nonreceptor transcription factors
like the nuclear respiratory factor 1 (NRF1) (22, 24, 26–28, 30).
A characteristic feature of PGC-1, not shared by other nuclear
receptor coactivators, is its C-terminal domain. It harbors se-
quence motifs typical of RNA processing regulators and has
been implicated in the regulation of pre-mRNA splicing (31).
The existence of sequence-related coactivators, such as the
three p160 SRC proteins, or CBP and p300, may reflect the
evolutionary adaptation of duplicated genes to similar but dis-
tinct biological functions. Recently, a PGC-1 related coactivator
(PRC) that is ubiquitously expressed and enhances the activity
of NRF1 was described (32). Here, we report the cloning and
characterization of a third member of the family. PERC (PGC-1
related estrogen receptor coactivator) is expressed in a tissue-
specific manner and displays a striking preference for func-
tional interactions with ER among the nuclear receptors.
EXPERIMENTAL PROCEDURES
Cloning of PERC—Total RNA was isolated from HeLa cells with the
Trizol reagent (Invitrogen). Full-length cDNA was synthesized either
by standard procedures using oligo(dT) primers or with the GeneRacer
kit (Invitrogen). Oligo(dT)-primed cDNA was used to amplify sequences
from exon 2 to the end of the predicted PERC open reading frame. The
5 part and first exon of the cDNA, which were absent from the pub-
lished genome sequence, were amplified in a nested polymerase chain
reaction (PCR), using internal exon 3-specific PERC primers, 5 Gene-
Racer Primers, and cDNA synthesized with the GeneRacer kit. Multiple
clones were analyzed and sequenced. Two types of PERC cDNAs were
found at a ratio of 1:1 (of 12 clones). They differed by a 117-bp sequence,
which corresponds to exon 4 of PERC. Restriction sites were introduced
by PCR at the 5 and 3 ends of the PERC coding sequences, and
full-length PERC (including the 117-bp exon 4) and PERC-s (lacking
exon 4) clones were constructed by standard subcloning procedures. The
PERC sequences have been submitted to the GenBankTM data base
under accession numbers AF468496 and AF468497. The full-length
PERC is the human homolog of the recently described mouse PGC-1
(33).
Expression Analysis—Total RNA was isolated from tissues of 6–8-
week-old mice using the Trizol reagent and checked for its integrity by
agarose gel electrophoresis and ethidium bromide staining. RNA (400
ng) was converted to cDNA in a 20-l reaction at 45 °C for 45 min using
MultiScribe reverse transcriptase (Applied Biosystems) and random
hexamer primers according to the manufacturer’s instructions. Real-
time PCR with the LightCycler system (Roche Diagnostics) was used for
the amplification and quantification of PERC, PGC-1, and -actin
cDNA. LightCycler reactions were performed in a final volume of 15 l,
using 3 l of cDNA, 10 pmol of specific primers, and the LC FastStart
SYBRGreen kit (Roche Diagnostics) as recommended by the manufac-
turer (denaturation at 95 °C for 15 s, annealing at 60 °C for 5 s, exten-
sion at 72 °C for 10 s; 40 cycles, with the PCR product being monitored
at 72 °C at the end of each cycle). A melting curve from 65 to 95 °C
(0.05 °C/s) at the end of the reaction was used to check the purity and
nature of the product. In all cases, a single PCR product was detected.
Primers were chosen with the help of the OLIGO 4 program and were
from different exons, so as to avoid amplification of possible DNA
contamination of the RNA preparation. The sequences of the primers
and the sizes of the PCR products were as follows: 5-CAA GCT CTG
ACG CTC TGA AGG-3 (exon 4) and 5-TTG GGG AGC AGG CTT TCA
C-3 (exon 5) for PERC (product 201 bp), 5-GGA GCC GTG ACC ACT
GAC A-3 (exon 4) and 5-TGG TTT GCT GCA TGG TTC TG-3 (exon 5)
for PGC-1 (product 176 bp), 5-GGT CAT CAC TAT TGG CAA CGA G-3
(exon 3) and 5-GTC AGC AAT GCC TGG GTA CA-3 (exon 4) for
-actin (product 196 bp). Control reactions performed on plasmid DNA
confirmed that the PGC-1 primers could not amplify PERC sequences
and vice versa. For quantification, standard amounts for each template
(from 400,000 to 128 plasmid copies, in 1:5 dilutions) were analyzed in
parallel to the samples. The cycle numbers needed for a log-linear phase
product to reach the crossing point, which was set above the back-
ground noise, were plotted against the logarithm of the input plasmid
copy number and fitted to a standard curve. The cDNA copy numbers
for each gene were calculated from the standard curve, and the copy
numbers of PERC and PGC-1 were normalized to the number of -actin
copies in the sample. Results shown are from duplicate reactions, using
the same cDNA preparation. Similar results were obtained from inde-
pendent preparations of cDNAs from two female and two male mice.
Plasmid Constructs—PERC deletion and point mutants were gener-
ated by standard PCR methods and verified by sequencing. All PERC
variants were subcloned into pcDNA3/HA, pcDNA3/GAL4DBD (con-
taining Gal4 DBD as a HindIII/NdeI fragment from pGBKT7 (CLON-
TECH)), and pGADT7 (CLONTECH). More information on the plas-
mids is available on request. Expression plasmids p6RGR, p6RMR,
pSVARo, pSG5/ER, pcDNA3/HA-hPGC-1, and pSG5/SRC-1e, as well
as the luciferase reporter plasmids pTAT3-Luc, pERE-tk-Luc (one copy
of the vitellogenin A2 ERE fragment (334 to 289 nucleotides, rela-
tive to transcription initiation) (vERE)), and pGK1 have been described
(24). The following expression and luciferase reporter plasmids were
generously provided: pSG5/hPR (34), pSG5/hER (E. Treuter), pSV-
SPORT1/mPPAR2 and p3xPPRE-tk-Luc (M. Meyer), pSG5/hTR and
pSG5/mRXR (H. Gronemeyer), pMMTV-LTR-Luc (35), pminPbLUC-
neo (F. Hamy), pC3-Luc (5). For the expression of the Gal4DBD/hER-
LBD fusion in yeast, the hER-LBD (308C) was amplified by PCR from
pSG5/ER and subcloned into pGBKT7 to yield pGBKT7/hER(308C).
To generate hER AF2 mutant L539/540A, the LBD was amplified by
PCR from pRST7/hER-LL (30) and subcloned either into pGBKT7 to
yield pGBKT/hER(308C)-LL or into pSG5/ER to yield pSG5/hER-
LL. The luciferase reporter plasmids p(vERE)x1-Luc and
p(vERE)x2-Luc were constructed by cloning the vERE-containing
HindIII fragment from pERE-tk-Luc into the HindIII site upstream of
the minimal alcohol dehydrogenase promoter of pLuc (35).
p(cERE)x1-Luc and p(cERE)x2-Luc have a monomer or dimer of the
sequence 5-GAG CTC GAG AGG TCA CAG TGA CCT GTC-3 (consen-
sus (cERE) half-sites are underlined) at the SalI site of p-Luc.
p(DR4)x2-Luc has the sequence 5-CTT AGG TCA CTT CAG GTC
AGC CTC GAG GGA GGT CAC TTC AGG TCA GTC-3 (DR4 half-sites
are underlined) at the HindIII/SalI sites of p-Luc.
Cell Culture and Transfections—COS7 and U2OS cells were cultured
in Dulbecco’s modified Eagle’s medium supplemented with 9% fetal
bovine serum. Charcoal-stripped fetal bovine serum was used when
assaying hormone responses. Media lacking phenol red were used in
experiments with AR or ERs. Cells were seeded into six-well plates 24 h
prior to transfection by the calcium phosphate precipitation method. All
transfections included 0.2 g of p6RlacZ for normalization of transfec-
tion efficiency. Standard amounts of expression and reporter plasmids
per transfection in coactivation assays were: 1 g of nuclear receptor
expression plasmid, 1 g of luciferase reporter, 0.5 g of
pcDNA3/HA-PERC (and its variants) or pcDNA3/HA-hPGC-1. For co-
activation of AR in COS7 and coactivation of ER in U2OS, 1 g of
pcDNA3/HA-PERC, pcDNA3/HA-hPGC-1, and pSG5/hSRC-1e was
used. When assaying the transcriptional activity of the Gal4DBD-
PERC fusion proteins in COS7, 0.5 g of pcDNA3/GAL4DBD-PERC (or
its variants) and 1 g of the Gal4-responsive pGK1 luciferase reporter
were transfected. After overnight exposure to the DNA-calcium phos-
phate precipitate, cells were washed and incubated for an additional
24 h in fresh medium containing either hormone or vehicle (0.1%
ethanol or Me2SO). Assays for luciferase and -gal activities were
performed as described previously (24). Luciferase values normalized to
-gal activity are referred to as luciferase units. Data shown represent
the mean  S.D. of four to six values from at least two independent
experiments performed in duplicates.
Yeast Two-hybrid Interaction Assay—A diploid yeast strain with
integrated Gal4-responsive -gal reporters (CG1945xY187, CLON-
TECH) was transformed by the lithium acetate transformation method
with pGBKT7/hER(308C) or pGBKT7/hER(308C)-LL (Gal4 DBD
fused to the hER LBD) and pGADT7/PERC constructs (Gal4 AD fused
to PERC wild type or mutants). Transformants were grown to station-
ary phase, diluted 1:20 in selective media containing either ethanol
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vehicle (0.1%) or 10 M 17-estradiol (E2), grown for an additional 16 h
at 30 °C in 96-well plates, and assayed for -gal activity as described
previously (35).
Immunofluorescence—COS7 cells were transfected with the HA-
PERC expression vector pcDNA3/HA-PERC using FuGENE (Roche Mo-
lecular Biochemicals). PERC was detected in fixed cells by fluorescence
microscopy, using a mouse monoclonal antibody against the HA epitope
(HA.11, Babco) and a rhodamine-conjugated goat anti-mouse antibody
(Jackson Laboratories) as described previously (24).
RESULTS
Identification and Sequence Analysis of a PGC-1-related
cDNA—Sequencing of the human genome revealed a locus on
chromosome 5 with significant sequence similarity to PGC-1
and distinct from the PGC-1-related coactivator PRC (32). Us-
ing primers designed against the predicted coding sequences,
we amplified and cloned cDNAs representing this PGC-1 hom-
olog (see “Experimental Procedures”). Sequence analysis of the
identified cDNAs indicated the existence of two isoforms, likely
resulting from alternative splicing. The longer cDNA encodes a
protein of 1023 amino acids (aa), which we named PERC. The
short isoform, referred to as PERC-s, is identical to PERC
except that it lacks aa 156 to 194, sequences that correspond to
exon 4 of the gene. Fig. 1A shows a diagram of the predicted
open reading frame of PERC, indicating interesting sequence
features and homologies to the related proteins PGC-1 and
PRC. The greatest similarity between the three proteins is in
the C-terminal half of PERC (45–46% over 450 aa). This region
includes a RNA recognition motif (RRM), which has been im-
plicated in the regulation of RNA processing (31), and two
FIG. 1. PERC is a new member of the PGC-1 protein family. A, schematic representation of the PERC protein, its sequence features, and
comparison with PGC-1 and PRC. The shaded part of the N terminus indicates the predominantly acidic region. Amphipathic -helical leucine-rich
motifs are marked as L1, L3, NR1, and NR2; of these, NR1 and NR2 conform to the LXXLL sequence. Also indicated are two regions rich in
glutamic acids (E) (aa 430–450 and 807–824), two sequence motifs (AGLTPP(T/A)TPP and GDHDYC) that are highly conserved among the three
proteins, and the putative RRM. The percent similarities of the conserved regions among PGC-1 and PERC, or among PGC-1 and PRC, are shown
in between the protein diagrams. Serine/arginine-rich regions (RS) are present in PGC-1 and PRC but not PERC. Finally, PRC is characterized
by a unique, long proline-rich region. B, multiple sequence alignment (Clustal W) of the conserved N-terminal region. The alternatively spliced
exon 4 of PERC is boxed. Identical residues in at least two of the proteins are shaded; residues marked by asterisk, colon, and period are identical,
conserved, or semi-conserved, respectively, in all three proteins. C, PERC localizes to the nucleus. Right, HA-tagged PERC protein in transiently
transfected COS7 cells was detected by immunofluorescence, using a monoclonal mouse anti-HA antibody and a goat anti-mouse rhodamine-
conjugated antibody. Left, differential interference contrast image acquisition of the same field. The arrow indicates the nucleus of a HA-PERC
expressing cell.
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conserved short motifs of as yet unknown function (Fig. 1A). In
contrast to PGC-1 and PRC, which have short serine/arginine-
rich stretches (RS motif) N-terminal to the RRM, PERC has no
RS domain. Instead, PERC has two glutamic acid-rich
stretches (aa 430–450 and aa 807–824). A similar stretch of
glutamic acids has been described in the nuclear receptor co-
activator PELP1 (10). The second conserved region between the
three proteins is the N-terminal region (Fig. 1, A and B). The
first 130 aa of PERC are predominantly acidic residues, inter-
spersed with leucines (25% aspartic and glutamic acids, 14%
leucines, and just one basic residue). Alignment of this region
with PGC-1 and PRC highlights the presence of a conserved
leucine-rich motif (aa 92–96 of PERC), termed L1 here. In
addition, PERC has two LXXLL motifs, indicated as NR1 and
NR2 in Fig. 1. NR1 shows sequence conservation to the LXXLL
motifs of PGC-1 and PRC, while NR2 is unique to PERC. The
similarity between PERC and PGC-1 extends beyond NR1 and
includes the region of a third Leu-rich motif of PGC-1; a Leu-
motif is, however, not discernible in this region of PERC (Fig.
1B). Finally, consistent with the presence of nuclear localiza-
tion signal sequences, PERC is a nuclear protein (Fig. 1C).
PERC Is Expressed in a Tissue-specific Manner—To deter-
mine PERC mRNA levels in different tissues in a quantitative
and sensitive manner, we employed real-time RT-PCR with
RNA from mouse tissues. Primers were chosen so as to detect
specifically the long, exon 4 PERC transcript. As seen in Fig.
2, PERC was detected at highest levels (20 copies of PERC/
1000 copies of -actin) in heart and skeletal muscle. Interme-
diate levels (5–10 copies of PERC/1000 copies of -actin) were
seen in brain, kidney, liver, and adrenal gland. Lower PERC
levels were detectable in ovary, intestine, and white adipose
tissue. Expression in spleen, thymus, testis, and lung was
below 1 copy/1000 copies of actin. The tissue distribution of
PERC appears very similar to that of PGC-1 (22–24). Quanti-
tation of PGC-1 mRNA in the same tissue samples demon-
strated that the two genes are indeed expressed with similar
profiles and at similar levels in most tissues. A notable excep-
tion is the kidney, where PGC-1 levels were significantly
higher.
The PGC-1 Homolog Selectively Enhances the Activity of
ER—The similarity to PGC-1 and the presence of two LXXLL
motifs suggested that PERC could function as a coactivator of
nuclear receptors. To test this, we evaluated the effect of PERC
overexpression on the ligand-dependent trancriptional activity
of different nuclear receptors. We introduced full-length nu-
clear receptors, with or without PERC, in COS7 cells and
assessed their ability to induce the expression of appropriate
luciferase reporters in the presence of hormone. To our sur-
prise, PERC had either no or just marginal effects on ER,
progesterone receptor (PR), mineralocorticoid receptor (MR),
GR, androgen receptor (AR), TR/RXR, or PPAR/RXR, es-
pecially when compared with the activity of PGC-1 under the
same conditions (Fig. 3). The one nuclear receptor where PERC
functioned as a potent coactivator was ER. The selective ac-
tivation of ER was not due to a special feature of the estrogen-
responsive luciferase construct (single copy of vERE upstream
of the thymidine kinase promoter), because ER function at the
same estrogen-responsive reporter was minimally affected by
PERC. Moreover, PERC had at most a 2-fold effect on GR
activity irrespective of whether this was measured with a re-
porter having three tyrosine aminotransferase GREs or part of
the MMTV LTR. Neither PERC nor PGC-1 had any effect on
AR, which was however responsive to the effects of SRC-1, a
coactivator of the p160 family. We concluded that PERC shows
a remarkable selectivity for ER, while its homolog PGC-1 can
activate potently most nuclear receptors.
PERC Interacts with ER in a LXXLL-, AF2-, and ligand-
dependent Manner—To determine whether PERC and ER
interacted physically, and if so, to find out the requirements for
such an interaction, we employed the yeast two-hybrid system.
As shown in Fig. 4, the LBD of ER interacted with full-length
PERC in a ligand-dependent manner. Mutations in helix 12 of
the ER LBD (L539A/L540A) abolished the interaction, indi-
FIG. 2. PERC mRNA is expressed in a tissue-specific manner.
Levels of mouse PERC and PGC-1 mRNAs in different mouse tissues
were determined by real-time quantitative RT-PCR (see “Experimental
Procedures”), normalized to -actin mRNA levels, and expressed as
copies of PERC or PGC-1 per 1000 -actin copies in each sample. Data
shown are from a 6–8-week-old male, except for the ovary RNA, which
is from a 6–8-week-old female. Comparable results were obtained with
cDNAs prepared from tissues of one more male and female. SKM,
skeletal muscle; ADG, adrenal gland; WAT, white adipose tissue.
FIG. 3. PERC selectively enhances the activity of ER. COS7
cells were cotransfected with expression plasmids for the indicated
nuclear receptors, the corresponding luciferase reporter constructs
(pERE-tk-Luc for ER and ER; pTAT3-Luc for PR, MR, and GR;
pMMTV-LTR-Luc for GR; pminPbLUCneo for AR; p(DR4)x2-Luc for
TR/RXR; 3xPPRE-Luc for PPAR/RXR), and either pcDNA3 control
vector (white bars) or expression vectors for PERC (dark gray bars),
PGC-1 (light gray bars), or SRC-1e (black bars). Cells were treated with
50 nM 17-estradiol (ER and ER), progesterone (PR), aldosterone
(MR), or corticosterone (GR), 100 nM dihydrotestosterone (AR), T3
(TR/RXR), or 1 M rosiglitazone and 1 M 9-cis-retinoic acid
(PPAR/RXR) for 24 h and assayed for luciferase activity. Data are
expressed as fold enhancement of nuclear receptor activity by coactiva-
tor in the presence of hormone, i.e. activity in the presence of hormone
and absence of coactivator was set equal to 1 for all receptors.
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cating that it depends on the structural integrity of the AF2
domain (4, 36). To test the involvement of the two LXXLL
motifs of PERC in the interaction with ER, we substituted the
leucines in each motif by alanines (Fig. 4A). Mutations in either
NR1 or NR2 alone reduced the interaction, while the double
nr1/nr2 mutation abolished it (Fig. 4C). In conclusion, PERC
interacts via two motifs, NR1 and NR2, with a ligand-depend-
ent conformation of the ER AF2 domain.
We next determined whether the requirements of the inter-
action detected by the two-hybrid assay were also important for
the ability of PERC to enhance the activity of full-length ER.
Coexpression of PERC with the receptor in COS7 cells en-
hanced the activity of ER in the presence of the agonist
estradiol, but had no effect in the absence of hormone or the
presence of the antagonist tamoxifen (Fig. 5A). Enhancement
required an intact AF2 function, because the AF2 mutation
L539A/L540A abolished responsiveness to PERC (Fig. 5A). Fi-
nally, mutations in either motif NR1 or NR2 reduced PERC
activity, and the double nr1/nr2 mutation abolished coactiva-
tion (Fig. 5B). These findings demonstrated that PERC func-
tion in ER signaling depends on an agonist ligand and intact
complementing interaction surfaces: AF2 of ER and NR1/NR2
of PERC. Interestingly, NR1 is missing in the natural isoform
PERC-s, which lacks the 39 aa encoded by exon 4. Coexpression
of this short isoform showed indeed that PERC-s had a reduced
ability, similar to that of the PERC nr1 mutant, to enhance the
hormone-dependent activity of ER. Consequently, mecha-
nisms that regulate the alternative splicing of exon 4 of PERC
could modulate cellular responses to estrogens.
A Potent Bipartite Transcriptional Activation Domain (AD)
in the N Terminus of PERC Is Required for Coactivation—The
N-terminal region and in particular motif L1 of PERC is well
conserved among the three members of the PGC-1 family (Fig.
1B). In PGC-1 and PRC, this region harbors a potent trancrip-
tional AD (24, 28, 32). To test whether PERC also carries such
an AD, we asked if full-length PERC tethered to DNA activates
transcription. A fusion of PERC to the DBD of Gal4, which
recruits PERC to a Gal4-responsive luciferase reporter, indeed
activated transcription strongly (Fig. 6A). Deletion of the first
91 aa of PERC abolished activation, indicating that the N-
terminal part is essential for the activation function (Fig. 6A).
The first 91 aa (N91) fused to the Gal4 DBD were sufficient to
activate transcription. However, full transcriptional activity of
PERC required additional sequences up to aa 128. Gal4 DBD
fused to aa 1–128 (N128) was the strongest PERC activator,
enhancing transcription by more than 20,000-fold in COS7
cells (Fig. 6A). Within the 91–128 region, the conserved motif
L1 contributed to the activation function. Point mutations that
substituted the leucines of L1 with alanines reduced PERC
transcriptional activity, in the context of both full-length PERC
and the N128 construct (Fig. 6A). Our findings suggest a bi-
partite N-terminal AD. The first part is encoded by aa 1–91 and
is essential, while the second part relies on motif L1 and con-
tributes to full activity. This bipartite AD function is crucial for
the ability of PERC to enhance the activity of ER (Fig. 6B).
Deletion of the first 91 aa or mutations in motif L1 abolished or
reduced, respectively, PERC coactivation (Fig. 6B), suggesting
that both components of the AD are required for full function of
PERC in ER signaling.
PERC and PGC-1 Confer Distinct Functional Properties to
Ligand-activated ER—To address whether PERC and PGC-1
fulfill similar functions when acting with ER, we compared
the effects of the two coactivators on estrogen signaling in
different contexts. First, we evaluated PERC and PGC-1 func-
tion on ER-activated transcription at different promoter con-
texts (Fig. 7A). A single consensus ERE upstream of the min-
imal alcohol dehydrogenase promoter was preferentially
responsive to PGC-1 activity. PERC caused a small, reproduc-
ible 2–3-fold enhancement, compared with a 10-fold increase by
PGC-1. ER acting from two copies of the consensus ERE or a
longer vitellogenin A2 ERE fragment (334 to 289 nucleo-
tides, relative to transcription initiation) upstream of the same
minimal promoter was equally responsive to the two coactiva-
tors. On the other hand, two copies of the vitellogenin ERE
fragment, or a 1.8-kb fragment of the estrogen-responsive com-
plement 3 (C3) promoter, were enhanced stronger by PERC
than by PGC-1 (Fig. 7A). These observations suggest that
PERC and PGC-1 may selectively activate distinct ER targets
genes.
ER signaling depends on the nature of the activating li-
gand, as well as the cellular and promoter context (5, 37, 38). In
particular, there are classes of ER ligands that act in a tissue-
selective manner. For example, tamoxifen is an antagonist in
the mammary gland but an agonist in the bone, uterus, and
cardiovascular system (reviewed in Ref. 39). One of the under-
lying molecular mechanisms for the agonist action of tamoxifen
is thought to involve the cooperation of tamoxifen-bound ER
with tissue-specific cofactors. To determine how PERC and
PGC-1 affect the response to tamoxifen, we employed the C3
promoter, which has been characterized for its responsiveness
to this agonist (38, 40). In the osteosarcoma cells U2OS, tamox-
ifen activated the C3 promoter strongly, although not as well as
estradiol (Fig. 7B). PERC expression further enhanced the
tamoxifen response by 2-fold. In contrast, PGC-1 modestly re-
pressed the tamoxifen-induced response (Fig. 7B). These find-
ings suggest that the relative activities of PERC and PGC-1
may contribute to the tissue-specific action of partial agonists
like tamoxifen.
DISCUSSION
We report here the cloning and characterization of PERC, a
new member of the PGC-1 family of proteins and a coactivator
of ER. In contrast to PGC-1, which activates many nuclear
receptors, PERC shows a unique receptor selectivity. It po-
FIG. 4. PERC interacts physically with the LBD of ER in a
ligand, AF-2, and LXXLL-motif dependent manner. A, amino acid
sequences of PERC motifs NR1 and NR2. Leucines indicated in bold
were substituted with alanines in PERC nr1 and nr2 mutants. B, yeast
expressing Gal4DBD-ER-LBD (wild type or AF2 mutant L539/540A)
and either Gal4AD alone (not shown) or Gal4AD-PERC were grown in
the absence or presence of 10 M 17-estradiol (E2) and assayed for
-gal activity. No activity was detected in yeast expressing Gal4DBD-
ER-LBD and Gal4AD. C, yeast expressing Gal4DBD-ER-LBD and
the indicated Gal4AD-PERC variants were grown in the presence of 10
M 17-estradiol and assayed for -gal activity.
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tently enhances the ligand-dependent activity of ER, while
having only minimal effects on the activity of the related re-
ceptor ER or other nuclear receptors tested here. Further-
more, PERC and PGC-1 confer distinct properties to ER sig-
naling. Thus, the relative activities of the two coactivators may
contribute to the specific profiles of estrogen responses in dif-
ferent tissues.
PERC, PGC-1, and the recently described PRC (32) define a
new, small family of coactivators. The conserved features of the
family reside primarily in the N- and C-terminal domains,
which carry the effector functions of these coactivators: activa-
tion of transcription and regulation of pre-mRNA processing
FIG. 6. A bipartite transcriptional activation domain in PERC
is required for coactivation of ER. A, transcriptional activity of
PERC. COS7 cells transfected with the luciferase reporter pGK1 and
either Gal4DBD control vector or the indicated Gal4DBD-PERC vari-
ants were assayed for luciferase activity. Data are expressed relative to
the activity in cells expressing the Gal4DBD alone (vector), which was
set equal to 1. Note that the y axis scales are different in the two panels.
B, coactivation function of PERC. COS7 cells transfected with an ER
expression plasmid, the ER-responsive luciferase reporter pERE-tk-
Luc, and either pcDNA3 vector control (white bars) or expression vec-
tors for PERC and its indicated variants (dark gray bars) were treated
for 24 h with 50 nM 17-estradiol and assayed for luciferase activity.
Data are expressed as fold enhancement of ER activity by PERC in the
presence of hormone. 91C, aa 91–1023 of PERC; N91, aa 1–91 of PERC;
N128 and N128/L1A, aa 1–128 of PERC wild type and PERC L1A
mutant, respectively.
FIG. 7. PERC and PGC-1 confer differential promoter- and
ligand-specific activation of ER. A, coactivation of ER by PERC
or PGC-1 in different promoter contexts. COS7 cells transfected with an
ER expression plasmid, the different ER-responsive luciferase report-
ers (cERE1, cERE2, vERE1, vERE2, and C3 promoter) and
either pcDNA3 control vector (white bars) or expression vectors for
PERC (dark gray bars) and PGC-1 (light gray bars) were treated for
24 h with 50 nM 17-estradiol and assayed for luciferase activity. Data
are expressed as fold enhancement of ER activity by each coactivator
in the presence of hormone. B, the activity of tamoxifen-bound ER in
U2OS osteosarcoma cells is enhanced by PERC but not by PGC-1. U2OS
cells transfected with an ER expression plasmid, the reporter pC3-
Luc, and either pcDNA3 control vector (white bars) or expression vec-
tors for PERC (dark gray bars) and PGC-1 (light gray bars) were treated
for 24 h with ethanol vehicle (), 50 nM 17-estradiol (E2), or 5 M
tamoxifen (Tam) and assayed for luciferase activity.
FIG. 5. Coactivation of ER by PERC depends on an agonist ligand and the integrity of AF2 of ER and NR1/NR2 of PERC. A, COS7
cells transfected with expression plasmids for ER (wild type or AF2 mutant), the ER-responsive luciferase reporter pERE-tk-Luc, and either
pcDNA3 control vector (white bars) or PERC expression vector (dark gray bars) were treated for 24 h with ethanol vehicle (), 50 nM 17-estradiol
(E2), 5 M tamoxifen (Tam) or both ligands (E2/Tam) and assayed for luciferase activity. Data are expressed as fold enhancement by PERC, with
activity in the absence of PERC and ligand set equal to 1. B, COS7 cells transfected with an expression plasmid for ER, the ER-responsive
luciferase reporter pERE-tk-Luc, and either pcDNA3 vector control (white bars) or expression vectors for PERC and its indicated variants (dark
gray bars) were treated for 24 h with 50 nM 17-estradiol and assayed for luciferase activity. PERC-s lacks exon 4 (aa 156–194). Data are expressed
as fold enhancement of ER activity by PERC in the presence of hormone.
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(24, 28, 31, 41). Thus, the three coactivators are likely to
employ similar mechanisms to mediate their biological func-
tions. Whether PERC, which lacks the RS domain of PGC-1, is
able to regulate RNA processing has to be addressed in future
experiments. PERC, PGC-1, and PRC also share sequence sim-
ilarities outside the effector domains: the LXXLL motifs that
enable interactions with nuclear receptors and additional small
conserved motifs that may represent interaction surfaces for
other transcription factors or regulators (Fig. 1). At the same
time, the significant sequence divergence, particularly in the
unique central domains of the proteins, suggests that the three
members of the family have acquired unique functions and
roles.
The mechanism by which the N-terminal AD of PERC regu-
lates transcription is not clear yet. The corresponding region of
PGC-1 can interact with SRC-1 and CBP, suggesting that it
acts as a scaffold for the recruitment of other coactivators (41).
Our studies here indicate a bipartite AD that contacts more
than one target. The reduced transcriptional activity of the
L1A mutant points to the conserved motif L1 as one of the
interaction surfaces. An additional contact must reside in the
first 90 aa, which are essential and sufficient for transcrip-
tional activation. Neither SRC-1 nor CBP overexpression en-
hanced PERC transcriptional activity, implicating targets
other than these two coregulators. Since PGC-1 and PERC are
strong activators of transcription in yeast, which do not have
SRC-1 or CBP, it seems likely that the N-terminal ADs can
contact evolutionary conserved components of the transcrip-
tional machinery (24).2 Delineation of the exact interaction
surfaces of PGC-1, PRC, and PERC, as well as identification of
the proteins they contact, will shed light on the mechanisms by
which these ADs act.
An important feature of the PGC-1 family is the presence of
LXXLL motifs, which mediate interactions with the LBDs of
nuclear receptors. PERC has two canonical LXXLL motifs:
NR1, which is conserved in PGC-1 and PRC, and NR2, which is
unique to PERC (28, 30, 32, 42). Both NR boxes contribute to
the physical interaction with ER and to efficient coactivation
of this receptor. Notably, the presence of NR1 depends on the
inclusion of the small exon 4. The detection of two PERC
isoforms, with and without this exon, and the decreased ability
of the short PERC-s to activate ER, suggest that regulation of
this alternative splicing event could be used to modulate ER
signaling. Interestingly, the mouse homolog of PERC, which
was recently described as PGC-1, harbors an additional
LXXLL motif that is upstream of NR1 (aa 140–144) and not
conserved in the human protein (33). We do not know yet
whether this third motif functions as a nuclear receptor inter-
action domain, and if so, whether it enables functional inter-
actions with ER or other receptors. Although no data have
been presented yet on the ability of the mouse protein to coac-
tivate the different receptors we have tested here, it is possible
that the mouse and human homologs may have diverged in
their nuclear receptor specificity.
Our experiments demonstrate clearly that PERC is a coac-
tivator of ER. The fact that this coactivation function depends
on a physical interaction between the LXXLL motifs of PERC
and the AF2 domain of ER raises the question of why PERC
has only minor effects on many other nuclear receptors that
harbor similar AF2 domains. The reason for this receptor se-
lectivity is not clear, particularly since PERC can interact
physically with other ligand-activated receptors, such as GR.2
One possible explanation is that the affinity of the GR-PERC
interaction is lower than that of GR with other endogenous AF2
coactivators. If so, PERC may not get recruited efficiently at
GR target sites. An alternative explanation is that the physical
interaction mediated by the PERC NR boxes and the receptor
AF2 binding pocket is a necessary, but not sufficient, step for
coactivation. Coactivators have been proposed to undergo con-
formational changes subsequent to docking to transcription
factors. These changes may enable their enzymatic activities or
the recruitment of additional regulators (41, 43). Similarly, the
conformation of nuclear receptors may change upon interaction
with coactivators. Thus, specificity in the functional interaction
between PERC and ER could be due to conformational
changes subsequent to binding that may activate either PERC,
by unmasking its AD, or ER, by enabling its AF1 activity.
Consistent with an activation step for PERC, we have observed
that deletion of C-terminal and central domains of PERC result
in a much more potent transcriptional regulator (Fig. 6). It
seems likely that the PERC AD is masked in the context of the
full-length protein, similar to what has been shown for PGC-1
(41).
Besides their differences in nuclear receptor specificity,
PERC and PGC-1 display distinct preferences for the promoter
context in which they enhance ER activity. The two types of
EREs we have tested, a vERE and a synthetic cERE, contain
the same consensus core but differ in the flanking sequences.
Such differences have been shown before to influence ER-ERE
interactions (44). Moreover, the vitellogenin fragment includes
additional 5 sequences, where a second, nonconsensus ERE
can be discerned (312 to 298 nucleotides, relative to tran-
scription initiation). Finally, due to the difference in the length
of the flanking sequences, the dimerized elements vERE2
and cERE2 present ER binding sites with different spacing.
Thus, multiple properties, such as flanking sequences, the
presence of additional nonconsensus sites, and the spacing
between EREs, may account for the distinct utilization of
PERC and PGC-1 at the different promoters. Notably, PERC
seems to prefer promoters with multiple sites, such as the
dimerized EREs, or the C3 promoter that has at least three
EREs (40). Different response elements may induce distinct
nuclear receptor conformations and thereby influence either
the recruitment of the coactivators or the activity of the re-
cruited coactivators (45, 46).
An additional context that reveals differences in PERC and
PGC-1 function is the ability of the two coactivators to promote
the agonistic effect of the partial agonist tamoxifen. In a cell
and promoter context where tamoxifen is an agonist, PERC
enhances this agonist activity, while PGC-1 represses it. In this
respect, PERC acts like the p160 coactivators, which can en-
hance the agonist activity of tamoxifen (47–49). Presumably,
PERC can interact, directly or indirectly, with the tamoxifen-
induced conformation of ER. PGC-1 cannot do so, at least in
the context of the C3 promoter in U2OS cells. Because of its
antagonist activity in the mammary gland, tamoxifen is used to
treat estrogen-dependent breast tumors. Many of these tumors
develop resistance to tamoxifen and some start recognizing it
as an agonist (reviewed in Ref. 39). Our findings suggest that
the nature, as well as the relative levels of different AF2
coactivators, may determine the cellular response to tamoxifen.
Evaluation of PERC and PGC-1 levels in breast tumors will be
important to test whether these two coactivators contribute to
the responsiveness, or lack of, to endocrine therapy.
PERC mRNA distribution is very similar to that of PGC-1.
PGC-1 function in heart, muscle, and liver may mediate phys-
iological state signals to tissue-specific transcriptional activa-
tion of proteins that regulate energy and glucose homeostasis.
For example, in response to exposure to cold, PGC-1 induces
the expression of uncoupling proteins and stimulates energy2 D. Kressler and A. Kralli, unpublished observations.
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expenditure in brown fat and muscle, while in response to
fasting, it stimulates gluconeogenesis in liver (Refs. 26 and 29
and reviewed in Ref. 50). The similar expression profile of
PERC may be indicative of a second pathway that relates
energy needs to specific metabolic responses, possibly under
different regulatory input and with a different outcome. This
could increase specificity and flexibility of the transcriptional
responses. Estrogens can have profound effects on systems
other than the reproductive one. In both males and females,
estrogens have protective effects on the cardiovascular and
skeletal system, regulate adipose function, and affect glucose
and lipid metabolism (51–54). Mice that lack a functional ER
have increased adipose mass, develop mild glucose intolerance
and insulin resistance, and show decreased energy expenditure
(54, 55). Similarly, humans with deficiencies in estrogen sig-
naling show a propensity for insulin resistance and altered
lipid metabolism (52). It will be interesting to test whether
these estrogen effects require PGC-1, PERC, or a combination
of the two coactivators.
The mechanisms by which estrogens act in a tissue- and
promoter-specific manner are complex (20, 21). Mice with ge-
netic ablations of the p160 coactivators SRC-1 or SRC-3/AIB1
show only mild defects in estrogen signaling (56–58). Thus, it
seems likely that multiple coactivators can cooperate with ERs
to mediate appropriate tissue-specific and physiological state-
dependent responses. The molecular unraveling of estrogen
activity will require an understanding of all ER and ER
interactors as possible contributors to estrogen signaling. Here,
we have described a tissue-specific coactivator, PERC, which
shows a remarkable selectivity for ER over other nuclear
receptors. Future studies will define the reason for selectivity,
as well as the biological role of PERC.
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Material and methods 
 
PGC-1α antibody 
The first 293 aa of PGC-1α were expressed as GST-fusion protein in E. coli (BL21) 
with a 2-2.5 hour induction by IPTG (0.1 mM). Lysis was performed with 50 mM 
Tris, pH 8.0, 1 mM EDTA, 100 mM NaCl containing 0.1 mM PMSF, protease 
inhibitors and 0.2 mg/ml lysozyme by incubating on ice for 30 minutes. Subsequent, 
0.1 % DOC was added and the lysate was incubated for 15 minutes at 37 °C. DNA 
was digested with 10 µg/ml DNase I for 30 minutes at room temperature and the 
reaction was stopped with EDTA. In the following, the lysate was cleared by 
centrifugation for 20 minutes at 4 000 g and the supernatant was loaded on a GST 
column. The following elution was performed with 10 mM reduced glutathione in 50 
mM Tris, pH 8.0 by incubating 10 minutes at room temperature. The eluate was 
injected into rabbits 5 times (Eurogentec Inc, Belgium) to produce antiserum. The 
final bleeding was purified by ammonium sulfate precipitation as followed: After 
clearance for 30 minutes at 3 000g, 0.5 x volume of saturated ammonium sulfate was 
added slowly while stirring and mixture was incubated over night at 4°C. Large 
protein aggregates or proteins precipitating with lower concentration of ammonium 
sulfate were removed by centrifugation for 30 minutes at 3 000g. In the second step 
with 1 x volume ammonium sulfate for at least 4 hours the antibodies were 
precipitated, then they were collected by centrifugation, solved in PBS-/- and dialyzed 
versus PBS-/- over night. 
 
Cell lines, Infections, and Transfections 
SAOS2-GR(+)(Rogatsky, 1997) cells were cultured in Dulbecco’s modified Eagle’s 
medium (sigma D6429, with 4500mg/l glucose, l-glutamine and sodium pyruvate, 
substitutes pyridoxine hydrochloride for pyridoxal hydrochloride) supplemented with 
charcoal-stripped 9% fetal calf serum (FCS) and 200ng/ml G418 at 37 °C with 7.5 % 
CO2 and split 1:3 every 4th to 5th day. For the analysis of the gene expression profiles, 
cells were kept in normal fetal calf serum. One day before infection, cells were plated 
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with 7-9x105 cells per well in a 10 cm dish with DMEM and stripped FCS and were 
kept from then on in medium with stripped FCS. For the other experiments cells were 
always kept in medium with charcoal-stripped fetal calf serum. The analysis of the 
mRNA levels, protein extracts, genomic DNA and living cells the FACS analysis was 
done with 1.8x105 cells in 6-well plates or 2-3x105 cells per well in 6 cm plates and 
around 8x104 cells were split in 12 well plates for immunofluorescence. Adenoviruses 
were thawn on ice and sonicated 3 times for around 10 sec and were pipetted (only 
with filter tips, dilutions were made to have always at least 10 µl volume per well) 
directly in the cell culture plates with fresh medium (5 ml for 10 cm, 1 ml for 6 well, 
0.5 ml for 12 well, 1.5 ml for 6 cm plate). Incubation occurred for around 2 hours and 
then cells were washed and fresh medium was added. Infections were done at a 
multiplicity of infection (moi) of 20 (mRNA analysis, protein analysis of the RNAi), 
40 (FACS analysis, DNA analysis and control protein analysis) or 100 (gene chip 
experiments). The adenoviruses expressing siRNA (pSUPER or ERR2-3) were 
always infected 3 days before the infection with GFP or PGC-1α at an MOI of 100. 
For transfections in presence of the siRNA for ERRα, around 8x105 cells were split in 
10 cm plates and infected with the adenoviral vectors expressing siRNA (pSUPER or 
ERR2-3). After 3 days, cells were split in 6-well plates with 1.6x105 cells per well. 
The next day, cells were incubated with fresh medium while the CaPO4 precipitate 
was prepared: DNA was mixed with 3 µl 2.5M CaCl2 and Tris up to 25 µl per well of 
a 6-well plate and 25µl 2x HBS was added dropwise while vortexing. Precipitates 
were allowed to form for 10 minutes before adding to the cells. After incubating over 
night for around 14-16 hours, cells were washed once with 1x PBS -/-. Cell lysates 
were prepared 40 to 48 h after transfection and assayed for luciferase activity.  
Transfections included 0.2 µg of p6RlacZ for normalization of transfection efficiency, 
100 ng pcDNA3.HA-hPGC-1 and 250 ng of the luciferase reporter 
pERRα.prom.short-Luc. Different amounts of pcDNA3/ERRα from 250 ng to 61 ng 
were obtained by 1:4 dilution steps, were cotransfected. Samples were filled up with 
pcDNA3 to have the same amount of DNA. 
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Luciferase reporter assay 
Cells were washed with PBS-/- (2 ml) twice, lysed by incubation with 100 µl reporter 
lysis buffer (Promega) on ice. Lysates were scraped off using a rubber policeman and 
transferred to an eppendorf tube. Next, the cell trash was removed by centrifugation 
for 3 minutes at 20 000 g, 4 °C. 20 µl of the lysate were used to measure luciferase 
activity using the Microlite TLX1 luminometer (Dynatech Laboraties, Inc.) and 20 µl 
were assayed for b-Gal activity using CPRG (Roche) as substrate and the Thermomax 
microplate reader (Molecular Devices, Inc.).  
 
Buffers and chemicals 
Buffers: The 2x HBS buffer for transfections contained 280 mM NaCl, 1.5 mM 
Na2HPO4 and 50 mM HEPES, pH 7.05. TBST consisted of 150 mM NaCl, 10 mM 
Tris pH 7.5, 0l05 % Tween-20. 
Chemicals: The 250x protease inhibitor mix included aprotinin, leupeptin and 
pepstatin each at 250µg/ml in DMSO. PMSF was dissolved in isopropanol as a 250 
mM (250x) stock. Corticosterone (Fluka, 27840) was diluted with 100 % EtOH down 
to 1x10-4 and added to the cells in a 1:2000 dilution (50 nM).  
 
Westernblot analysis 
Cells were incubated in lysis buffer (100 mM Tris pH 8, 0.5% NP40, 150 mM NaCl, 
1 mM EDTA) supplemented with fresh 1mM PMSF and protease inhibitor mix for 10 
min, 4˚C. Proteins separated by SDS-PAGE (7,5 % gels) were blotted onto 
nitrocellulose membranes using the semi-dry electrophoresis transfer system. 
Membranes were blocked for around 30 minutes to one hour at room temperature or 
over night (4 °C) by incubation with 9 % milk in TBST. The primary antibodies were 
diluted in TBST with 4.5 % milk for the PGC-1α antibody (Schreiber et al., 2003) in 
concentrations from 1: 6000 to 1: 8000 and with 9 % milk for the ERRα antibody 
(Johnston et al., 1997) in a concentration of 1:3000 to 1:3300 (kept at 4 °C with 0.018 
% NaN3 and recycled for several weeks). Incubation occured over night at 4 °C or at 
least for 1 hour at room temperature. Secondary antibodies were purchased from 
Biorad. Bound antibodies were detected by enhanced chemiluminescence SuperSignal 
(Pierce). 
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RNA analysis 
Total RNA was isolated using the TRIzol® reagent (Invitrogen Life Technologies). 
Cells were washed once with PBS-/- and TRIzol® reagent was added to the cells (1ml 
per well in a 6-well plate, 2 ml for a 10 cm dish). After incubating the cells at room 
temperature for 3-5 minutes, cells were harvested by pipetting up and down. RNA 
was extracted with 0.2ml chloroform per 1ml Trizol, incubated for 2-3 minutes at 
room temperature and centrifuged for 15 minutes at 4°C, not more than 12 000 g. 
Next, the aqueous phase was transferred into a fresh tube and 0.5ml isopropanol was 
added. After 10 minutes incubation at room temperature, samples were centrifuged 
for 10 minutes at 4˚C at not more than 12 000 g. Supernatants were removed and 
washed with 1 ml 75% ethanol (DEPC treated water) and centrifuged for 5 minutes at 
4˚C for not more than 7 500 g. After aspirating the ethanol, the pellets were dried for 
maximum 5 minutes and resuspended with 10-15 µl H2O (DEPC treated). Samples 
were incubated for around 20 minutes on ice and then frozen at -70˚C. RNA was 
checked for its integrity by agarose gel electrophoresis and ethidium bromide staining. 
 
DNA isolation 
Infected cells were trypsinized after 48 or 60 hours of infection. One half was 
analyzed by westernblot to control for PGC-1α wt and mutant expression, from the 
other half, genomic and mitochondrial DNA was isolated. Cells were lysed with 
10mM Tris, pH 8, 100 mM EDTA, 0.5 % SDS and RNA was digested with 100 
µg/ml RNase A for 30 min at 37˚C, followed by incubation with 100 µg/ml proteinase 
K at 50 ˚C over night. After three extractions with 25:24:1 phenol/chloroform/isoamyl 
alcohol, aqueous phases were precipitated with one volume of isopropanol and 
incubated for around 3-4 hours at 4˚C with gentle inversion. Precipitates were 
collected by centrifugation at 9.000 x g for 20 min, dried and solved in TE buffer pH 
8 over night at 4˚C. To completely solve the DNA and make it more accessible for 
quantitative PCR it was sheared with a syringe and subsequently incubated at 60 ˚C 
for around 20 min. The specificity of the signals was controlled by RNAse treatment, 
which did not have an effect, and DNAse treatment, which led to a destruction of the 
signal. 
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Quantitative RT-PCR analysis of mRNA and DNA 
Per sample, 800 ng RNA was converted to 20 µl cDNA (TaqMan, Applied 
Biosystems) with random hexamer primers (25°C, 10 minutes, 46 °C, 45 minutes, 95 
°C, 5 minutes) and specific transcripts were quantified by real-time PCR using the 
Light Cycler system (Roche Diagnostics). Samples were measured in a 15 µl volume 
with 1.5µl of a 5 µM primer stock solution for each primer, 1.2 µl MgCl2 (25 mM) 
and 1.2 µl of the Mix including enzyme and SYBR green provided with the 
LightCycler FastStart DNA Master SYBR green I kit (Roche Diagnostics). At the 
end, 2 µl of the cDNA were added and samples were centrifuged for 1 minute at 
770g. After preincubation at 95°C for 10 minutes, products were amplified (95°C for 
15 seconds, 60 °C for 5 seconds and 72 °C for 10 seconds) for 40 cycles. A melting 
curve from 65 to 95°C (0.05°C/sec) at the end of the reaction was used to check the 
purity and nature of the product. In all cases, a single PCR product was detected. The 
sequences of the primers, which were designed in two different exons to avoid DNA 
contamination and the sizes of the PCR products are listed in a supplementary table 
following the material and method section. For quantification, either plasmid dilutions 
(5 dilutions 1:5) or 5 serial (1:3) cDNA dilutions from not infected cells were used as 
standard. All values were normalized to the mRNA levels of 36B4. 
DNA was diluted down to 1 ng/µl. Cytochrome oxidase II was measured as 
mitochondrial encoded gene and normalized to β-actin as nuclear encoded gene. For 
the standards, DNA of not infected cells was serially diluted 4 times from 10 ng in 1:3 
dilution steps. Copy numbers for quantification were set arbitrary. Quantification of 
both mRNA and DNA levels was done with the arithmetic fit points method, whereas 
the noise band and crossing line were set mostly around 0.4. 
 
FACS analysis 
After 48 hours of infection, SAOS2-GR(+) cells were incubated for 30 min at 37˚C 
with 500 nM MitoFluor Red 594 for flow cytometry (Molecular Probes Inc.), diluted 
in medium. To accumulate the dye in actively respiring mitochondria, cells were 
incubated for another 30 min with fresh medium at 37˚C. Cells were trypsinized, 
washed twice with PBS-/- and resuspended in 300-500 µl PBS-/- containing 1 mM 
EDTA to avoid cell clumps. Mitochodrial density was analyzed in living cells by flow 
cytometry (FACSCalibur, Beckton Dickinson) and data were analyzed using the 
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software WinMDI 2.8 developed by Joseph Trotter (http://www.scripps.edu). Each 
measurement represents 20 000 events. Similar GFP expression for PGC-1α wild type 
and mutant was detected in the FL1 channel, mitochondrial density was measured in 
the FL4 channel. In parallel, extracts were analyzed by western blot analysis to 
control for similar expression levels of PGC-1α wild type and mutant and the 
induction of ERRα protein levels. 
 
Immunofluorescence 
Cells were grown in 12well plates on coverslips with around 8x104 cells per well. 
When mitochondrial density was analyzed, cells were incubated for 30 min at 37˚C 
with 500 nM CM-H2XRos (Molecular Probes, Inc.) diluted in medium. To 
accumulate the dyes in actively respiring mitochondria, cells were incubated for 
another 30 min with fresh medium at 37˚C. Mitochodrial density was analyzed in 
living cells or after fixation with 3 % PFA in PBS+/+ by light microscopy (Zeiss, 
Axioplan 2). For staining with the PGC-1α antibody, cells were fixed with 3 % PFA, 
washed with PBS+/+, permeabilized with 0.1 % triton X-100 for 5 minutes and again 
washed with PBS+/+. After blocking for 30 minutes with 1 % BSA in PBS+/+, cells 
were incubated with the primary PGC-1α antibody (1:500) for 1-2 hours and 
subsequently washed twice with 0.5 % BSA and twice with PBS+/+. Staining with a 
secondary anti-rabbit antibody coupled to Cy3 was done for 30 minutes. After the 
subsequent washing steps as before, nuclei were stained with 50 ng/ml DAPI for 1-2 
minutes, cells were washed and mounted with the vectashield mounting reagent 
(Vector Laboratories Inc., Burlingame, CA).  
 
Target preparation and hybridization of the HG-U133A GeneChips 
Microarray analysis was performed using HG-U133A GeneChips™ (Affymetrix, 
Santa Clara, USA). 10 µg of total RNA (isolated from SAOS2-GR(+) cells) was 
reverse transcribed using the SuperScript Choice system for cDNA synthesis (Life 
Technologies) according to the protocol recommended by Affymetrix (GeneChip 
Expression Analysis: Technical Manual (2001) p. 2.1.14-2.1.16). The oligonucleotide 
used for priming was 5’-ggccagtgaattgtaatacgactcactatagggaggcgg-(t)24-3’ (Genset 
Oligo, France) as recommended by Affymetrix. Double-stranded cDNA was cleaned 
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by phenol:chloroform extraction and the aqueous phase removed by centrifugation 
through Phase-lock Gel (Eppendorf). In vitro transcription was performed on 1 µg of 
cDNA using the Enzo BioArray High Yield RNA transcript labelling kit (Enzo 
Diagnostics, USA) following the manufacturer’s protocol. The cRNA was cleaned 
using RNAeasy clean-up columns (Qiagen). To improve the recovery from the 
columns the elution water was spun into the matrix at 27 g and then left for one 
minute prior to the standard 8000 g centrifugation recommended by Qiagen. The 
cRNA was fragmented by heating in 1x fragmentation buffer (40 mM Tris-acetate pH 
8.1, 100 mM KOAc, 30 mM MgOAc) as recommended by Affymetrix. 10 µg of 
fragmented cRNA were hybridised to a HG-U133A GeneChip (Affymetrix) using 
their standard procedure (45°C, 16 hours). Washing and staining was performed in a 
Fluidics Station 400 (Affymetrix) using the protocol EukGE-WS2v4 and scanned in 
an Affymetrix GeneChip scanner.  
 
Microarray analysis 
Chip analysis was performed using the Affymetrix Microarray Suite v5 and 
GeneSpring 5.1 (Silicon Genetics). Changes in gene expression were assessed by 
looking for concordant changes between replicates using a signed Wilcoxon rank test 
(as recommended by Affymetrix). The “change” p-value threshold was < 0.003. Any 
gene whose detection p-value was > 0.05 in all experimental conditions was discarded 
from the analysis as being unreliable data. The differentially regulated genes 
overlapping in all three experiments were identified using the GeneSpring software. 
Classification into functional groups was done with help of the annotations of the 
Affymetrix NetAffx Analysis Center, SOURCE, the National Center for 
Biotechnology Information PubMed and LocusLink and with the OXPHOS and 
human mitoDB_6_2002 lists curated at the Whitehead Institute Center for Genome 
Research (Mootha et al., 2003). 
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